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ABSTRACT  
The ionotropic γ-aminobutyric acid (GABA) type A receptor (GABAAR) constitutes the 
major inhibitory neurotransmitter receptor type in the mammalian brain. The binding of 
GABA to the pentameric receptor complex results in opening of an integral anion channel, 
chloride influx, membrane hyperpolarization, and reduction in neuronal excitability. Synaptic 
GABAARs mediate classic phasic “point-to-point” inhibition, whereas extrasynaptic 
GABAARs give rise to persistent tonic inhibition. The exact roles of phasic and tonic 
inhibition in normal or pathological conditions, or in drug therapy, are unknown. GABAARs 
contain allosteric binding sites for numerous clinically and experimentally important drugs, 
such as benzodiazepines (BZ), barbiturates, neuroactive steroids, anesthetics and convulsants. 
Many of these compounds are used to enhance GABAAergic activity for treating, e.g., 
epilepsy, anxiety and sleep disorders, and in general anesthesia. The pharmacological and 
functional diversity of GABAAR subtypes is a consequence of variable receptor subunit 
compositions originating from different brain regional/cellular subunit expression patterns. 
Different GABAAR subtypes mediate different behaviors, e.g., hypnotic effects of BZs by α1- 
and anxiolytic effects by α2-GABAARs. Targeting drug action to certain receptor subtypes 
might offer a possibility to avoid the problems of nonselective drugs, such as development of 
tolerance and dependence. Thus far, only the BZ site heterogeneity has been exploited in 
pharmacotherapy, as indicated by the good efficacy and low abuse potential of zolpidem-like 
α1-preferring hypnotics. However, a similar diversity is also expected to exist in the other 
allosteric drug binding sites of the GABAARs, which makes it important to discover novel 
pharmacological heterogeneities. 
The aim of the thesis study was to develop a receptor autoradiographic method to better 
visualize the atypically weak displacement of the convulsant site ligand [35S]TBPS by high 
concentrations of GABA [GABA-insensitive (GIS) [35S]TBPS binding] in the cerebellar 
granule cell layer, and thereafter, to characterize the atypical receptors responsible for this 
heterogeneity. After development of the method, GIS-[35S]TBPS was detected in human, 
rodent and avian brains, and also outside the cerebella. Using genetically engineered mice and 
recombinant receptors expressed in cell lines it was demonstrated that extrasynaptic α6β2/3, 
α6β2δ, α1β3 and α1β2δ receptors display GIS-[35S]TBPS, as can also be suggested for α4β 
and α4βδ receptors, while inclusion of γ2 subunit abolishes GIS-[35S]TBPS. The formation of 
GIS-[35S]TBPS could be explained, at least in part, by the finding that GABA might act as a 
partial agonist in the native receptors responsible for GIS-[35S]TBPS. In a mouse line with 
ectopic extrasynaptic α6 subunit expression in the hippocampus (Thy1α6) in conjunction 
with increased tonic but decreased phasic inhibition, expression of α6βγ2 and α6β receptors 
was detected. In Thy1α6 mice the altered balance between synaptic and extrasynaptic 
inhibition caused increased seizure sensitivity. Antiepileptic tiagabine at a low dose was more 
effective in the Thy1α6 than control mice, presumably due to increased tonic inhibition by 
heightened GABA levels, but at higher doses the tiagabine effect was smaller in the Thy1α6 
mice. The results revealed the first behavioral correlate of tonic inhibition, but also 
emphasized the importance of phasic inhibition in circumstances with strong stimuli. In the 
last part of the project, GIS-[35S]TBPS was used to reveal the dual actions of a non-steroidal 
anti-inflammatory drug, niflumate, on brain GABAARs. In α6-receptors it had negative, but in 
α1βγ2 receptors positive, effects on GABAAR function. 
The results of the thesis project indicate that GIS-[35S]TBPS can be used as a tool to visualize 
extrasynaptic GABAARs in animal models of neurological and psychiatric diseases, and in 
drug development in a search for subtype-selective compounds.  
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1. INTRODUCTION 
During the last hundred years or so, it has become evident that brain function can be 
ultimately explained by current flow across neuronal cell membranes. How this movement of 
charged particles, ions, results, e.g., in higher cognitive functions and emotions, such as 
memory and fear, is probably the outcome of a complex puzzle including electrochemical 
signal-transduction between neurons, spatial and temporal summation of currents and precise 
control of the whole neuronal network. 
The mammalian central nervous system consists of brain and spinal cord. While the 
spinal cord is specialized to carry mainly sensory and motor information between the brain 
and rest of the body, in both directions, the brain is devoted to react to incoming information, 
to generate commands, and to execute them. To succeed in the challenge of creating 
meaningful orders to guarantee the survival of the individual, the brain has to compare, 
integrate and modulate the information it receives. For this, the mammalian brain is highly 
organized: it contains several functionally different units that are interconnected by certain 
pathways. The information reaching one of these units is usually modulated before it is 
conveyed to the next target. The brain can be divided into parts such as the brain stem, 
cerebellum, diencephalon and cerebrum. The brain stem is involved, e.g., in modulation of 
autonomic functions and regulation of sensory and motor information. The cerebellum 
modulates movements. In the diencephalon, the thalamus serves as processing station for 
information that is heading to the cerebral cortex, while the hypothalamus has neuroendocrine 
functions. The cerebrum itself consists of the cerebral cortex, the hippocampus, the amygdala 
and the basal ganglia. The cerebral cortex is primarily responsible for cognitive functions. The 
hippocampus has a role, e.g., in the memory and the organization of behavioral pathways, and 
the amygdala regulates responses according to different emotional values of inputs. The basal 
ganglia are involved in modulation of movements. 
The brain, like the whole body, is a collection of different cells with extracellular matrix 
in between them. Neurons are cells that connect with each other to form tracts that enable 
information to move between different parts of the brain or from the brain to the periphery 
and back. A string called the axon originates from the neuronal body, i.e., the soma. At the 
distal end of the axon an expansion, the axon terminal, comes close to the neighboring 
neuron. Together, these two neurons form a synapse, which enables transfer of information 
between the presynaptic cell’s axon and a postsynaptic cell’s branch called a dendrite. As the 
dendrite is connected to the postsynaptic neuron’s body, there is a functional link between the 
two neuronal bodies separated only by a tiny cleft in the synapse. In addition to neurons, other 
types of cells are also found in the brain. These glial cells do not deal directly with 
information transfer but are responsible for a variety of tasks that aim to maintain homeostasis 
in the brain, e.g., they, provide mechanical support, immunoprotection and vital nutrients for 
neurons.    
In the resting state, a neuronal membrane is negatively charged as a result of differential 
distribution of anions and cations between the intracellular and extracellular spaces. Different 
permeability of ions across the neuronal membrane and active transport by Na+-K+-ATPase 
against the chemical gradients leads to low intracellular Na+ and Cl- concentrations, whereas 
the K+ concentration becomes high. The starting point of any brain function is an action 
potential. Action potential is a summation of excitatory signals that cause Na+ flux into the 
neuron. Na+ influx and the resulting inward current shifts the membrane potential to a more 
positive value to the limit where “all-or-nothing” action potential is triggered. During the 
action potential the membrane potential is depolarized. Depolarization propagates along the 
axon to the axon terminal, where Ca2+ enters the cell and neurotransmitters are released to the 
synaptic cleft. Whether the neuron at the postsynaptic side of the synapse is excited or 
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inhibited depends on the nature of the neurotransmitters released by the presynaptic neuron. 
The postsynaptic cell in turn summates excitatory and inhibitory signals, and, if enough 
excitation is gained, action potential is triggered. This type of information flow, consisting of 
propagation of electrical impulses within neuron and conversion of electrical impulses to 
chemical signals in the synapses between neurons, offers several advantages that are essential 
for brain function. First, information is conveyed only in the anterograde direction, since 
synapses relay signals only from presynaptic to postsynaptic cells. Second, spatial and 
temporal summation of information flow is possible, because many presynaptic neurons have 
synapses with a single postsynaptic cell and action potential is generated only if enough 
excitation is achieved. Thirdly, while action potential carries only messages of one modality, 
depolarization, the chemical signal transduction in synapses enables this message to be 
converted to either an excitatory or an inhibitory one. 
Excitation in the mammalian brain is mainly mediated by the neurotransmitter 
glutamate. Like all neurotransmitters, glutamate exerts its actions through specialized 
membrane proteins, receptors. Glutamate receptors fall into two main categories, the 
ionotropic ligand-gated ion channels and the metabotropic receptors that are coupled to 
intracellular G-proteins. Both categories can be further divided into several receptor types on 
the basis of their structural and functional properties. It is generally accepted that glutamate 
plays a pivotal role in many important brain functions, and its role in so-called “long-term 
potentiation” (LTP), which confers the capacity to learn and remember, has been particularly 
well studied. It is also know that overt glutamate-mediated excitation is toxic to cells, long-
lasting excitation leading to cell death. When hyperexcitability is spread in the neuronal 
circuitry, it causes convulsions and ultimately death of the individual. Thus, while 
neurotransmitter-mediated excitation and the following action potentials are essential for any 
event to take place in the brain, an equally important factor in normal brain function is control 
of excitation. 
The mechanism that controls excitation in the brain is called inhibition. It derives 
basically from outward currents that oppose depolarization and may lead to membrane 
hyperpolarization. Hyperpolarization shifts resting potential to a more negative value, at 
which more excitation is needed to trigger action potential. Inhibition has many ways to affect 
brain function. It directly balances neuronal excitability, coordinates various rhythmic 
activities, and modulates information flow in different circuits by complex feedback systems. 
Deficiencies in inhibition have been found in a number of brain diseases, e.g., generalized 
anxiety disorder and schizophrenia. Like the effects of excessive excitation, convulsions may 
result from lack of inhibition even in the presence of normal amounts of excitation. From the 
1960’s, γ-amino butyric acid (GABA) has been suggested to be responsible for the major part 
of inhibition in the brain, and today we know that this is true. As in the case of glutamatergic 
transmission, the actions of GABA are mediated by specialized receptors. As brain function is 
a fine-tuned balance between receptor-mediated excitation and inhibition, it is understandable 
that the receptors for GABA are key-players in controlling brain activity, and ultimately the 
behavior of the individual.  
More complexity to the brain function is brought about by the heterogeneity of any 
given neurotransmitter receptor system. The complexity of GABA receptors exceeds that of 
any other receptor type. While it offers an infinite field of research for many generations of 
neuroscientists, it, more importantly, enables a delicate control over excitation, since different 
receptor subtypes have different functional properties. The different properties are derived 
from different structures. In addition to functional heterogeneity, structural variability causes 
pharmacological heterogeneity. This means that a given drug doesn’t necessarily affect all 
receptor subtypes, or that its actions on different subtypes may vary. This forms the basis for 
modern drug design, where attempts are made to create selective ligands for certain receptor 
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subtypes with defined functional and/or behavioral roles. With selective drug therapy more 
effective and safer treatment may be achieved.   
14 Review of the literature 
2. REVIEW OF THE LITERATURE  
2.1. GABA as neurotransmitter  
By definition, a neurotransmitter is a substance with specific presynaptic synthesis and 
storage, inactivation mechanisms after release, and comparable effects to a postsynaptic cell 
when applied exogenously as with electrical stimulation of a presynaptic cell. In addition, if 
the action of the neurotransmitter can be blocked with another compound after presynaptic 
release, the compound should also block the action of the exogenously applied transmitter. 
GABA fulfills all these criteria (reviewed in Oja and Kontro, 1987). It is synthesized from L-
glutamate by the enzyme glutamate decarboxylase (GAD). From the cytoplasm, GABA is 
actively transported to the synaptic vesicles (Kish et al., 1989), where it is stored and released 
in a Ca2+-dependent way by action potential. After release to the synaptic cleft, GABA is 
largely taken up by active GABA-transporters to neurons and glial cells. The uptake is not 
complete, since 0.1 – 0.8 µM GABA concentrations can be detected in the extracellular space 
depending on the brain region (Lerma et al., 1986; Tossman et al., 1986). This is in 
accordance with theoretical calculations using transporter models, which suggest that GABA 
transporters are unable to lower extracellular GABA below 0.1 - 0.4 µM  concentrations 
(Attwell et al., 1993; Richerson and Wu, 2003). The first demonstration of exogenous GABA 
mediating similar inhibitory effects on postsynaptic cells as normal neuronal activity came 
from Obata and colleagues (1967). Soon after this Obata and Highstein extended the studies 
by showing that picrotoxin blocks both the neuronal inhibition and the inhibitory effect of 
GABA on rabbit oculomotor neurons (1970). Since then, over 40,000 reports concerning 
GABA have been published, and its central role as an inhibitory neurotransmitter has been 
generally accepted. 
 It has been estimated that, depending on the brain region, up to 30 - 40 % of brain 
synapses use GABA as their transmitter (Bloom and Iversen, 1971; Iversen and Bloom, 
1972). Immunohistochemical detection of GAD and GABA receptors made it possible to map 
GABAergic neurons and their pathways in the brain. From this extensive work carried out 
during recent decades it is obvious that GABAergic cells are found throughout the brain, and 
innervation is especially rich in, for example, the cerebral cortex, hippocampus, thalamus, 
substantia nigra, striatum and cerebellum. GABA seems to control brain excitation in two 
major patterns. First, inhibitory GABA transmission may be the main output of a brain circuit 
as seen in the cerebellar cortex, where Purkinje cells use GABA to inhibit the deep cerebellar 
neurons that further project to motor systems (Curtis et al., 1970). In the other type of 
inhibition, GABA has more restricted actions, as GABAergic inhibitory interneurons control 
the principal neurons’ firing, and thus serve more as integrative tools in local circuits (Cobb et 
al., 1995). 
In addition to the brain, GABAergic inhibition is important in the spinal cord (reviewed 
in Malcangio and Bowery, 1996). GABA also has peripheral actions, for it participates in the 
operation of the peripheral nervous system, it has endocrine functions, and it regulates various 
peripheral organs, such as female reproductive systems (reviewed in Ong and Kerr, 1990).  
 
2.2. GABA receptors 
GABA exerts its actions by interacting with specialized membrane proteins, receptors. From 
early on pharmacological data suggested the existence of at least two different types of 
receptors for GABA (Naik et al., 1976), and later it was shown that the fast component of 
inhibitory postsynaptic potentials was selectively blocked by bicuculline but the slow 
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component by phaclofen (Soltesz et al., 1988). Applying molecular cloning and following 
heterologous expression of recombinant receptors established the current view of two basic 
types of GABA receptors, which were named in order of their discovery as type A (GABAA) 
and type B (GABAB) receptors.  
The GABAA receptors, together with nicotinic acetylcholine, strychnine-sensitive 
glycine and serotonin 5-HT3 receptors, form the superfamily of ligand-gated ion channels 
(reviewed in Leite and Cascio, 2001). Characteristic to these receptors composed of five 
polypeptide subunits, agonist binding causes a conformational change in the receptor complex 
and opening of the integral ion channel. Depending on the ion selectivity of the channel, fast 
neuronal depolarization or hyperpolarization results. The GABAA receptors are the main 
targets for GABAergic drugs in various neurological and psychiatric diseases, and their 
properties and significance will be dealt with in forthcoming sections. Later on, another 
GABA receptor was found that was insensitive to selective GABAA and GABAB receptor 
ligands bicuculline and baclofen, respectively, and it was termed the GABAC receptor (Drew 
et al., 1984). To date, three different subunits (ρ1-3) for GABAC receptors have been cloned, 
and they form homo- or hetero-oligomeric GABA-gated chloride channels mainly in the 
retina (reviewed in Bormann, 2000). While it has been suggested that GABAC receptors 
should be considered as a subgroup of GABAA receptors, the classification to different 
categories is more applicable due to the unique pharmacological properties of these two 
receptor types.  
GABAB receptors belong to the family of seven transmembrane domain G-protein 
coupled receptors. They are basically composed of a single polypeptide chain, but 
functionally they are coupled in dimeric units (reviewed in Couve et al., 2000). GABA 
binding leads to activation of inhibitory G-proteins that cause inhibition of adenylyl cyclase 
and agonist-induced inositol triphosphate synthesis, inhibition of Ca2+ channels and activation 
of inwardly rectifying K+ channels. GABAB receptors may be located either pre- or 
postsynaptically, the former causing inhibition of neurotransmitter release and the latter 
hyperpolarization of postsynaptic membrane. Activation of GABAB receptors has long-lasting 
inhibitory effects, and it has been shown to contribute to several important phenomena, such 
as regulation of LTP (Davies et al., 1991) and rhythmic activity in the hippocampus 
(Scanziani, 2000). While widespread distribution of GABAB receptors in the brain offers 
possibilities to affect behavior, and alterations in GABABergic function have been detected in 
animal models of depression, epilepsy and addiction (reviewed in Couve et al., 2000), 
currently the only pharmacotherapy targeted specifically to GABAB receptors consists of 
baclofen treatment of spasticity associated with multiple sclerosis (Beard et al., 2003). 
 
2.3. GABAA receptor structure 
2.3.1. Subunit genes 
Pharmacological and biochemical studies (Squires et al., 1979; Sieghart and Karobath, 1980) 
suggested heterogeneity of GABAA receptors before cloning of different receptor subunits. 
Schofield et al. (1987) used partial amino acid sequences of benzodiazepine (BZ) column 
affinity chromatography purified proteins to design oligonucleotides that enabled them to 
clone the first GABAA receptor α and β subunits from bovine brain. Sequence homology 
made it possibly to screen brain cDNA libraries with oligonucleotide probes, which resulted 
in identification of a large repertoire of subunits in various species. Today, altogether 16 
different mammalian subunits [α1-6, β1-3, γ1-3, δ, ε, θ, π (for references see Whiting et al., 
1995; Davies et al., 1997; Hedblom and Kirkness, 1997; Whiting et al., 1997; Bonnert et al., 
1999; Sinkkonen et al., 2000)] have been cloned. All the subunits are encoded by separate 
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genes, which are arranged in clusters in chromosomes (Russek, 1999). While it is likely that 
various receptor subunits are formed by duplication of a common ancestor, the need for such 
multiplicity is not totally clear. However, the different subunits confer individual properties to 
the receptor complex, and at least it allows differential regulation of subunit expression even 
if the gene products were largely similar. 
The subunits display 70-80 % sequence homology within a subunit class and 30-40 % 
homology between classes (Macdonald and Olsen, 1994). In addition to numerous different 
subunits, the heterogeneity is increased by alternative exon splicing of the mRNA (two forms 
of α6: Korpi et al., 1994; two forms of β3: Kirkness and Fraser, 1993; three forms of γ2: 
Whiting et al., 1990; Kofuji et al., 1991; Jin et al., 2004a). The receptor subunit genes are 
expressed in the brain with well characterized spatial and temporal patterns (e.g., Laurie et al., 
1992; Wisden et al., 1992; Sinkkonen et al., 2000). Other transcripts, such as α1 and β2 
subunit mRNAs are found throughout the brain throughout life, whereas others, such as α6, ε 
and θ have extremely restricted spatiotemporal expression (Laurie et al., 1992; Wisden et al., 
1992; Sinkkonen et al., 2000). The mechanisms controlling the expression patterns of the 
different subunits are largely unknown, and this study is in its early phase (reviewed in 
Steiger and Russek, 2004). 
 
2.3.2. Subunit proteins 
The GABAA receptor subunits display many features similar to the subunits of other members 
of the ligand-gated ion channel family (Schofield et al., 1987; McKernan and Whiting, 1996; 
Leite and Cascio, 2001). The subunits are 450-550 residue polypeptides with four 
hydrophobic transmembrane domains (TM1-4), and a large aminoterminal (N-terminal) tail 
containing a cysteine loop and agonist binding site. A large intracellular loop between TM3 
and TM4 has the highest amino acid diversity between subunits and contains putative 
phosphorylation sites. The short carboxy-terminal (C-terminal) tail is also extracellular. 
Immature subunits contain an N-terminal signal sequence needed to address the subunits on 
cell membranes, and the sequence is presumably cleaved after membrane insertion. 
 
2.3.3. Receptor assembly 
The subunit translation, post-translational modification and receptor assembly of ligand-gated 
ion channels take place in the endoplastic reticulum (ER, reviewed in Green and Millar, 
1995). Like other members of the ligand-gated ion channels, the GABAA receptors are 
composed of five subunits (Nayeem et al., 1994; Green and Millar, 1995; Tretter et al., 1997). 
To allow formation of receptor complexes composed of several subunits, sequences for 
specific interactions of subunits are required. Detailed analysis of the subunit residues 
responsible for the interaction has been performed, and the amino acids in the N-terminal 
extracellular domain of α, β and γ subunits are important (Taylor et al., 1999; Klausberger et 
al., 2000; Taylor et al., 2000; Klausberger et al., 2001; Sarto et al., 2002; Jin et al., 2004b). 
Bollan et al. (2003) provided a summary figure of the complex organization of assembly 
signals between the α, β and γ subunits. Currently no data is available for assembly signals of 
other receptor subunit classes. 
After oligomerization in ER, GABAA receptor subunits are targeted to the cell surface 
(Connolly et al., 1996). While α1β2 and α1β2γ2 combinations are capable of leaving ER and 
be transported to the cell membrane, the single α1, β2 and γ2 subunits and binary 
combinations of α1γ2 and β2γ2 are retained in ER (Connolly et al., 1996; Kittler et al., 2000), 
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and rapidly degraded (Gorrie et al., 1997). This suggests that assembly of α1γ2 and β2γ2 
receptors is stopped in the absence of β2 or α1 subunits, respectively. This indicates that 
strict, although partially unknown, rules for receptor assembly regulate the number of 
different GABAA receptor subtypes in the brain.  
 
2.3.4. Heterologous receptor expression 
GABAA receptors can be transiently or stably expressed in a number of different cells that are 
introduced to suitable RNA or DNA encoding for receptor subunits. Xenopus laevis oocytes 
can be individually injected with RNA purified from the brain (Smart et al., 1983), with 
synthetic subunit cRNAs (Schofield et al., 1987) or with subunit cDNAs (Ebert et al., 1994), 
which results in functional expression of GABAA receptors. The receptors can subsequently 
be studied with electrophysiological methods, but the oocytes do not provide enough 
membranes for simple binding studies with radioligands. Some binding studies have been 
performed with single oocytes. Another possibility for transient expression of GABAA 
receptors is to transfect cell lines (Lüddens and Korpi, 1997; e.g., human embryonic kidney 
cells, mouse fibroblasts, Chinese hamster ovary cells) with cDNA cocktails of different 
subunits. While both electrophysiological and binding studies can be used, only some of the 
cells express receptors, and it is possible that not all cells express all receptor subunits. A third 
possibility is to use cell lines that endogenously express GABAA receptors (Hales and 
Tyndale, 1994) or to produce cell lines with stable expression of desired subunits (e.g., 
α1β2γ2; Hamilton et al., 1993). The possible problems with these cell lines are low efficiency 
of receptor expression (Hamilton et al., 1993) or its long-term unstability (Valeyev et al., 
1993). Common to all these approaches, recombinant technologies and stable cell lines yield 
subunits in artificial amounts, which might cause discrepancies in the data between different 
laboratories. The relative amounts of subunits may vary a lot because of different constructs, 
transfection methods or model systems. Thus, it is important to try to validate the expression 
levels of the different subunits using pharmacological or other methods (Boileau et al., 
2002a). One possibility to control the coassembly of subunits in different transfection 
protocols is to use tandem-constructs, where different subunits are linked to each other by 
gene fusion (Baumann et al., 2001). 
If there were no rules for receptor assembly, a theoretical maximum of how 16 different 
receptor subunits can be assembled in a pentamer results in over one million (165) receptor 
subtypes. This number would be still further increased by alternative splicing of subunits. 
Even though receptor assembly in many cases works properly in heterologous systems, it is 
possible that they might produce such receptors that would not exist in the native brain. This 
is the core problem of heterologous expression of GABAA receptors. It is easy to imagine that 
introduction of large quantities of cRNA to cells leads to mass production of proteins that are 
processed differentially from the native situation. This is the possible explanation for the 
results of electrophysiological studies which show that α1 (Blair et al., 1988; Pritchett et al., 
1988; Verdoorn et al., 1990), α2 (Blair et al., 1988), α3 (Blair et al., 1988), β1 (Blair et al., 
1988; Pritchett et al., 1988; Sigel et al., 1989), β2 (Verdoorn et al., 1990), β3 (Wooltorton et 
al., 1997), γ2 (Shivers et al., 1989; Verdoorn et al., 1990; Martínez-Torres and Miledi, 2004) 
and δ (Shivers et al., 1989) subunits are able to form functional receptors by themselves. 
However, no expression was observed in some other studies with single subunits (Schofield et 
al., 1987; Sigel et al., 1990), which might reflect different expression levels. Another possible 
explanation for the apparent functional expression of homomeric receptors in transfected cell 
lines are endogenously expressed subunits [e.g., small amounts of α1, β3 and γ2 subunit 
mRNAs in HEK (human embryonic kidney) 293 cells ; Fuchs et al., 1995].  
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When subunits from two different classes are co-expressed, receptors are formed more 
efficiently, they are more sensitive to GABA and have larger chloride currents than 
homomeric receptors (Sigel et al., 1990). This suggests a preferential subunit assembly of 
receptors composed of dual combinations over homomeric subunits. With subunits from two 
classes, a large number of combinations produces detectable levels of functional receptors in 
electrophysiological studies (reviewed in Sieghart, 1995). However, subunit composition 
seems to affect the expression efficiency, since αβ receptors are produced on a large scale, 
whereas data from αγ and βγ combinations are somewhat controversial, but they seem to form 
less functional receptors (Sigel et al., 1990; Verdoorn et al., 1990; Knoflach et al., 1996). This 
is supported by the findings that αγ and βγ combinations are retained in ER and only αβ reach 
the cell surface (Connolly et al., 1996; Kittler et al., 2000). Furthermore, it seems that αγ and 
βγ combinations mostly form dimmers, while αβ combination preferentially forms tetramers 
and pentamers (Tretter et al., 1997).   
Transfection with subunits from three or more classes is efficient and makes it possible 
to produce receptors with many properties similar to native GABAA receptors (reviewed in 
Sieghart, 1995).  
In addition to electrophysiological methods, recombinant receptors can be studied with 
binding studies. The results of binding studies (reviewed in Sieghart, 1995) using cell 
membrane homogenates are even more confusing, since, in addition to the receptors on cell 
membranes studied in electrophysiology, the radioligand binding also takes place in 
intracellular subunit combinations that would never reach the cell surface. Thus, having 
radioligand binding in a given recombinant receptor subtype on membrane homogenates does 
not necessarily mean that these receptors are found on the cell surfaces of native neurons. 
Using intact cells instead of cell membrane homogenates offer a possibility to study ligand 
binding to only those recombinant GABAA receptors that are properly transported to cell 
membranes. While intact cells have successfully been used with the water-soluble radioligand 
[3H]muscimol (Chang et al., 2002), most other GABAAergic radioligands are lipid soluble 
(such as BZs and convulsant site ligands), and they easily pass through cell membranes, 
resulting in ligand binding to both membrane-targeted and intracellular receptors. 
One possible problem common to all approaches concerning the heterologous 
expression of recombinant GABAA receptors is the lack of neuron-specific intracellular 
proteins that interact with the receptor complexes. Although many candidate proteins have 
been found that are suggested to affect the receptor clustering, trafficking and function of the 
native brain (reviewed in Lüscher and Keller, 2004), demonstration of their exact roles or 
direct interaction between these proteins and GABAA receptors in most cases is still lacking. 
However, recently Everitt et al. (2004) showed that in mouse L929 fibroblasts co-expression 
of GABAA receptor subunits with an intracellular GABAA receptor-associated protein 
(GABA-RAP), known to directly interact with the γ2 subunit (Wang et al., 1999), remarkably 
affected the functional properties of the receptors, which then closely resembled those 
detected in native neurons. This suggests that in the future, in addition to GABA-RAP, 
different neuron-specific intracellular proteins should be co-transfected with the GABAA 
receptor in order to obtain more physiological results.     
The problems concerning heterologous receptor expression are obvious. However, 
recombinant receptors can be used in many applications, and owing to the largely 
homogenous pool of receptors, accurate information, e.g., about the pharmacological 
properties of the given receptor subtype, are obtained. However, one should preferentially use 
subunit combinations that are known to be formed in the native brain on the basis of 
immunohistochemical, biochemical or pharmacological data.  
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2.3.5. Receptor subtypes in the native brain  
The exact number of GABAA receptor subtypes and their subunit stoichiometry in the native 
brain is still unknown. Several methods may be used to deduce the receptor subunit 
composition. In situ hybridization (ISH) can be used to localize different subunit mRNAs, and 
co-localization reveals the possibility for coassembly. However, mRNA expression does not 
necessarily mean protein translation, and a given cell type may express up to 12 different 
subunits, as is the case in hippocampal dentate granule cells (Wisden et al., 1992). A 
traditional but indirect method is to use receptor subtype specific pharmacological 
heterogeneities in receptor autoradiography or ligand binding studies with subsequent 
demonstration of the heterogeneity in recombinant receptors (e.g., Korpi et al., 1995a). 
Immunoprecipitation of solubilized receptors from brain homogenates with subunit-specific 
antibodies and subsequent Western blot analysis may be used to reveal protein level 
interactions (e.g., Benke et al., 1994). However, this method requires high-affinity and high-
specificity antibodies, and its sensitivity is questionable. For example,  solubilization and 
precipitation of the receptors may result in loss of about 50 % of the receptors from the 
original brain homogenate (Tretter et al., 2001). Similar to ligand binding studies of brain or 
cell homogenates, it is possible that immunoprecipitation detects intracellular receptors. 
Immunoaffinity columns with subsequent Western blot analysis also allow identification of 
two different subunits in the same receptor (e.g., Pöltl et al., 2003), but it has the disadvantage 
of possible detection of intracellular receptors. Still another possibility to identify different 
subtypes is to use direct localization of receptor subunits with immunofluoresence or electron 
microscopy. This has been successfully used to reveal many native receptor subtypes (e.g., 
Benke et al., 1994; Nusser et al., 1998a), but may have limited sensitivity. Despite the 
limitations of the detection methods, it has been possible, by combining the results of various 
studies, to determine the major GABAA receptor subtypes in different brain regions (Table 1). 
However, due to the limited sensitivity of the detection methods, many unknown low-
abundant subtypes exist, and their roles in certain neuronal populations may be significant. 
 Colocalization of subunits in clusters on neuronal membranes, as in 
immunocytochemical studies, show that most native GABAA receptors are composed of α, β 
and γ subunits (Fritschy et al., 1992; Somogyi et al., 1996). The preferable stoichiometry of 
these receptors is 2α, 2β and 1γ subunits (Im et al., 1995a; Chang et al., 1996; Tretter et al., 
1997; Farrar et al., 1999; Baumann et al., 2001). In some α4 and α6 subunit-containing 
receptors δ substitutes for the γ subunit (Quirk et al., 1995; Nusser et al., 1998a; Bencsits et 
al., 1999). Minimal structural requirements for membrane localization of the receptor are the 
α and β subunits (Connolly et al., 1996; Kittler et al., 2000), and the presence of αβ receptors 
in the brain is confirmed (Bencsits et al., 1999). Suggested stoichiometry of αβ receptors is 
3α and 2β subunits or vice versa (Im et al., 1995a; Kellenberger et al., 1996; Baumann et al., 
2001). The π and ε subunits are considered as possible substitutes for γ (Davies et al., 1997; 
Hedblom and Kirkness, 1997; Whiting et al., 1997). The θ seems to be able to replace β 
subunits in some receptors (Bonnert et al., 1999). Further multiplicity of receptor subtypes is 
provided by findings that two different subunits from the same subunit class can be assembled 
in the same receptor complex (e.g., different α subunits: Lüddens et al., 1991; Jechlinger et 
al., 1998, or different β subunits: Li and De Blas, 1997; Jechlinger et al., 1998).  
 
2.4. GABAA receptor function 
GABAergic cells have two distinct functions, both of which are mainly mediated by GABAA 
receptors. In the first case GABA is used by the principal neuron of the brain circuit, and thus 
the   main output   is  inhibitory  (Curtis et al.,  1970). Secondly, in the more  common type of  
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Table 1. Major GABAA receptor subtypes in the brain. 
 
 
Subunit 
combination 
 
 
Relative 
abundance 
in rat brain 
(%) 
 
Examples of brain regional localization 
 
 
 
References 
 
 
 
 
α1β2γ2 
 
 
43 
 
 
Present in most brain areas; hippocampus, 
cortex and cerebellar Purkinje cells 
 
Benke et al., 1991 
Fritschy et al., 1992 
Somogyi et al., 1996 
α2β2/3γ2 
 
18 
 
Spinal cord motoneurones and hippocampal 
pyramidal cells 
Benke et al., 1994 
Fritschy et al., 1998 
α3βγ2/3 
 
17 
 
Cholinergic and monoaminergic neurons 
 
Fritschy et al., 1992 
Quirk et al., 1994 
α2β2/3γ1 8 Bergmann glia, nuclei of the limbic system Quirk et al., 1994 
α5β3γ2/3 
 
4 
 
Hippocampal pyramidal cells 
 
McKernan et al., 1991 
Fritschy and Möhler, 1995 
α6βγ2 
 
2 
 
Cerebellar granule cells 
 
Quirk et al., 1994 
Nusser et al., 1998a 
α6βδ 
 
2 
 
Cerebellar granule cells 
 
Quirk et al., 1994 
Nusser et al., 1998a 
α4β 
 
2 
 
Thalamus and hippocampal dentate gyrus 
 
Bencsits et al., 1999 
 
α4βγ2 
 
2 
 
Thalamus and hippocampal dentate gyrus 
 
Bencsits et al., 1999 
 
α4βγδ 
 
1 
 
Thalamus and hippocampal dentate gyrus 
 
Bencsits et al., 1999 
 
Other minor 
subtypes 
 
1 
 
 
 
  
 
Modified from McKernan and Whiting, 1996. 
 
inhibition, GABAergic cells act as inhibitory interneurons that control principal neuron 
activity (Cobb et al., 1995). Interneurons can control principal cells in a variety of ways 
(reviewed in Paulsen and Moser, 1998; Freund, 2003). The inhibition may be of phasic or 
tonic nature (see next sections), and it may arise from feedback or feedforward circuits. In 
addition to directly controlling network oscillations, which are considered essential for higher 
brain functions, the interneurons regulate dendritic calcium influx and backpropagation of 
action potentials, which affects synaptic plasticity. 
Knowledge about the actual GABAA receptor activation is derived from the predicted 
homology to nicotinic acetylcholine receptors. Binding of an agonist causes a small rotation 
of extracellular domains of subunits, which opens the channel formed by TM2 regions of 
adjacent subunits (Unwin, 1998). The homology to GABAA receptors is supported by the 
finding that in recombinant α1β1 receptors the α and β subunits rotate asymmetrically after 
GABA binding, which causes channel opening (Horenstein et al., 2001). 
When the GABAA receptor-associated channel is opened, various anions may pass 
through it in both directions (Bormann et al., 1987). The fact that GABA usually causes 
neuronal hyperpolarization is a result of a favorable electro-chemical gradient for chloride 
influx, not that of channel selectivity (reviewed in Kaila, 1994). For this reason GABAA 
receptor activity may also cause depolarization, which is the case in the developing brain, 
where the intracellular chloride concentration is elevated (Cherubini et al., 1991). During 
hippocampal maturation, induction of the expression of the K+/Cl- co-transporter causes an 
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adult-like shift in chloride equilibrium, which turns GABA from excitatory to inhibitory 
(Rivera et al., 1999). By studying the permeability of different anions through GABAA 
receptors, it has been possible to predict a diameter of 5.6 Å for the anion pore (Bormann et 
al., 1987). So, in theory, all anions smaller than this may flow through GABAA receptors, but, 
in the native brain, the main anion passing through the channel is chloride, and the second 
most important is bicarbonate (Kaila and Voipio, 1987; Kaila, 1994). 
 
2.4.1. Phasic inhibition 
Phasic inhibition is crucial for normal brain function, since it shapes the amplitude and 
duration of excitatory post-synaptic currents (EPSC) of the principal cells in the feed-back 
and feed-forward loops. In this prototypic inhibition GABAA receptors enriched in the 
postsynaptic cell membranes are activated by GABA, which is released from presynaptic 
terminals by the action potential. Many synapses are activated simultaneously, which causes a 
rapidly activating inhibitory postsynaptic current (IPSC; Figure 1) and hyperpolarization of 
the postsynaptic cell. The IPSC is terminated within milliseconds when GABA is eliminated 
from the synapses by diffusion and uptake by transporters to neurons and glia (Clements, 
1996). Another factor contributing to the magnitude of IPSC is the receptor desensitization 
caused by high agonist concentrations. During desensitization, the agonist is still bound to the 
receptor, but the channel enters a closed state. Since the GABA concentration in a synapse 
may rise to 300 µM or 3 mM (Mozrzymas et al., 1999; Perrais and Ropert, 1999), whereas the 
concentration producing a half maximal effect (EC50) of the GABAA receptor subtypes is 
usually below 50 µM (reviewed in Hevers and Lüddens, 1998), some degree of receptor 
desensitization takes place, which additionally affects the size of  the IPSCs (Jones and 
Westbrook, 1996).  
Receptor enrichment to synaptic membranes exactly opposite to the presynaptic 
terminals is essential for efficient synaptic transmission. Like glycine receptors (Meier et al., 
2001; Rosenberg et al., 2001), GABAA receptors are thought to diffuse freely around the 
plasma membrane after membrane insertion but before their aggregation to synaptic clusters. 
Gephyrin is a protein that causes anchoring of glycine receptors to synapses by interaction 
with the cytoskeleton (Kirsch et al., 1991). Gephyrin can be found colocalized with GABAA 
receptor α1, α2, α3 and γ2 subunits in many brain regions, but it does not colocalize with α6 
or δ (Sassoè-Pognetto et al., 2000). Direct molecular interaction between gephyrin and 
GABAA receptor subunits has not been shown (Kannenberg et al., 1997), but gephyrin-
deficient mice show decreased clustering of major GABAA receptor subtypes (Kneussel et al., 
1999). However, it does not affect clustering of some other receptor subtypes, and therefore, 
other clustering proteins must also exist (Kneussel et al., 2001). Of the different GABAA 
receptor subunits, γ2 is essential for synaptic anchoring, since in the lethal phenotype of γ2 
subunit knockout mice (γ2-/-), postsynaptic GABAA receptor clusters are dramatically 
decreased (Essrich et al., 1998). Gephyrin clusters are also abolished (Essrich et al., 1998). 
However, in the γ2-/- mice, overexpression of γ3 subunits is sufficient to restore synaptic 
receptor clustering (Baer et al., 1999), which suggests that other γ subunits are also capable of 
interaction with anchoring proteins, but γ2 is favored for some reason in vivo. GABA-RAP is 
another protein possibly involved in GABAA receptor clustering, and it has been shown to 
interact directly with the γ2 subunit (Wang et al., 1999). In addition to gephyrin and GABA-
RAP, many other intracellular proteins have been proposed to affect GABAA receptor 
clustering and trafficking (reviewed in Luscher and Keller, 2004). 
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Figure 1. Schematic presentation of phasic 
and tonic GABAAergic currents recorded 
from a single neuron. A. Typical sIPSC 
arising from simultaneous activation of 
many synapses by action potential-
triggered GABA release. B. GABAAergic 
currents composed of sIPSCs and mIPSCs 
(either of which indicated with an arrow), 
and tonic background conductance 
(revealed after application of the GABA 
antagonist bicuculline, BIC). mIPSCs 
represent the release of a single or a few 
neurotransmitter quanta from presynaptic 
terminal to postsynaptic receptors. It is 
action potential independent, and thus 
might be considered as a form of tonic 
conductance. Bicuculline (BIC) blocks all 
currents, which is illustrated by abolition of 
sIPSCs and mIPSCs, a decrease in 
background “noise”, and a shift in mean 
membrane current. C. Tetrodotoxin (TTX) 
blocks action potential triggered GABA 
release and thus sIPSCs. mIPSCs are still 
detected. Bicuculline blocks mIPSCs and 
tonic conductance. D. The GABA uptake 
blocker tiagabine raises the extracellular 
GABA level, which increases background 
conductance (increased “noise” and shift in 
mean current) without affecting sIPSCs or 
mIPSCs. E.g., in the recordings by Bai et al. 
(2001) largely similar traces are shown.  
 
 2.4.2. Tonic inhibition 
In addition to classical phasic synaptic transmission, GABAA receptors also exert their actions 
by tonic inhibition, which is common also to other neurotransmitters (reviewed in Zoli et al., 
1999). Tonic GABAAergic conductance was first proposed by Birnir et al. (1994) in the 
hippocampal dentate gyrus. Thereafter it was found and characterized in the cerebellar 
granule layer (Kaneda et al., 1995; Brickley et al., 1996; Tia et al., 1996a; Wall and Usowicz, 
1997; Rossi and Hamann, 1998; Hamann et al., 2002). Also the hippocampus (CA1 region: 
Birnir et al., 2000; Bai et al., 2001; Semyanov et al., 2003; Caraiscos et al., 2004; dentate 
gyrus: Nusser and Mody, 2002; Stell et al., 2003; Wei et al., 2003), the cerebral cortex (Salin 
and Prince, 1996), and the thalamus (Porcello et al., 2003) display tonic GABAAergic 
inhibition. The contribution of tonic conductance to the total inhibitory charge transfer varies 
depending on the brain region, but in the cerebellar granule cell layer the vast majority of the 
inhibition is of a tonic nature (Brickley et al., 1996; Wall and Usowicz, 1997; Hamann et al., 
2002). The exact functional roles of the tonic inhibition are unknown, but it is suggested to set 
a background level for overall neuronal excitability (reviewed in Mody, 2001). It has been 
suggested to control the synaptic responses by regulating general membrane properties, such 
as membrane input resistance and time constant (Häusser and Clark, 1997; Mitchell and 
Silver, 2003). In the cerebellar granule cells, tonic inhibition is shown to decrease the number 
of excited cells, which is suggested to improve information storage capacity (Hamann et al., 
2002). In the hippocampus, tonic inhibition may affect learning and memory processes 
(Caraiscos et al., 2004). 
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Tonic inhibition (Figure 1) results basically from the incapacity of GABA transporters 
to lower extracellular GABA concentration below 0.1 - 0.4 µM, and neurons seem to be in 
permanent agonist bath of ≥ 0.1 µM (Lerma et al., 1986; Tossman et al., 1986; Attwell et al., 
1993; Richerson and Wu, 2003). Extracellular GABA may originally have been spilled-over 
from neighboring synapses (Brickley et al., 1996; Rossi and Hamann, 1998) or released from 
the surface matrix reservoir that becomes exposed during vesicular exocytosis (Vautrin et al., 
2000). Non-vesicular release of GABA from astrocytes or neurons is also possible (Liu et al., 
2000; Rossi et al., 2003), which might be due to reverse operation of the GABA transporters 
(Gaspary et al., 1998). Thus, the functional state of the transporters seems to be very 
important in regulating tonic inhibition (Richerson and Wu, 2003; Wu et al., 2003). Anyway, 
the presence of permanent agonist stimulation results in continuous receptor activation 
causing tonic inhibition. Another possibility leading to tonic conductance is receptors that are 
constitutively active without agonist application. Such receptors are found at least in the 
hippocampus (Birnir et al., 2000).  
A clear-cut distinction between the receptor subtypes responsible for phasic and tonic 
conductances is difficult, if not impossible to make, but some general points may be drawn. 
Tonic conductance may be derived from receptors located on both synaptic and extrasynaptic 
membranes, but owing to receptor properties, extrasynaptic receptors are primarily activated. 
Since ambient GABA concentrations are maximally in a low micromolar range, the receptor 
subtypes responsible for tonic inhibition need to have high affinity to GABA. In addition, 
despite the persistent presence of an agonist, the receptors must not desensitize, otherwise 
they would be nonconducting. Taking these considerations into account, and the results from 
genetically engineered animals, the roles of certain GABAA receptor subtypes in tonic 
inhibition may be addressed. Most convincing evidence indicates that α6 and δ subunit-
containing receptors are responsible for tonic conductance in the granule cells of the 
cerebellum. The α6 subunit protein is found on both synaptic and extrasynaptic membranes 
(Nusser et al., 1998a). The α6 subunit-containing receptors have a high affinity to GABA 
[EC50 0.2-2 µM depending on other subunits (Ducic et al., 1995; Knoflach et al., 1996; 
Saxena and Macdonald, 1996)], and they desensitize poorly (Tia et al., 1996b). Tonic current 
in cerebellar granule cells is detected after developmental induction of α6 subunit expression 
(Brickley et al., 1996), and is blocked by α6-specific antagonist furosemide (Hamann et al., 
2002). In addition, tonic inhibition is abolished in the α6 knockout mice (Brickley et al., 
2001), but it is enhanced after ectopic expression of α6 subunits in the hippocampal CA1 
neurons of Thy1α6 mice (Wisden et al., 2002). The δ subunit-containing receptors are located 
exclusively extrasynaptically (Nusser et al., 1998a), have an extremely high affinity for 
GABA [EC50 0.2-0.5 µM (Saxena and Macdonald, 1996; Hevers et al., 2000; Brown et al., 
2002)] and desensitize poorly (Haas and Macdonald, 1999). In addition, tonic conductance is 
greatly reduced in the δ knockout mice (Stell et al., 2003). As δ is preferentially assembled 
with α6 (Jones et al., 1997), most of the tonic conductance in the cerebellar granule cells is 
probably mediated by α6βδ receptors. 
 Since α6 is exclusively expressed in the cerebellar granule cells (Wisden et al., 1992), 
it cannot explain the tonic conductance in forebrain areas. The δ subunit-containing receptors 
(presumably combined with α4; Sur et al., 1999) give rise to tonic conductance in 
hippocampal dentate granule cells (Stell et al., 2003) and thalamic relay neurons (Porcello et 
al., 2003). The α5 subunit in the hippocampal CA1 pyramidal cells is exclusively 
extrasynaptic (Brünig et al., 2002; Crestani et al., 2002a). The α5 subunit-containing 
receptors are more sensitive to GABA than α1-containing receptors, and they desensitize 
more slowly (Caraiscos et al., 2004). Tonic inhibition in the CA1 pyramidal cells is greatly 
reduced in α5-knockout mice (Caraiscos et al., 2004), but it is BZ-sensitive in the wild-type 
mice, which suggests the presence of γ2 subunit in the receptor complex (Bai et al., 2001; 
Lindquist et al., 2003). The α3 subunit is found both in synapses and on extrasynaptic 
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membranes (Brünig et al., 2002), and might thus cause tonic inhibition. In addition, 
pharmacological evidence suggests that the most prevalent and prototypic receptor subtype, 
α1βγ2, also contributes to tonic inhibition in the hippocampal interneurons (Semyanov et al., 
2003).  
The interplay between phasic and tonic inhibition is still largely unknown, but recent 
studies with genetically engineered animals suggests a precise balance between these two 
components. In the GABA transporter (GAT) -1 knockout mice, which display increased 
tonic inhibition due to increased extracellular GABA levels, spontaneous IPSCs (sIPSC) are 
unchanged, but the frequency of miniature IPSCs (mIPSC) is reduced (Jensen et al., 2003). 
Somewhat similarly ectopic expression of the GABAA receptor α6 subunit in the 
hippocampus of Thy1α6 mice increases tonic inhibition but decreases sIPSC frequency and 
mIPSC amplitude (Wisden et al., 2002). In addition, in the α6 knockout mice, where tonic 
GABAAergic inhibition in the cerebellar granule cells is abolished, induction of potassium 
leak conductance restores neuronal excitability (Brickley et al., 2001). 
 
2.4.3. Inhibition in the cerebellar granule cell layer  
The cerebellum is highly conserved across different species. It is devoted to maintaining 
balance and orientation of the body, adjusting and learning motor tasks, and it contributes to 
some aspects of cognition (Ito, 1972; Modianos and Pfaff, 1976; Fiez, 1996; Asanuma and 
Pavlides, 1997; Ito, 2002). Different cortical regions of the cerebellum share the same basic 
organization, which consists of circuits that are used to modulate the afferent information on 
its way through the cerebellar cortex to the descending systems (Figure 2; Ito, 2002). The 
cerebellum has two main inputs, both of which are excitatory, the climbing fibers arising from 
the inferior olivary nucleus, and the mossy fibers arising from the precerebellar nuclei. The 
only output of the cortex, from Purkinje cells to deep cerebellar neurons, is inhibitory and 
uses GABA as a transmitter. Each Purkinje cell receives input from just one climbing fiber, 
but each climbing fiber excites about 10 Purkinje cells (not drawn in the figure). Mossy fibers 
influence Purkinje cell firing indirectly through interneurons as they excite granule cells. 
Granule cells, in turn, excite several Purkinje cells by parallel fiber contacts. Parallel fibers 
also excite inhibitory Golgi interneurons, which inhibit granule cells and Purkinje cells. In 
addition, stellate cells and basket cells, which are also excited by parallel fibers, inhibit 
Purkinje cells. Purkinje cells have feed-back inhibition to basket cells. Thus, excitatory mossy 
fiber input is conferred to a complex excitation-inhibition of Purkinje cells, which is thought 
to enable spatial and temporal integration of information flow through the cerebellar cortex.  
The diversity of GABAA receptors in the cerebellum has been reviewed extensively 
(Wisden et al., 1996). In brief, prototypical BZ-sensitive receptors composed of α1, β2/3 and 
γ2 subunits are expressed predominantly in the molecular layer and in Purkinje cells (Wisden 
et al., 1992; Gutiérrez et al., 1994). In contrast, the cerebellar granule cells express a unique 
repertoire of subunits, namely α1, α6, β2, β3, γ2 and δ subunits (Wisden et al., 1992; 
Thompson et al., 1992; Benke et al., 1994; Gutiérrez et al., 1994). The cerebellar granule cells 
are the most abundant cells in the brain, amounting to about half of all neurons. They possess 
several distinct anatomical and physiological features. They receive GABAergic input to their 
distal dendrites from the Golgi interneurons. The excitatory mossy fibers meet the inhibitory 
connection and together they form a special structure called the glomerulus. In addition to 
synaptic GABAA receptors, the granule cells have extrasynaptic receptors on their cell soma 
and dendrites (Baude et al., 1992; Nusser et al., 1996). The organization of these receptors in 
synaptic  and  extrasynaptic  locations  gives  rise  to  phasic and tonic  inhibition, respectively  
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(Brickley et al., 1996; Wall and Usowicz, 1997; Brickley et al.,1999). Based on 
immunohistochemical data, Nusser et al. (1998a) have drawn a schematic representation of 
the differential distribution of GABAA receptor subtypes on granule cells: α6βδ receptors 
(Caruncho and Costa, 1994; Quirk et al., 1994; Jones et al., 1997) are exclusively 
extrasynaptic (Nusser et al. 1998a), whereas α6βγ2 receptors (Khan et al., 1994; Quirk et al., 
1994; Pollard et al., 1995; Jones et al., 1997) are found in Golgi synapses, in some of the 
mossy fiber to granule cell synapses, and on extrasynaptic membranes (Nusser et al., 1998a). 
The α1βγ2 receptors  (Quirk et  al.,  1994; Jones et  al., 1997;  Nusser et al. 1998a) are mainly 
located  in the Golgi  synapses but at  lower concentrations also  on extrasynaptic  membranes  
                                                                                                                                            
 
 
Figure 2. Information flow through the cerebellar cortex. B; basket cell; G, golgi interneuron; Gr, 
granule cell; P, Purkinje cell. (+), glutamatergic excitatory synapse; (-), GABAergic inhibitory synapse. 
Modified from Wisden et al. (1996). 
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(Nusser et al., 1995; Nusser et al. 1998a). The α1 and α6 subunits are colocalized in some 
Golgi synapses (Nusser et al., 1996), and immunoprecipitation data suggest that some 
receptors harbor both α1 and α6 subunits (Pollard et al., 1995; Khan et al., 1996). In the 
cerebellum granule cells, no coassembly of α1 and δ subunits is found (Quirk et al., 1994), or 
the abundance of α1βδ-receptors is very low (Pöltl et al., 2003). 
 
2.4.4. Inhibition in the hippocampus 
The basic anatomy and neurophysiology of the hippocampus has been reviewed extensively 
(e.g., Knowles, 1992). In brief, the hippocampus receives input from cortical and subcortical 
structures. Cortical input derives from, e.g., the controlateral hippocampus and entorhinal 
cortex, which in turn receives input from many regions, including the amygdala, the medial 
septum and the thalamus. The subcortical input derives from many brain areas, including the 
hypothalamus, the raphe nucleus and the locus coeruleus. Input from cortical areas uses 
glutamate to directly excite the hippocampus, whereas input from subcortical areas uses 
several kinds of transmitters and tends to have more indirect and modulatory actions.  
In the classical glutamatergic trisynaptic pathway (Figure 3), granule cells of the dentate 
gyrus are excited by the perforant pathway coming from the entorhinal cortex. The granule 
cells excite the CA3 (cornu ammonis subregion 3) pyramidal cells by their axons called 
mossy fibers. CA3, in turn, excites CA1 pyramidal cells via Schaffer collaterals. The CA1 
pyramidal cell axons are the main output from the hippocampus, and they project into, e.g., 
the subiculum, the entorhinal cortex, the nucleus accumbens, the amygdala and the 
hypothalamus. The projections to the subiculum and the entorhinal cortex provide indirect 
pathways to several cortical areas, and to the amygdala and thalamus. Excitation is mediated 
by α-amino-3-hydroxy-5-methylisoxazole-propionic acid (AMPA) and N-methyl-D-aspartate 
(NMDA) type glutamate receptors. The activation of NMDA receptors in principal cells is 
required for formation of LTP, which is considered as synaptic counterpart for formation of 
memory (Tsien et al., 1996). 
 In addition to synapses between the hippocampal principal cells, the granule cells and 
the pyramidal cells, glutamate is used in synapses between the principal cells and various 
types of interneurons. The interneurons are GABAergic and inhibit the principal cells by 
activating postsynaptic GABAA receptors in feedback and feedforward inhibitory loops 
(Figure 3; reviewed in Paulsen and Moser, 1998). Interneurons also inhibit each other by 
synaptic contacts and by direct electrical coupling through gap junctions (Skinner et al., 1999; 
Klausberger et al., 2002). In the feedback inhibition, axon collaterals from the principal cells 
excite inhibitory interneurons (e.g., basket cells), which in turn produce an IPSP in pyramidal 
cells. Feedback inhibition strongly controls the activity of the principal cells. In feedforward 
inhibition of CA1 pyramidal cells, Schaffer collaterals excite interneurons that directly inhibit 
CA1 pyramidal cells, which restrict the duration and strength of CA1 pyramidal cell 
excitation. Different types of interneurons have specific roles and they innervate different 
parts of the principal cells (Figure 3; Paulsen and Moser, 1998; Klausberger et al., 2003). 
Basically, perisomatic interneurons (basket and axo-axonic cells) control output and 
synchronize the firing of the principal cells, while dendritic interneurons control the efficacy 
and plasticity of the excitatory input. Basket cells can be divided into two populations with 
different properties and inputs (Freund, 2003). Parvalbumin-positive cells are interconnected 
and act as nonplastic synchronizers of pyramidal cells through α1 subunit-containing GABAA 
receptors (Klausberger et al., 2002; Freund, 2003). The other, cholecystokinin-positive basket 
cells, serve as sensors for mood and fine-tune  firing of the pyramidal cells through α2 
subunit-containing GABAA receptors (Nyíri et al., 2001; Freund, 2003), which are known to 
mediate the anxiolytic effects of BZs (Löw et al., 2000). Of the other receptor subunits, the α5 
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subunit is exclusively extrasynaptic in CA1 pyramidal cells (Brünig et al., 2002; Crestani et 
al., 2002a), and causes tonic inhibition (Lindquist et al., 2003; Caraiscos et al., 2004). The α3 
is found both in synapses and on extrasynaptic membranes (Brünig et al., 2002). The α4 is 
present in pyramidal cells and dentate granule cells (Wisden et al., 1992; Sperk et al., 1997), 
but its subcellular localization is unknown. The δ subunit is expressed in dentate granule cells 
(Sperk et al., 1997) and gives rise to tonic conductance (Stell et al., 2003), which suggests an 
extrasynaptic localization similar to the cerebellar granule cells (Nusser et al., 1998a). 
Localization of δ in the forebrain is largely similar to the α4 subunit (Wisden et al., 1992; 
Sperk et al., 1997), and these subunits display a preferential coassembly (Sur et al., 1999). In 
addition to α and δ subunits, virtually all β and γ subunit variants are expressed in the 
hippocampal principal cells (Wisden et al., 1992; Sperk et al., 1997). In the interneurons, 
mainly α1, β2 and γ2 subunits are found (Schwarzer et al., 1997; Sperk et al., 1997).  
 
 
 
Figure 3. Information flow through the 
hippocampus (A.) and inhibitory loops in 
the hippocampal CA1 region (B.). A. The 
classical glutamatergic trisynaptic pathway 
and examples of its inputs and outputs are 
illustrated. DG, dentate granule cells; EC, 
entorhinal cortex; MFP, mossy fiber 
pathway; PP, perforant pathway; S, 
subiculum; SCP, Schaffer collateral 
pathway. The hippocampus receives input 
from cortical and subcortical structures. 
Output from CA1 regions goes to, e.g., the 
subiculum, the entorhinal cortex, the 
nucleus accumbens, the amygdala and the  
hypothalamus. The projections to the 
subiculum and the entorhinal cortex 
provide indirect pathways to several 
cortical areas, the amygdala and the 
thalamus. Based on Knowles (1992). B. 
The interneurons are excited by Schaffer 
collaterals from the CA3 region and inhibit 
CA1 pyramidal cells by activating 
postsynaptic GABAA receptors in feedback 
and feedforward inhibitory loops. Different 
types of interneurons have specific roles, 
and they innervate different parts of the 
principal cells. Interneuron-interneuron 
contacts, synapses and gap junctions 
(Skinner et al., 1999; Klausberger et al., 
2002), are not shown. AA, axo-axonic cell; 
B, baskel cell; BS, bistriatal cell; Pyr, 
pyramidal cell. Modified from Paulsen and 
Moser (1998). 
 
2.5. Molecular pharmacology of GABAA receptor binding sites 
Extensive reviews of different GABAA receptor binding sites, their structural requirements, 
and the modes of action of different GABAAergic drugs have been published (e.g., Sieghart, 
1995; Hevers and Lüddens, 1998; Korpi et al., 2002a), and thus only those compounds 
essential for the thesis are presented here. However, a simplified summary is provided in 
Figure 4.  
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Figure 4. Most of the known GABAAergic drugs and their effects on receptor function in a 
hypothetical model. (?), positive modulation of the receptor function; (?|), negative modulation of 
the receptor function; (- - <), antagonistic action of the benzodiazepine binding site. Data are from 
Sieghart (1995) and Korpi et al. (2002a).   
 
 
2.5.1. GABA 
The GABAA receptor agonist binding sites can be labeled with [3H]GABA or [3H]muscimol. 
The receptor has both high- and low-affinity binding sites for GABA, the affinities being at 
low nanomolar and low micromolar range, respectively (Olsen et al., 1981; Agey and Dunn, 
1989). The extracellular N-terminal amino acids Phe64 (phenylalanine at position 64; Sigel et 
al., 1992; Smith and Olsen, 1994), Arg66 (Boileau et al., 1999), Ser68 (Boileau et al., 1999), 
Arg120 (Westh-Hansen et al., 1999), Val178 (Newell and Czajkowski, 2003), Val180 
(Newell and Czajkowski, 2003), and Asp183 (Newell and Czajkowski, 2003) of the α1 
subunit form part of the  low-affinity  GABA  binding  pocket.  These amino  acids  are 
otherwise  conserved  in all α subunits, but there is some variability of the amino acids in 
positions 68 (Boileau et al., 1999) and 183 (personal amino acid sequence comparison). In the 
β subunit, the extracellular amino acids (named after β2 amino acid numbering) Tyr97 
(Boileau et al., 2002b), Leu99 (Boileau et al., 2002b), Tyr157 (Amin and Weiss, 1993), 
Thr160 (Amin and Weiss, 1993), Thr202 (Amin and Weiss, 1993), Ser204 (Wagner and 
Czajkowski, 2001), Tyr205 (Amin and Weiss, 1993), Arg207 (Wagner and Czajkowski, 
2001) and Ser209 (Wagner and Czajkowski, 2001) are important for forming the low-affinity 
GABA binding site. The low-affinity GABA binding site is located in the extracellular 
interface between the α and β subunits (Smith and Olsen, 1995), and GABA binding to it is 
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important for channel opening, since mutation of the above mentioned residues affects 
channel activity, and there is a correlation between the GABA concentrations needed to 
activate the channel and the affinity of this site (Hevers and Lüddens, 1998). 
The functional role of the high-affinity binding site is unclear, but the [3H]muscimol 
autoradiographic data suggest that in the native brain it is associated with receptors containing 
the δ subunit together with α4 or α6 (Quirk et al., 1995; Mihalek et al., 1999; Korpi et al., 
2002b). However, [3H]muscimol binding in test tube conditions with brain homogenates or 
recombinant receptor preparations seems not to depend on the δ subunit (Tretter et al., 2001). 
It has been demonstrated that the Tyr62 amino acid of the β2 subunit is important for 
[3H]muscimol binding, but not for channel gating (Newell et al., 2000). 
The type of α subunit in the receptor complex largely defines the affinity for GABA 
(reviewed in Hevers and Lüddens, 1998). α6 subunit-containing receptors are the most 
sensitive (EC50 0.2-2 µM: Ducic et al., 1995; Knoflach et al., 1996; Saxena and Macdonald, 
1996), whereas EC50 for GABA is about ten or a hundred times higher in α3 subunit-
containing receptors (Sigel et al., 1990; Ebert et al., 1994; Verdoorn, 1994). Receptors with 
α1, α2, α4 and α5 have intermediate affinity (e.g., Wafford et al., 1993; Ebert et al., 1994; 
Knoflach et al., 1996). The type of β and γ variant has a minor effect (Hevers and Lüddens, 
1998), but the role of the δ subunit is clear: the receptors with δ instead of γ are ten times 
more sensitive to GABA (Saxena and Macdonald, 1996; Hevers et al., 2000; Brown et al., 
2002). Inclusion of the γ subunit with αβ receptors reduces the affinity to GABA (Sigel et al., 
1990; Horne et al., 1993). 
In addition to GABA, the agonist site recognizes several conformationally restricted 
analogs, such as muscimol and thiomuscimol, which act as full agonists in most receptors 
(Ebert et al., 1997). THIP is a restricted GABA analog, which is a partial agonist in some 
receptor subtypes (e.g., α1βγ2: Ebert et al., 1994; Ebert et al., 1997), while it acts as a full 
agonist in α4βδ receptors (Brown et al., 2002). Interestingly, GABA is only a partial agonist 
in α4βδ receptors (Brown et al., 2002). In addition to agonists and partial agonists, several 
competitive antagonists, such as bicuculline and SR 95531, are known (Heaulme et al., 1986). 
 
2.5.2. Picrotoxinin/TBPS 
Blockage of ion flux through the GABAA receptor with various allosteric modulators, such as 
picrotoxin (an equimolar mixture of active picrotoxinin and inactive picrotin), t-
butylbicyclophosphorothionate (TBPS; Squires et al., 1983), t-butylbicycloorthobenzoate 
(TBOB; Lawrence et al., 1985), 4’-ethynyl-4-n[2,3-H2]propyl-bicycloorthobenzoate (EBOB; 
Kume and Albin, 1994), pentylentetrazol (Squires et al., 1983) and many insectides (e.g., 
lindane and dieldrin; Huang and Casida, 1996) cause convulsions. These compounds compete 
with each other, which has led to the assumption of a single “convulsant” binding site (Ticku 
and Maksay, 1983). 
In electrophysiological studies, picrotoxinin block has been detected in homomeric 
receptors composed of α, β, γ or δ subunits (Shivers et al., 1989; Atkinson et al., 1992). 
However, [35S]TBPS binding was detected only in homomeric β3 receptors (Slany et al., 
1995), which might suggest somewhat different minimal structural requirements for the 
binding of these compounds. [35S]TBPS binding and picrotoxinin block can be detected in 
various αβ, βγ and αβγ combinations (reviewed in Sieghart, 1995). Using site-directed 
mutagenesis and the cysteine accessibility method (Xu and Akabas, 1993) several amino acids 
in the pore-lining TM2 region of the α1 (Val257, Thr261, Thr267, Ser272), β2 (Thr246), β3 
(Ala252, Leu253) or γ2 (Thr271, Thr277) subunits have been revealed to be important for 
picrotoxinin or TBPS sensitivity (Gurley et al., 1995; Xu et al., 1995; Perret et al., 1999; 
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Jursky et al., 2000; Buhr et al., 2001). These data strongly suggest that the convulsant binding 
site is located in the ionophore. Picrotoxinin and TBPS also block GABAC receptors in 
electrophysiological recordings (Vale et al., 1999), and may also bind [35S]TBPS, but this has 
not been published. 
[35S]TBPS binding can be used to image the convulsant/ionophore sites (Squires et al., 
1983; Ticku and Maksay, 1983; Supavilai and Karobath, 1984; Trifiletti et al., 1984). 
[35S]TBPS binding is absolutely anion dependent (Squires et al., 1983; Trifiletti et al., 1984), 
and anion permeability though the GABAA receptor ionophore bears a direct relationship to 
[35S]TBPS affinity (Havoundjian et al., 1986). Since changes in the chloride concentration 
affect mainly [35S]TBPS binding association, but not dissociation, rate constants (Garrett et 
al., 1989), Maksay (1996) has speculated that chloride ions are needed for the formation of 
the binding site for [35S]TBPS. In the presence of chloride, [35S]TBPS associates with 
picrotoxinin-sensitive sites slowly, and equilibrium is reached in 3 h (Edgar and Schwartz, 
1990). [35S]TBPS dissociates in a monophasic way with a dissociation constant of 88 min 
(Edgar and Schwartz, 1990). [35S]TBPS binding has a pH optimum at 7.5-8.5, and the optimal 
temperature is about 21 °C (Squires et al., 1983). Picrotoxinin block of GABA currents have 
been shown to be use-dependent (Yoon et al., 1993). In addition, Yoon et al. (1993) described 
a picrotoxinin block in dissociated rat hippocampal neurons that was not use-dependent and 
suggested two different binding sites in one receptor or in different receptors (Figure 4). 
Whether the same applies to receptors outside the hippocampus or to TBPS binding, is 
currently unknown. However, [35S]TBPS binding is accelerated in the presence of nanomolar 
GABA concentrations (Korpi and Lüddens, 1993), and electrophysiological block by TBPS is 
achieved more rapidly with repeated or prolonged GABA applications (Van Renterghem et 
al., 1987; Dillon et al., 1995). [35S]TBPS binding is inhibited by micromolar GABA 
concentrations (Squires et al., 1983), its dissociation correlating with the chloride flux (Im and 
Blakeman, 1991), and recovery from the block can be speeded up with repeated GABA 
applications in electrophysiological experiments (Van Renterghem et al., 1987). These data 
together show that TBPS (and picrotoxinin) dissociation is use-dependent, and association is 
accelerated by agonist application. Both TBPS and picrotoxinin are suggested to stabilize the 
inactivated state of the receptor, because they decrease the channel open probability without 
affecting the mean open times (Hamann et al., 1990; Newland and Cull-Candy, 1992). Thus, 
[35S]TBPS binding represents resting or non-conducting receptors, whereas dissociation of the 
binding by GABA and other positive modulators serves as a biochemical measure of receptor 
activation (Im and Blakeman, 1991). While TBPS and picrotoxinin bind to both GABA-
bound and unbound receptors, their affinity to the former is about 10 times higher (Dillon et 
al., 1995). This suggests that TBPS has better access to its binding site in the open 
configuration of the receptor. 
While it is clear that GABAA receptor agonists and other positive modulators at high 
concentrations cause [35S]TBPS dissociation (e.g., GABA: Squires et al., 1983; muscimol: 
Wong et al., 1984; benzodiazepine agonists: Gee et al., 1986; barbiturates: Squires et al., 
1983), and antagonists or negative modulators inhibit the effect of GABA (e.g., bicuculline 
and SR 95531: Squires and Saederup, 1987; furosemide: Korpi et al., 1995a), it is not so clear 
how low agonist concentrations seem to enhance [35S]TBPS binding (Supavilai and Karobath, 
1984; Korpi and Lüddens, 1993). Studying the effects of GABA agonists and antagonists on 
[35S]TBPS binding kinetics Maksay and Simonyi (1986)  proposed a model for convulsant 
site binding, which explains these “low-dose hooks”. They assume the existence of two 
interconvertible states of the convulsant binding sites, one with slow and the other with rapid 
kinetics, representing the closed and open forms of the GABAA receptor ionophore, 
respectively. In the model, agonists accelerate both association and dissociation of [35S]TBPS, 
low concentrations more inducing the association rate while and higher concentrations 
predominantly speeding up the dissociation rate. Bimodal actions seen in [35S]TBPS binding 
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with different agonist concentrations are thus caused by a shift in receptor kinetics from slow 
([35S]TBPS bound) to rapid ([35S]TBPS dissociated) when shifting from low to high agonist 
concentrations (Maksay and Simonyi, 1986). According to this model, agonists accelerate 
reaching of the binding equilibrium, whereas antagonists delay it. This stresses the importance 
of using equilibrium conditions (at least 180 min incubation in the presence of chloride) when 
probing for the effects of different compounds on [35S]TBPS binding. Otherwise a “low-dose 
hook” (where there is more [35S]TBPS binding in the presence of an agonist at 
nonequilibrium than at equilibrium) might cause misleading results (Maksay and Simonyi, 
1986). However, if one uses [35S]TBPS binding to reveal receptor subtype heterogeneities, 
nonequilibrium conditions may also be used, especially in autoradiography, when the tissue 
might deteriorate during prolonged incubation at room temperature.  
 
2.5.3. Benzodiazepines 
The GABAA receptor BZ binding site has been extensively studied due to it’s clinical 
importance and due to it’s heterogeneity, which has enabled development of subtype-
preferring drugs and elucidation of the significance of certain receptor subtypes (reviewed in 
Rudolph et al., 2001). BZ site full agonists, such as diazepam and flunitrazepam, are 
anxiolytic, anticonvulsant, sedative and myorelaxant. They potentiate the actions of GABA 
(Macdonald and Barker, 1978) by increasing the frequency of channel openings (Study and 
Barker, 1981) and by increasing channel conductance (Eghbali et al., 1997) due to increased 
affinity to GABA (Skerritt et al., 1982; Hattori et al., 1986). In the absence of an agonist, 
however, BZs are without effect (Study and Barker, 1981; Hattori et al., 1986) and are thus 
unable to increase the maximal effect of GABA (Hattori et al., 1986), which makes them safe 
when used as a single therapeutic. In addition to full agonists, the entire spectrum of 
compounds from partial agonists (only partial efficacy; e.g., bretazenil; Martin et al., 1988) to 
antagonists (blocking the effect of agonists and inverse agonists without affecting the effect of 
GABA per se; e.g., flumazenil; Hunkeler et al., 1981) and inverse agonists (decreasing the 
effect of GABA, e.g., Ro 15-4513 (ethyl-8-azido-5,6- dihydro-5-methyl-6-oxo-4H-
imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate); Bonetti et al., 1988) exist. The mode of 
action of the given compound varies depending on the receptor subtype (see below). 
 Prior to cloning of GABAA receptor subunits, the BZ binding sites were divided into 
types I and II, the former having a higher affinity to CL218,872 and zolpidem (Squires et al., 
1979). In addition, a third group of receptors were found that bound Ro 15-4513 with high 
affinity, but were insensitive to classical BZs such as diazepam (Sieghart et al., 1987; 
Malminiemi and Korpi, 1989). Subsequent cloning of receptor subunits and heterologous 
expression of different subunit combinations provided a molecular explanation for the 
previous findings: the type of α subunit variant in the receptor complex largely determines the 
BZ pharmacology (Pritchett et al., 1989a; Lüddens et al., 1990). [3H]Ro 15-4513 can be used 
to label all BZ binding sites (Sieghart et al., 1987). However, it can be displaced by full 
agonists, such as diazepam, only from receptors containing α1, α2, α3 or α5 subunits. These 
subunits differ from α4 and α6 in having a critical amino acid (His in the position of about 
100 in α1, α2, α3 and α5; Arg in position 99 and 100 in α4 and α6, respectively), which 
makes α4/6βγ2 receptors diazepam-insensitive (Wieland et al., 1992). Vice versa, 
introduction of arginine to α1 makes receptors diazepam-insensitive (Wieland et al., 1992), 
and α6 receptors can be converted into diazepam-sensitive ones by exchanging histidine for 
glutamine (Korpi et al., 1993). While Ro 15-4513 is a partial inverse agonist (i.e., it decreases 
the effect of GABA; Bonetti et al., 1988) in most receptor subtypes, it has an agonist effect in 
α4/6βγ2 receptors (Knoflach et al., 1996). Mutating the α1 subunit His101 can be used to 
convert flumazenil to a partial agonist and Ro 15-4513 to a partial agonist or antagonist, 
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depending on mutation, in the α1β2γ2 receptors (Dunn et al., 1999; Crestani et al., 2002b), 
which further demonstrates the importance of this residue in both BZ binding and signal 
transduction. Recently, a demonstration of the direct interaction of the diazepam molecule and 
α1 His101 was provided (Berezhnoy et al., 2004). 
The key role of the aforementioned histidine/arginine heterogeneity of α subunits in the 
BZ binding domain pharmacology has been exploited to elucidate the significance of receptor 
subtypes with different α subunits. Replacing the natural histidine with arginine in α1, α2, α3 
and α5 subunits, and subsequent generation of transgenic mouse lines with these “knock-in” 
mutations, have enabled a very elegant dissection of the different behavioral effects of BZ 
agonists. The α1 subunit-containing receptors are mainly responsible for sedation, 
anterograde amnesia and anticonvulsive effects (Rudolph et al., 1999; McKernan et al., 2000). 
The α2 subunit-containing receptors mediate anxiolysis selectively and myorelaxation 
partially (Löw et al., 2000; Crestani et al., 2001). The α3 subunit-containing receptors 
partially mediate myorelaxation (Löw et al., 2000; Crestani et al., 2001). The α5 subunit-
containing receptors affect trace fear conditioning and exert partially myorelaxation (Crestani 
et al., 2002a). These findings at present contribute the best rationale for future subtype-
selective compounds (Rudolph et al., 2001). 
In addition to diazepam sensitivity, the type of α subunit also determines the BZ I and 
BZ II type pharmacology (Pritchett et al., 1989a). The α1 Gly201 confers high affinity to 
CL218,872 and zolpidem (Pritchett and Seeburg, 1991). If the amino acid volume in position 
201 is increased from that of glycine, a suggested steric inhibition confers BZ pharmacology 
to type II (Wingrove et al., 2002). The α1 subunit preference of zolpidem has also been 
confirmed in vivo (Crestani et al., 2000). 
In addition to the α subunit, γ2 is needed for high-affinity BZ binding (Pritchett et al., 
1989b), and the BZ binding site is located at the interface between the α and γ2 subunits 
(reviewed in Smith and Olsen, 1995). The type of β subunit variant has no major role 
(Pritchett et al., 1989a). The δ subunit-containing receptors have no BZ binding sites (Quirk et 
al., 1995). In the γ2 subunit at least the amino acid residues Phe77 (Buhr et al., 1997) and 
Met130 (Buhr and Sigel, 1997) are shown to be important. Thr142 seems to be the critical 
amino acid in determining the efficacy of the BZ ligand, since mutations in this amino acid 
may convert negative or neutral modulators to positive ones (Mihic et al., 1994). Receptors 
containing γ1 or γ3 subunits also possess a BZ binding site, and the affinity and efficacy of 
BZ ligands are modulated by the type of γ variant (Knoflach et al., 1991; Puia et al., 1991; 
Herb et al., 1992; Wafford et al., 1993; Lüddens et al., 1994). Since the γ2 subunit is the 
major γ subunit in the brain, the γ1- and γ3-containing receptors are of minor importance in 
BZ modulation, as supported by the finding that in the γ2 knockout mice, 94 % of the brain 
BZ binding sites are abolished (Günther et al., 1995).  
 
2.5.4. DMCM 
DMCM (methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate) has two distinct binding 
sites in GABAA receptors. It is a BZ site inverse agonist in the receptors containing α subunit 
other than α6 (Im et al., 1995b; Knoflach et al., 1996; Saxena and Macdonald, 1996). 
Through BZ inverse agonism, DMCM has in vivo stimulant, anxiogenic and proconvulsant 
actions. Whether partial agonism of α6 subunit-containing receptors’ BZ site takes place in 
vivo, is currently unknown. However, the His101Arg mutation of α1 subunit is enough to 
confer DMCM from an inverse agonist to a partial agonist in vitro, and leads to complete 
abolition of proconvulsant actions of DMCM in vivo (Crestani et al., 2002b). 
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In addition to the BZ site, DMCM acts as a low-affinity positive modulator independent 
of BZ binding (Im et al., 1995b). This action is dependent on the presence of the β2/3 subunit, 
since DMCM is inactive in the β1 subunit-containing receptors (Stevenson et al., 1995). 
Similarly to antiepileptic loreclezole (Wingrove et al., 1994), anesthetic etomidate (Belelli et 
al., 1997) and loop diuretic furosemide (see below), Asn290 in β2/3 (Ser in β1) is the crucial 
amino acid for low-affinity positive actions of DMCM (Stevenson et al., 1995). It is currently 
not known whether this residue forms a binding site for the compounds, or is merely a site for 
allosteric coupling. The potentiation is basically independent of the type of α subunit, but it is 
more pronounced in α6 subunit-containing receptors, possibly due to the lack of DMCM 
inverse agonism via the BZ site (Stevenson et al., 1995).  
 
2.5.5. Furosemide 
Furosemide is a loop diuretic widely used in cardiovascular diseases. Its diuretic actions are 
mediated by reversible binding to the Na+/2Cl-/K+ transporter in the renal loops of Henle, 
which results in decreased reabsorption of NaCl and water. In addition to the peripheral 
effects, furosemide has been found to block GABA currents in frog spinal cord (Nicoll, 1978). 
However, since furosemide does not cross the blood-brain barrier, it does not have central 
effects in vivo. Korpi et al. (1995a) showed that furosemide interacts specifically with 
recombinant α6β2/3γ2 GABAA receptors and antagonizes the effects of GABA in the 
cerebellar granule cell layer, although it was inactive in other brain regions and in 
recombinant α6β1γ2 and α1β1/2/3γ2 receptors. Since another loop diuretic, bumetadine, was 
without an antagonistic effect, the furosemide antagonism was concluded to be independent of 
the ion transporter actions (Korpi et al., 1995a). Since furosemide did not interact with 
GABA, BZ or diazepam-insensitive Ro 15-4513 binding, a novel allosteric binding site was 
suggested (Korpi et al., 1995a). Later on furosemide actions were demonstrated to be 
independent of the presence of γ or δ subunits (Korpi and Lüddens, 1997). Antagonism has 
also been detected in recombinant α4β2γ2 receptors (Knoflach et al., 1996; Wafford et al., 
1996), but the effect was not observed in [35S]TBPS autoradiography in brain regions where 
an α4 subunit was expressed (Korpi and Lüddens, 1997). However, furosemide-sensitive 
GABA currents have been detected in hippocampal slices (Pearce, 1993). 
Furosemide antagonism of α6 subunit-containing receptors has been studied with α1/α6 
subunit chimeras and point mutations. It was first shown with chimeric constructs that the 
main determinant for furosemide action is located in the N-terminal part of the TM1 of the α6 
subunit (Fisher et al., 1997; Jackel et al., 1998), and isoleusine at position 228 was later 
shown to be  the most important amino acid (Thompson et al., 1999). However, all other α 
subunit variants have threonine in this position (personal observation), including the 
furosemide-sensitive α4 subunit, and thus additional factors conferring furosemide sensitivity 
must also exist. Furosemide has only intermediate sensitivity in α4 subunit-containing 
receptors (> 50 fold more sensitive than α1, α2, α3 or α5) when compared to α6 (> 500-fold 
more sensitive; Wafford et al., 1996), which might be explained by Ile228 in α6. Another 
domain of lower potency for furosemide might be present in the C-terminal part of the α6 
subunit starting from TM2 (Jackel et al., 1998). Similar β subunit selectivity as for DMCM 
(see above), the antiepileptic loreclezole (Wingrove et al., 1994) and anesthetic etomidate 
(Belelli et al., 1997) suggested that furosemide shared the requirement for Asn in TM2 of the 
β2/3 subunits (Ser in β1), which was later on confirmed (Thompson et al., 1999). 
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2.6. Tiagabine 
After synaptic release, GABA is taken up to neurons and glial cells by GABA transporters 
(GAT-1-4) together with Na+ and Cl- ions (1:2:1 ratio, respectively; reviewed in Borden, 
1996). GAT-1 is the major transporter subtype throughout the brain. Tiagabine is a selective 
GAT-1 blocker (Borden et al., 1994), that is used in the treatment of epilepsy. Tiagabine 
exerts its antiepileptic actions by raising the extracellular GABA levels (Fink-Jensen et al., 
1992) to the submicromolar range (Dalby, 2000). Tiagabine and/or other GAT-1 blockers 
have been shown to increase tonic background inhibition (Frahm et al., 2001; Overstreet and 
Westbrook, 2001; Nusser and Mody, 2002; Wisden et al., 2002; Jensen et al., 2003), and 
GAT-1 knockout mice display increased tonic inhibition (Jensen et al., 2003). In addition, 
tiagabine and/or other GAT-1 blockers have been shown to increase synaptic inhibition by 
prolonging the decay of evoked IPSCs and IPSPs (Dingledine and Korn, 1985; Roepstorff and 
Lambert, 1992; Thompson and Gähwiler, 1992; Draguhn and Heinemann, 1996; Overstreet 
and Westbrook, 2003). Usually, no changes in mIPSC amplitude or decay are detected 
(Jensen et al., 2003; Overstreet and Westbrook, 2003). These data suggest that GAT blockers 
do not affect individual synapses, but somehow regulate cross talk between synapses 
(Overstreet and Westbrook, 2003). However, Nusser and Mody (2002) found no effects on 
synaptic GABAAergic inhibition by these drugs.  
 
2.7. GABAA receptors in disease 
It is difficult to demonstrate a causative role for disturbed GABAA receptor function in the 
pathophysiology of any disease, but a connection between these two may be surmised on the 
basis of the following findings: 1) a genetic linkage between disease incidence and, e.g., 
receptor mutation, 2) altered GABAA receptor function (due to changes in receptor subunit 
composition or subunit expression) in the disease, 3) mouse models with selective GABAA 
receptor alterations displaying similarities to human disease, 4) good efficacy of GABAAergic 
drugs in the treatment of the disease. Based on these criteria, a role for the GABAAergic 
system may be proposed in a variety of neurological and psychiatric diseases. A detailed 
description of GABAA receptor function in anxiety and in epilepsy is given in the following 
sections. Other diseases linked with an altered GABAAergic system, or which can be 
efficiently treated with GABAAergic drugs, include at least alcoholism (Davies, 2003), 
Angelman’s syndrome (DeLorey and Olsen, 1999), autism (Buxbaum et al., 2002), depression 
(Brambilla et al., 2003), premenstrual syndrome (Smith et al., 1998), schizophrenia (Benes, 
1999) and sleep disorders (Lancel, 1999). 
 
2.7.1. Anxiety 
Anxiety is a normal response to stressful stimuli, but purposeless or prolonged anxiety is 
pathological. In stress, the hypothalamic-pituitary-adrenal (HPA) axis is activated, including 
hypothalamic corticotropin releasing hormone (CRF) secretion and adrenal cortisol secretion. 
HPA is inhibited by cortisol via a negative feedback mechanism. In anxiety (including panic 
disorder, post-traumatic stress disorder and generalized anxiety disorder) elevated HPA 
activation persists, which affects the CRF-containing neurons in the hypothalamus, but also in 
many other brain regions such as the hippocampus, amygdala, locus coeruleus, prefrontal 
cortex and cingulate gyrus. These areas are important in the expression of anxiety (reviewed 
in Coplan and Lydiard, 1998). GABA, with other neurotransmitter systems, is important in 
keeping homeostasis during stress, for it opposes the actions of CRF on the HPA axis 
(reviewed in Lydiard, 2003).  
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 Patients with anxiety have decreased BZ binding in many brain regions (Tiihonen et 
al., 1997; Malizia et al., 1998; Bremner et al., 2000a; Bremner et al., 2000b). These findings 
are supported by the decreased BZ binding in the mouse line heterozygous for GABAA 
receptor γ2 subunit deletion (γ2+/-), which displays a behavioral phenotype of the human 
generalized anxiety disorder (Crestani et al., 1999). Brain GABA levels have been shown to 
be decreased in anxious patients (Goddard et al., 2001), but the results of measuring plasma or 
cerebrospinal fluid GABA levels are controversial, and no firm conclusion about GABA 
levels can be drawn. 
Strong evidence for a role of GABAA receptors in anxiety derives from its treatment. 
Traditionally, anxiety has been relieved by self-administration of ethanol. Barbiturates have 
also been found to efficiently decrease anxiety, but due to side effects their use in anxiety 
disorders is nowadays minimal. Elevating brain GABA levels with tiagabine has been shown 
to be promising approach to treat anxiety (Zwanzger et al., 2003). THIP has also been shown 
to have anxiolytic activity in animal models (Gulinello et al., 2003; Liang et al., 2004). 
Today the BZs are by far the most widely used anxiolytic agents in Finland, as in 1995-
1996 2.6 % of the population used them daily (Klaukka, 1999). Even though antidepressants 
are now suggested as the first choice treatment for anxiety (Gorman, 2003), largely due to 
their safety profile, BZs are very effective in short-term use. While full positive BZ site 
ligands, such as diazepam, are anxiolytic, inverse agonists are anxiogenic (reviewed in Korpi 
et al., 1997), which suggests a key role for the BZ binding site in the pathophysiology of 
anxiety. The aforementioned α subunit-dependent BZ binding site heterogeneity has made it 
possible to dissect the different behavioral actions of BZs to different receptor subtypes. In 
studies with transgenic mouse lines, an animal model with a point mutation in GABAA 
receptor α2 subunit was created that selectively lacked the anxiolytic effects of BZs, while 
other pharmacological effects of BZs were restored (Low et al., 2000). The α2 subunit-
containing receptors are found mainly in the pyramidal cells of the hippocampus, where they 
are selectively modulated by a subset of interneurons (reviewed in Freund, 2003). These 
interneurons are modulated by serotonin, acetylcholine and cannabinoid systems, and act like 
sensors for mood. This link may explain the efficacy of antidepressants in the treatment of 
anxiety. Demonstration of the key role of the GABAA receptor α2 subunit in anxiolytic 
effects of BZs considerably strengthens the GABAAergic hypothesis of anxiety, and leads the 
way for selective drug design (Rudolph et al., 2001). Unfortunately, no α2-selective ligands 
are currently available, but they are supposed to largely lack the sedative, amnesic and muscle 
relaxant side effects of classical BZs, and hopefully possess a lower liability for abuse 
(Rudolph et al., 2001). 
 
2.7.2. Epilepsy 
Epilepsy is a heterogeneous neurological disorder characterized by involuntary seizures. The 
etiology of epilepsy varies from brain injuries or tumors to genetic abnormalities, and in many 
cases the cause is unknown. The exact mechanisms underlying seizure induction and 
propagation are still unrevealed, but, basically, epilepsy is a consequence of imbalance 
between excitation and inhibition leading to intense spontaneous local activity of neurons.  
Seizures may be categorized as partial or generalized, the former usually not including 
disturbed consciousness, while the latter always does. In the normal brain, cortical pyramidal 
cell groups undergo rhythmic depolarizations mediated by glutamate and voltage-dependent 
channels resulting in synchronous bursts of action potentials (reviewed in Dichter, 1997). This 
depolarization shift is followed by prolonged hyperpolarization mediated at least by voltage-
dependent potassium currents, calcium-dependent potassium currents, and GABAA and 
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GABAB receptors. In partial epilepsy the hyperpolarization phase is gradually decreased, and 
neurons are tonically depolarized. Depolarization leads to simultaneous and repetitive 
neuronal firing, which generates a seizure. Generalized seizures result from hypersynchrony 
of thalamocortical oscillations (Dichter, 1997), and are categorized to absence and tonic-
clonic seizures. Absence seizures are characterized by short loss of consciousness without 
convulsions, and they originate from a disturbed thalamocortical loop. Generalized tonic-
clonic seizures correspond to the most well-known “classical epileptic attack” with 
generalized motor seizures and loss of consciousness. Cortex, limbic structures (such as the 
hippocampus and amygdala) and the thalamus are important in the generation of clonic 
convulsions, whereas tonic convulsions originate from the brainstem (Browning and Nelson, 
1986; Gale, 1992). However, both clonic and tonic seizures, once commenced, strongly 
activate the forebrain regions (Samoriski et al., 1997). Absence and motor seizures might 
share a common pathophysiology, as suggested by the finding that a rat line with genetic 
absence epilepsy is also more sensitive to convulsions produced by GABAA receptor negative 
modulators than a control rat line (Vergnes et al., 2000).  
The role of GABAA receptors in the generation of seizures is supported by animal 
studies where convulsions may be produced by systemic administration of GABAA receptor 
negative modulators, such as DMCM and picrotoxinin. Cortical areas are most susceptible to 
picrotoxinin-induced convulsions (Vergnes et al., 2000), and the frontal cortex seems to be 
the lead area (Medvedev et al., 1996). In addition to cortical areas, the hippocampus and 
amygdala are also highly sensitive to the convulsive properties of DMCM (Vergnes et al., 
2000). Picrotoxinin usually causes progressive convulsions, where writhing clonus (a brief 
episode of symmetrical forelimb clonus and a jerk of the neck) is followed by a generalized 
tonic-clonic convulsion, and then by a tonic hindlimb extensor convulsion. DMCM usually 
induces writhing clonus, which is only sometimes followed by a generalized tonic-clonic 
convulsion (Kosobud and Crabbe, 1990). During a prolonged seizure, status epilepticus, the 
GABAA receptor function has been shown to be decreased in the hippocampal CA1 region 
due to the reduced potency and efficacy of GABA and the reduced driving force for GABA-
gated chloride currents (Kapur and Coulter, 1995). 
In addition to acute seizures, which may be triggered by various stimuli, epilepsy may 
be examined from a developmental point of view. The hippocampus has proved a suitable 
model region in research of the development of epilepsy (reviewed in Avoli et al., 2002). 
During epileptogenesis, complex changes in the neuronal circuits take place, since 
hippocampal formation is one of the most seizure-prone areas in the brain. Synchronous ictal 
activity in the entorhinal cortex may paradoxically be initiated by the GABAA receptor-
mediated mechanisms. From the entorhinal cortex, ictal activity propagates successively to 
the dentate gyrus, the CA3 and CA1 regions, and the subiculum. Seizures cause destruction of 
the CA1 and CA3 pyramidal cells and the dentate hilus, with relative sparing of the dentate 
granule cells and sprouting of their axon terminals (Figure 5). Axonal sprouting leads to 
recurrent excitation of dentate granule cells and increased excitability (Cronin et al., 1992). In 
addition to the dentate gyrus, extensive reorganization of axon collaterals has also been 
detected in the CA1 region, including formation of intra-CA1 and retrograde CA1-CA3 
connections as well as retrograde connection between the  subiculum and the CA1 region 
(Lehmann et al., 2001). In addition to the altered excitation, GABAergic inhibition in the 
epileptic hippocampus is impaired. Possible mechanisms include disconnection of inhibitory 
interneurons from excitatory inputs (Sloviter, 1987), use-dependent reduction of excitatory 
drive to inhibitory interneurons (Doherty and Dingledine, 2001), alterations in the number of 
GABAA receptors (Titulaer et al., 1994; Titulaer et al., 1995a, b; Nusser et al., 1998b), 
alterations in GABAA receptor subunit composition (Rice et al., 1996; Brooks-Kayal et al., 
1998; Sperk et al., 1998), increased sensitivity to Zn2+ inhibition of GABAA receptors in the 
dentate granule cells (Buhl et al., 1996; Gibbs et al., 1997; Brooks-Kayal et al., 1998), and a 
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decrease in GABA transporter function (Williamson et al., 1995). In addition, mutations in 
GABAA receptor subunits have been described in patients with epilepsy. A point mutation in 
the γ2 subunit that greatly decreased the efficacy of GABA was detected in a family with 
inheritable generalized epilepsy (Baulac et al., 2001). Another mutation in the γ2 subunit, 
which abolishes the BZ sensitivity of the receptor in vitro, has been linked to childhood 
absence epilepsy and febrile seizures (Wallace et al., 2001). In juvenile myoclonic epilepsy, a 
mutation in α1 subunit, which decreases receptor function (Cossette et al., 2002; Fisher, 
2004), has been detected (Cossette et al., 2002). Recently, a genetic variation in δ subunit, 
which decreased GABA-induced currents, was associated with generalized epilepsy with 
febrile seizures (Dibbens et al., 2004). 
 The essential role of GABAA receptors both in acute seizures and in epilepsy is 
supported by the mechanisms of action of anticonvulsive and antiepileptic drugs. In acute 
seizures, and during the status epilepticus, BZs are the most effective treatment. In the long 
term treatment of epilepsy, drugs that inhibit voltage-dependent sodium currents (e.g., 
carbamazepine, phenytoin) are most widely used, but also enhancement of the actions of 
GABA is also applied by, e.g., tiagabine, vigabatrin and topiramate.  
 
 
 
 
Figure 5. A simplified presentation 
of a dentate granule cell (DG) circuit 
in the normal (A.) and the epileptic 
(B.) hippocampus. A. Perforant 
pathway (PP) from the entorhinal 
cortex excites dentate granule cells, 
which relay excitation via the mossy 
fiber pathway (MFP) to the CA3 
region.  Mossy fibers also excite 
inhibitory interneurons (IIN) and 
mossy cells (MC), which project to 
other dentate granule cells. B. 
Seizures destroy mossy cells, which 
causes mossy fiber sprouting. 
Seizures also increase the rate of 
granule cell replication leading to 
generation of granule cells with both 
apical and basal dendrites (BD) and 
generation of ectopic hilar granule 
cells (HG). Also inhibitory 
interneurons are damaged (not 
shown). Mossy fiber collaterals form 
synapses with granule cell apical 
dendrites, with atypical basal 
dendrites and with ectopic hilar 
granule cells. Through these 
synapses granule cells excite other 
granule cells with glutamate. Zn2+ is 
co-released and it blocks inhibitory 
GABAA receptors of granule cells, 
leading to further excitation. 
Modified from Nadler (2003). 
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2.8. GABAAergic drug therapy and its problems 
Drugs potentiating GABAA receptor function are widely used clinically to treat alcohol 
withdrawal, anxiety disorders, epilepsy, febrile convulsions, and sleep disorders. They are 
also used in general anesthesia. The problem of GABAAergic drug therapy is not insufficient 
efficacy but nonselective actions. The GABAAergic system is so widely distributed in the 
brain, that receptor subtype nonselective drug therapy by, e.g., classical BZs cause too 
powerful and nonspecific actions. Use of nonselective BZs, in addition to the desired 
anticonvulsive, muscle-relaxant, sedative and anxiolytic effects, leads to many side-effects 
(dizziness, ataxia, dysarthria, drowsiness, paradoxical anxiety/hostility, mild cognitive deficits 
and amnesia), development of dependence, tolerance and abuse, and to potentiation of the 
effects of other CNS-affecting drugs (reviewed in e.g., Lader, 1995). These are clinically 
important issues and have lead, e.g., to avoidance of BZ use in the long-term treatment of 
anxiety (Gorman, 2003), even though, in acute situations, BZs are the most potent anxiolytics. 
As indicated in section 2.5.3., studying the heterogeneity of the BZ binding site has 
revealed that different behavioral effects of BZs are mediated by receptors containing 
different α subunits. Selective therapy against different subtypes might offer the possibility to 
escape the problems of nonselective drugs. This idea is strengthened by the finding that abuse 
of non-anxiolytic α1 subunit-preferring zolpidem-like sedatives is low (Jaffe et al., 2004). In 
addition to the BZ binding site, another heterogeneity, now in β subunits, has recently been 
introduced that mediates different behavioral effects. By mutating the residue in the β3 
(Asn265 to Met) subunits that differentiates β1 from β2 and β3 in respect to loreclezole, 
DMCM, furosemide and etomidate sensitivity, resulted in decreased anesthetic actions of 
etomidate and propofol, but not clearly those of neurosteroids and inhalation anesthetics (Jurd 
et al., 2003). These data suggest that, in addition to BZ binding sites, significant 
heterogeneities exist in the other GABAA receptor effector sites as well. The therapeutic 
potential of the heterogeneity of these binding sites is still unrevealed. 
In addition to the binding site heterogeneities, there is another possibility for receptor 
subtype specific drug treatment. It is offered by the differential subcellular distribution and 
special pharmacological properties of receptor subtypes in synaptic and extrasynaptic loci. 
Traditionally, GABAAergic drug therapy has been thought to affect synaptic receptors, but a 
recent study raised the possibility that the major site of actions of the anesthetic propofol 
might be the extrasynaptic receptors (Bieda and MacIver, 2004). With knowledge of the 
probable subunit composition of extrasynaptic receptors, it might be possible to selectively 
modulate tonic inhibition. This might lead to novel therapeutic strategies and safer treatment. 
This is supported by a recent finding that THIP, a GABA binding site partial agonist in most 
receptor subtypes but a full agonist in α4 and δ subunit-containing receptors (Brown et al., 
2002), more efficiently relieved anxiety in a rat model of the premenstrual syndrome, where 
extrasynaptic α4βδ receptors are upregulated, than in control rats (Gulinello et al., 2003). In 
addition, there seems to be no development of tolerance to the anxiolytic effects of THIP 
(Liang et al., 2004). 
Taken together, the future directions in GABAAergic drug research should include 
identification and characterization of novel receptor subtypes in the brain and elucidation of 
behavioral significance of already known receptor subtypes. Subsequent development of 
selective ligands for these receptor subtypes would offer the possibility to avoid the problems 
of nonselective therapy.  
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3. AIMS OF THE STUDY 
The current project was targeted to characterize the atypically weak coupling between 
GABAA receptor agonist and convulsant binding sites (GIS-[35S]TBPS binding) detected 
previously in the rat cerebellar granule cell layer (Korpi and Lüddens, 1993). The 
characterization was aimed to consist of a multilevel approach to ultimately elucidate, which 
receptor subtypes are responsible for GIS-[35S]TBPS binding, and what are their properties 
and possible functions in the brain. For this, the following specific aims were placed: 
 
1. to develop a receptor autoradiographic method to better visualize the GIS-[35S]TBPS  
    binding 
 
2. to investigate the prevalence of GIS-[35S]TBPS binding in different species 
 
3. to reveal the molecular determinants and the mechanisms leading to GIS-[35S]TBPS      
    binding 
 
4. to study the functional and behavioral significance of receptors showing GIS-[35S]TBPS   
    binding 
 
5. to search for novel drug interactions in GABAA receptors with GIS-[35S]TBPS binding    
    autoradiography.  
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4. MATERIALS AND METHODS 
All the experiments were done with the permission of the Institutional Animal Use and Care 
Committee of the University of Turku, Turku, Finland. When needed, permissions were 
obtained from the Western Finland Provincial Government. 
 
4.1. Experimental animals 
Male Wistar and Sprague-Dawley rats aged 4 months (I, n = 26; II, n = 8; V, n = 4) were 
used.  
The human brain (I, n = 1) was obtained from clinical autopsy at the Department of 
Forensic Medicine, University of Oulu, Oulu, Finland. The brain autopsy was approved by 
the Ethics Committee of the University of Oulu and National Institute of Medicolegal Affairs, 
Helsinki, Finland. On the basis of medicolegal autopsy findings and medical records the case 
was determined as a normal control without medications affecting the central nervous system.  
One-day-old White Leghorn chickens (I; n = 6) were used. 
The following genetically-engineered mouse lines were used in the study and they were 
produced by collaborators as described below in the original references: three adult (one male 
and two females) β3-/- mice (Homanics et al., 1997a) with three wild-type controls (II); four 
male α6-/- (Homanics et al., 1997b), three male δ−/− (Mihalek et al., 1999) and five male 
wild-type control mice (II); ten adult male γ2+/- mice (Crestani et al., 1999) with nine 
littermate controls (III); male and female Thy1α6; Wisden et al., 2002; n = 85 and 61) and 
control (n = 86 and 47 for males and females, respectively) mice at the ages of 2 – 5 months 
or 16 – 20 days (IV). 
Oocytes from female Xenopus laevis frogs were used (V). 
 
 4.2. Ligand autoradiographic assays (I, II, III, IV, V) 
Receptor autoradiography of brain sections with selective ligands for GABAA receptor 
binding sites can be used to image the different GABAA receptor populations in the brain. 
Basically, thin sections are cut from frozen brain, and the sections are adhered to microscope 
slides. While most cells are destroyed during preparation, receptors remain intact. During 
incubation in optimized conditions, the radioactively labeled ligand binds to its binding site in 
the receptor complex on the brain section. After incubation, the unbound ligand is washed 
away in conditions that do not cause dissociation of the bound ligand. The washed sections 
are then dried, and microscope slides containing brain sections are exposed to irradiation-
sensitive films. When the films are developed during the linear phase of exposure, the amount 
of irradiation detected by the film reflects the amount of ligand bound to the receptors in any 
particular brain area. All ligands have some nonspecific binding to brain tissue, but the 
amount of nonspecific binding can be determined by displacing the radioactively labeled 
ligand from its specific binding sites by competitive compounds.    
 
4.2.1. Preparation of brain sections (I, II, III, IV, V) 
To avoid degradation of receptor proteins, the brain samples were frozen on dry ice (solid 
CO2) as soon as possible after dissection. Thereafter, they were wrapped in plastic and stored 
at - 80 °C until cut. Thin (14-µm for all other but 100-µm for human cerebral hemispheres) 
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frozen brain sections were cut in a cryostat at -20 °C. The sections were thaw-mounted onto 
gelatin-coated object glasses, air-dried, and stored frozen under desiccant at -20 °C. Freezing 
and sectioning of the brain destroy individual neurons, but when handled and stored properly, 
the receptor proteins on sections are preserved for several years. The macroscopic anatomy, 
i.e. the arrangement of the different brain regions on the sections, is also well preserved.  
 
4.2.2. [35S]TBPS binding (I, II, III, IV, V) 
First autoradiographic studies with [35S]TBPS showed that it might be used on brain sections 
(Gee et al., 1983; Wamsley et al., 1983). In slide-mounted cerebrocortical mash slice receptor 
autoradiography [35S]TBPS had Kd of about 20 nM and only 2-4 % of the binding was 
nonspecific with 2 nM [35S]TBPS (Edgar and Schwartz, 1990). In the same study with brain 
sections, nonspecific binding was not detectable. 
In the present study, two procedures for [35S]TBPS autoradiography were used. In 
general, the frozen object glasses with brain sections were thawed and encircled with a PAP-
pen. Thereafter, sections were preincubated in ice-cold buffer containing 50 mM Tris 
[tris(hydroxymethyl)aminomethane]-HCl (pH 7.4) supplemented with 120 mM NaCl for 15 
min to remove endogenous GABA. In the final incubation at room temperature for 90 min, an 
800-µl bubble of incubation medium was applied on sections that were placed horizontally on 
an incubation platter. This reduced the required amount of radioactive ligand. In the standard 
assay (III; Edgar and Schwartz, 1990; Olsen et al., 1990; Korpi et al., 1995b) the final 
incubation in preincubation buffer was done with [35S]TBPS (PerkinElmer Life Sciences Inc., 
Boston, MA, USA; diluted with cold TBPS to a final concentration of 6 nM, about 150 
dpm/µl). After incubation, the sections were washed 3 x 15 s in ice-cold 10 mM Tris-HCl (pH 
7.4). The sections were then dipped in distilled water, air-dried at room temperature, and 
exposed with a plastic 14C-standard to autoradiographic films for 2 weeks. Nonspecific 
binding was determined with 100 µM picrotoxinin, which competitively bound to the same 
binding site, and displaced [35S]TBPS.  
A modified [35S]TBPS binding assay (I, II, III, IV, V) was developed to reveal the 
GABA-insensitive [35S]TBPS binding component. The procedure was otherwise similar to the 
standard assay, but final incubation was performed with 3-6 nM (as high as possible without 
the brain labeling exceeding the activity of the highest 14C-standard) hot [35S]TBPS (about 
350 – 800 dpm/µl), and the washing time was lengthened to 3 x 30 min. Sections were 
exposed to autoradiographic films with 14C-standard for 2 days to several weeks. 
Modulation of [35S]TBPS binding by various GABAA receptor agonists and antagonists 
in both procedures was studied by incubating those compounds together with [35S]TBPS. 
Because we always used TBPS concentrations (3-6 nM) well below Kd of about 50 nM under 
our experimental conditions (Figure 7, Sinkkonen S.T. et al., unpublished results), our results 
only partially mirror the total amount of [35S]TBPS binding sites in the brain. As well, we 
used pre-equilibrium binding of 90 min, which, in the absence of positive GABAA receptor 
modulators,  yields only about 70 % of the total binding (Maksay and Simonyi, 1986). 
However, as discussed above, pre-equilibrium conditions may be used deliberately when 
screening for receptor subtype heterogeneities.   
 
4.2.3. [3H]Ro 15-4513 binding (I, III, IV) 
The autoradiographic procedure for [3H]Ro 15-4513 binding to GABAA receptor BZ binding 
site was performed as described (Olsen et al., 1990; Mäkelä et al., 1997). BZ binding site 
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hereterogeneity prevents labeling of all sites with full agonists such as flunitrazepam, but 
[3H]Ro 15-4513 binds to all known BZ sites (Sieghart et al., 1987). In autoradiography, the 
brain sections were preincubated in ice-cold incubation buffer (50 mM Tris-HCl 
supplemented with 120 mM NaCl; pH 7.4) to remove endogenous GABA. Thereafter 5-10 
nM [3H]Ro 15-4513 (PerkinElmer Life Sciences Inc., Boston, MA, USA) binding in plastic 
20-ml incubation containers was performed at 0-4 °C for 60 min. Since [3H]Ro 15-4513 can 
be used to photoaffinity label BZ sites (Sieghart et al., 1987), incubation was performed in the 
dark. Nonspecific binding was determined with the BZ site competitive antagonist flumazenil, 
which displaced [3H]Ro 15-4513 totally. After incubation, the sections were washed, air-
dried, and exposed with a plastic 3H-standard to autoradiographic films. Since only one 
concentration of [3H]Ro 15-4513 near the Kd (Korpi et al., 1993; Löw et al., 2000) was used, 
our results with [3H]Ro 15-4513 binding only partially reflect the total amount of BZ binding 
sites in the brain.  
 
4.2.4. [3H]Muscimol binding (I, III) 
The autoradiographic procedure for [3H]muscimol binding to GABAA receptor GABA 
binding site was carried out as described (Olsen et al., 1990; Mäkelä et al., 1997). While it is 
meaningful that all native GABAA receptors contain an agonist binding site, [3H]muscimol 
under our experimental conditions seems to preferentially label receptors containing α6 
and/or δ subunit (Korpi et al., 2002b). In the autoradiographic procedure, to remove 
endogenous GABA, slides were preincubated in ice-cold 0.31 M Tris-citrate (pH 7.1) for 15 
min. Final incubation in the preincubation buffer was performed with 6-10 nM [3H]muscimol 
(Amersham Biosciences Corp.) at 0-4 °C for 30 min in plastic 20-ml incubation containers. 
[3H]Muscimol binding was performed at low temperature without sodium ions to inactivate 
the GABA transport system. Since [3H]muscimol can be used to photoaffinity label GABA 
sites (Cavalla and Neff, 1985), incubation was performed in the dark. Nonspecific binding 
was determined with GABA, which bound competitively to the GABA sites, and displaced 
[3H]muscimol totally. After incubation, sections were washed, air-dried, and exposed with a 
plastic 3H-standard to autoradiographic films. Since only one concentration of [3H]muscimol 
near the Kd (Uusi-Oukari and Korpi, 1989; Wisden et al., 1991) was used, our results only 
partially reflect the total amount of high-affinity [3H]muscimol binding sites in the brain. 
 
4.3. Localization of GABAA receptor subunits by in situ hybridization (II)  
In the in situ hybridization (ISH) procedure a radioactively labeled nucleic acid probe is 
allowed to hybridize with its complementary mRNA molecule on brain sections. The probe-
mRNA duplex formed can be visualized on irradiation-sensitive films similar to ligand 
binding receptor autoradiography. Since proteins are synthesized according to the directions 
encoded in mRNAs, radioactive signals from ISH can be used to map the cells and brain areas 
that express the proteins of interest. As with receptor proteins, mRNA remains intact and 
detectable on brain sections when processed properly. When working with mRNA, 
contamination by the RNA degrading enzyme RNAse must be avoided by using plastic 
gloves, sterile equipment, and diethyl-pyrocarbonate-treated and autoclaved solutions. Brain 
samples were processed identically to ligand autoradiography, but poly-L-lysine-coated 
microscope slides and storage at -80 °C were used. Paraformaldehyde fixation inactivates 
endogenous RNAse. After fixation, the sections were stored in 95 % ethanol at 4 °C until 
used. 
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ISH for detection of GABAA receptor subunit transcripts was done using the protocol 
described by Wisden and Morris (1994). Briefly, 36-45 base-long antisense oligonucleotide 
probes were synthesized complementary to rat (Institute of Biotechnology, University of 
Helsinki, Helsinki, Finland) GABAA receptor subunit cDNA sequences. Probes were [α-33P] 
(NEN Life Science Products, Boston, MA, USA) 3’end-labeled with terminal transferase. 
Unincorporated nucleotides were separated by chromatography columns. Hybridization buffer 
containing labeled probe was applied to each slide, and hybridized under parafilm coverslips 
overnight at 42 °C. Sections were then washed, dehydrated, dried and exposed to 
autoradiographic films with 14C standards. Specificity of probes was determined with 100 x 
excess of unlabeled probes. 
 
4.4. Quantitative autoradiographic film analysis (I, II, III, IV, V) 
To get quantitative measures of ligand binding and GABAA receptor subunit mRNA 
expression levels, autoradiography and ISH films were quantified using MCID AIS image 
analysis devices and programs (Imaging Research Inc., St. Catharines, Ontario, Canada) as 
described (Korpi et al., 1995b). Films were digitized and the plastic standards exposed 
simultaneously with the brain sections were used as references to create a standard curve. The 
binding densities for each brain area were quantified, and the resulting binding values were 
converted to radioactivity levels estimated for gray matter areas (in nCi/mg or nCi/g) using 
the standard curve. The specific binding or hybridization values were determined by 
subtracting the nonspecific binding or hybridization values from the corresponding total 
binding or hybridization values, respectively. 
 
4.5. Recombinant GABAA receptors in HEK 293 cells (III) 
Human embryonic kidney cells (HEK 293) are immortalized cancer cells that can be 
transfected with exogenous cDNA to produce various proteins. Protein targeting takes place 
according to the signal sequence of the transfected cDNA. Transfection with different 
GABAA receptor subunits results in receptor expression on cell surfaces. The receptor 
subtypes formed were then used in binding studies. 
 
4.5.1. Receptor expression 
Expression vectors (Shivers et al., 1989; Pritchett and Seeburg, 1990) for rat GABAA subunits 
were transfected into HEK 293 cells using a calcium phosphate precipitation method (Chen 
and Okayama, 1987) as described (Lüddens and Korpi, 1997). HEK 293 cells were plated on 
tissue culture dishes filled with medium. Cultures were incubated at 37 °C in a humidified 
95% O2/5% CO2 atmosphere for 2-3 days. In the transfection process, vectors containing the 
desired subunit cDNAs were mixed with phosphate-buffered saline and CaCl2. Calcium 
phosphate precipitates containing an arbitrary mixture of cDNA vectors were taken up by 
HEK 293 cells, which resulted in transient expression of recombinant GABAA receptors. Two 
days after transfection the cells were harvested, homogenized, washed by centrifugation and 
stored at –80 °C until binding experiments. 
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4.5.2. [35S]TBPS binding assay 
The membrane pellets were thawed and resuspended in 50 mM Tris/citrate buffer, pH 7.3. 
Resuspended cell membranes were incubated at room temperature with 6 nM [35S]TBPS in 50 
mM Tris-HCl (pH 7.3) supplemented with 200 mM NaCl in the absence or presence of 
GABA. Non-specific binding was determined by picrotoxinin. After incubation, the bound 
fraction of [35S]TBPS was separated by rapid filtration of the membrane homogenates with 
ice-cold 10 mM Tris/HCl onto glass fiber filters under reduced pressure. Thereafter, the filters 
were dried, immersed in scintillation fluid, and the radioactivity determined in a liquid 
scintillation counter. 
 
4.6. Electrophysiological recordings from acutely isolated mouse hippocampal 
CA1 pyramidal cells (IV) 
In order to study the possible functional expression of α6 subunit in the Thy1α6 mouse 
hippocampus, mice at the ages of 16 – 20 days were decapitated, their brains were dissected, 
and 300 – 400 µm thick coronal brain slices were cut. The CA1 neurons were dissociated by 
gentle mechanical trituration, and the whole-cell patch-clamp method (Hamill et al., 1981) on 
CA1 pyramidal cells was applied as described (Möykkynen et al., 2003). Cells were patch-
clamped at a holding potential of –60 mV. During the recording, the cells were constantly 
superfused with recording solution. Drugs were diluted in recording solution and applied to 
the cells with a multi-barrel fast solution application system. Currents evoked by drug 
application were recorded, filtered and digitized. Current amplitudes were measured from the 
baseline to the peak of the current trace using pClamp 8.0 software (Axon Instrument, Inc., 
Union City, CA, USA). 
 
4.7. Determination of receptor subunit composition (IV)  
To determine the abundance of αβ GABAA receptors in the hippocampi of control C57BL/6 
and mutant Thy1α6 mice, all receptors were first extracted from hippocampal brain 
membranes. Receptors were then immunoaffinity chromatographed with a series of columns 
containing subunit-specific antibodies. The subunit composition of the remaining receptors 
was then determined by immunoprecipitation with subunit-specific antibodies, and their 
amount was quantified with subsequent [3H]muscimol binding. 
 
4.7.1. Preparation of receptor extracts 
C57BL/6 and Thy1α6 adult mouse hippocampi in pools of 10 or 5, respectively, were used. 
The pools were suspended in deoxycholate buffer. The suspension was homogenized and 
incubated with intensive stirring for 1 hour at 4° C. After centrifugation at 150,000 g for 45 
min, the clear supernatant was used in immunoaffinity chromatography. 
 
4.7.2. Immunoaffinity chromatography 
Immunoaffinity columns were prepared by coupling 3-5 mg of the purified antibodies to  
ImmunoPure immobilized protein A using the ImmunoPure Protein A IgG Orientation Kit 
(Pierce, Rockford, IL, USA) according to the manufacturer’s instructions. The hippocampal 
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extract was chromatographed slowly at 4° C up to two times on the same affinity column in 
order to completely remove the receptors containing the respective subunit from the extract, 
regenerating the respective column after each chromatography step by washing it. 
 
4.7.3. Quantification of GABAA receptor subtypes by immunoprecipitation and 
[3H]muscimol binding assays 
For immunoprecipitation of the GABAA receptors present in the hippocampal extract, a 
sample of immunoaffinity column efflux was mixed with a solution containing subunit-
specific antibodies in order to precipitate receptors containing the respective subunit (Pöltl et 
al., 2003). For determination of the total amount of receptors before and after immunoaffinity 
columns, an antibody mixture containing antibodies for β1, β2, β3 and α1 was mixed with the 
original extract or column efflux. This antibody composition was used because all functional 
GABAA receptors are supposed to contain at least one of the three β subunits, and most of 
them contain an α1 subunit (Tretter et al., 2001; Pöltl et al., 2003). The mixtures were then 
incubated overnight with gentle shaking at 4 °C. The receptors were then precipitated, and the 
precipitate was centrifuged for 5 min at 2 300 g, and washed three times. 
 In order to quantify the amount of receptors in the original hippocampal extract or 
column efflux, or the amount of receptors precipitated by subunit-specific antibodies (α4, α6, 
γ1-3, δ; Pöltl et al., 2003) from the column efflux, [3H]muscimol binding was performed 
(Pöltl et al., 2003). The precipitated receptors were suspended in 1 ml of a solution containing 
0.1 % Triton X-100, 50 mM Tris/citrate buffer (pH 7.1) and 40 nM [3H]muscimol (29.5 
Ci/mmol, PerkinElmer Life Sciences) in the absence or presence of 1 mM GABA. After 
incubation for 1h at 4 °C, the suspensions were rapidly filtered through Whatman GF/B 
filters, washed twice with 3.5 ml of 50 mM Tris/citrate buffer (pH 7.1) and subjected to liquid 
scintillation counting. Binding in the presence of 1 mM GABA (nonspecific binding) was 
then subtracted from binding in the absence of GABA (total binding), resulting in specific 
binding to the precipitated GABAA receptors. 
 
4.8. Mouse behavioral studies (IV) 
4.8.1. Observational functional analysis by the SHIRPA protocol 
Even though transgenic animals offer the possibility to determine the role of a given gene in 
animal behavior, the effects of virtually selective genomic rearrangements might be 
widespread and nonselective. For this reason it is important to perform a basic observational 
functional analysis of new transgenic mouse lines before starting a detailed behavioral test.  
A modification of the primary screen of the SHIRPA protocol 
(www.mgu.har.mrc.ac.uk/mutabase/shirpa_summary.html) was used to analyze the 
physiology and basic neurological and behavioral properties of the Thy1α6 mice and their 
C57BL/6 controls, as described (Vekovischeva et al., 2004). Mice were observed with the 
bare eye in a viewing glass jar, in an open arena and on a grid floor. Mouse body position, 
spontaneous activity, respiratory rate and presence of tremor were evaluated in a viewing 
glass jar. The first behavioral reaction of a mouse placed at the centre of an open arena 
(transfer arousal), the number of crossed squares, the gait, the pelvic and the tail elevations 
were assessed. The grid floor was used as a support for the viewing jar and to measure tail 
suspension, grip strength and the negative geotaxis reflex. The negative geotaxis reflex was 
assessed as the possibility of a mouse to turn around and climb up on the grid floor quickly 
raised to the vertical plane. The sensorymotor response consisted of pinna, corneal and toe 
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pinch reflexes. Pinna and corneal reflexes were provoked by a stainless steel wire with a 
gentle touch on the ear lobe or the cornea of the eye. The toe pinch reaction was measured by 
pinching the central toe of the right hind paw with forceps. A click box generating a sudden 
tone at 90 dB was held 30 cm above the mouse to measure the startle reflex. Touch-escape 
behavior was determined as a response to a finger stroke of the back. Struggle-escape 
behavior combined the body position, touch-escape response and aggression toward an 
experimenter and the mouse vocalization provoked by handling.  
 
4.8.2. Light-dark choice test 
Mice and other rodents have a congenital aversion of brightly illuminated areas but 
simultaneously display spontaneous exploratory behavior. In the light-dark choice test 
(Crawley and Goodwin, 1980), mice have to make a decision between a “familiar - safe” dark 
area and a “new - fearful” illuminated area. Normally, mice have a high tendency to explore, 
and they often visit the illuminated area even though they prefer the dark compartment. 
Anxiety heightens the aversion to the novel environment (Crestani et al., 1999), and the light-
dark choice test can be used to test for this disturbance (Crawley and Goodwin, 1980). The 
light-dark test was started by placing a mouse in the light compartment of two-compartment 
box divided into one dark and one lit area with an open door between them (Crawley and 
Goodwin, 1980). The time before the first crossing to the dark compartment (latency), the 
number of crossings between compartments, and the time spent in the light compartment 
(minus the latency) were recorded (Vekovischeva et al., 2004). 
 
4.8.3. T-maze test 
Similar to the light-dark choice test, the T-maze test is based on the mouse’s natural desire to 
explore its territory. Exploration is important for learning and memory, which, in turn, are 
crucial for survival, because they enable the animal to know, e.g., where food is to be found 
and how to avoid predators. The T-maze alternation procedure allows measuring of 
exploratory behavior in an unbiased way (Gerlai, 1998). The T-maze consisted of three arms 
with three removable guillotine doors separating a short compartment at the beginning of the 
start arm and the other arms. The procedure consisted of one forced trial followed by choice 
trials during 10 min. Mice were individually placed in the short compartment. After 5 s of 
confinement, the door was lifted and the mouse was allowed to explore the start arm and one 
of the goal arms. Entry to the other goal arm was blocked. After this first, “forced” trial, the 
mice explored the areas available to them and eventually re-entered the start arm and moved 
down to the start compartment. When they entered the start compartment they were confined 
there for 5 s by closing the start compartment door. Before reopening the door, the door 
blocking one of the goal arms was also lifted. The start compartment door was then lifted and 
the first free choice trial began: the mice could choose between the two goal arms. After the 
mouse had chosen and entered half way down one goal arm, the other arm was blocked by the 
door. The mice left the explored goal arm and moved down to the start box again. They were 
confined there for 5 s and the testing cycle continued with another free choice trial as 
described above. The number of free choice trials was calculated as the level of mouse 
activity. An important aspect of the procedure was that the mice were not allowed to go from 
the chosen goal arm directly to the opposite goal arm. Once they had entered one of the goal 
arms at a particular choice trial, the opposite arm was blocked by closing the entrance door. 
This door was opened for the subsequent choice trial, which presented a novel change for the 
mouse at each choice trial. Since the presence of a novel stimulus in the goal arm has been 
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shown to elicit exploration of that goal arm, the mice were expected to explore the arm that 
was blocked at the previous trial. Consecutive choices made by the mice were measured, and 
the overall alternation rate was calculated (0 % = no alternation, 100 % = alternation at each 
trial).  
 
4.8.4. Convulsion tests 
GABAA receptor antagonists block GABA-induced chloride currents and cause neuronal 
hyperexcitability leading to brain seizures and involuntary muscle jerks called convulsions. 
Latency to convulsions after GABAA receptor antagonist administration can be used to 
determine the sensitivity of the mice to convulsions (Kosobud and Crabbe, 1990). In the 
present experiments, mice were injected intraperitoneally (i.p.) with different doses of either 
DMCM or picrotoxinin. After injection, the mice were placed in a transparent Plexiglass 
cylinder, their tails were tape-fixed, and latency to different convulsions was measured 
(Kosobud and Crabbe, 1990). The anticonvulsive effect of tiagabine was tested with i.p. 
injections 30 min prior to picrotoxinin administration. Mice were killed by cervical 
dislocation immediately after observing a generalized tonic-clonic convulsion or at the end of 
the 15 min observation period, whichever came first.  
 
4.9. Recombinant GABAA receptors in Xenopus oocytes (V) 
Xenopus oocytes can be used as protein expression machines, since they express and target 
proteins according to the RNA injected into their cytoplasm. Injection with a mixture of 
different GABAA receptor subunit cRNAs results in the formation of different receptor 
populations on the cell surface. The properties of these receptor subtypes can then be studied 
using electrophysiological techniques. 
 
4.9.1. Receptor expression 
Capped cRNAs coding for rat GABAA receptor subunits (Shivers et al., 1989; Ymer et al., 
1989; Seeburg et al., 1990; Jackel et al., 1998) were transcribed in vitro from pRK5 plasmids 
using mMessage mMachine kit (Ambion Inc., Austin, TX, USA). Oocytes from adult 
Xenopus laevis females were injected with mixtures of subunit cRNAs. After injection the 
oocytes were collagenase-treated to remove the follicular cell layer and incubated at 19 °C 
until recordings. 
 
4.9.2. Electrophysiological recordings 
To allow production of receptors, the electrophysiological recordings were made 1-3 days 
after cRNA injection. The function of recombinant GABAA receptors was studied using the 
two-electrode voltage-clamp method as described (Kuner et al., 1993). Oocytes were impaled 
with two microelectrodes and voltage-clamped at – 50 mV. Agonist application to the oocytes 
caused receptor activation and an inward current. The inward current needed to maintain the 
potential at -50 mV was measured. Currents were modulated by simultaneous drug 
applications. The amplitudes of the peak currents induced by GABA + drug applications were 
determined from the recorded traces, normalized to the corresponding GABA-induced peak 
currents. The peak currents induced by various GABA concentrations for each oocyte were 
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normalized by setting the saturating GABA-current at 100 %, and the GABA concentration-
response curves were generated using nonlinear regression fit. 
 
4.10. Statistics (I, II, III, IV, V) 
Statistics were performed with GraphPad Prism (GraphPad Software, San Diego, CA, USA) 
and SAS-STAT (SAS Institute, Cary, NC, USA) software programs. When the statistical 
significance of the difference between two groups was assessed, Student’s t-test was used. 
One-way analysis of variance (ANOVA) and Dunnett or Newman-Keuls post tests were used 
when the means of three or more groups were compared. Two-way ANOVA (factors: mouse 
line, brain region) with a Bonferroni post test was used to assess the statistical significance of 
the difference in ligand autoradiography of different brain regions between the γ2+/+ and 
γ2+/- mice. Behavioral tests were analyzed by two-way ANOVA (factors: gender and mouse 
line). Three-way ANOVA (factors: gender, mouse line, drug dose) was used to analyze the 
data from the convulsion experiments. When ANOVA revealed significant differences (p < 
0.05), it was followed by decreased-factor ANOVA or Dunnett post tests. 
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5. RESULTS AND DISCUSSION  
5.1. Development of a receptor autoradiographic method to reveal GABA-
insensitive [35S]TBPS binding (I) 
GABAA receptors in the brain can be imaged using radioactively labeled ligands for specific 
binding sites. Ligand binding can be studied with brain homogenates, brain sections or with 
PET or SPECT. Experimental studies are usually carried out with brain homogenates or 
sections, while PET and SPECT can be applied in clinical studies with living patients. 
Working with brain section receptor autoradiography instead of ligand binding to brain 
homogenates offers the advantage of spatial resolution. Since GABAA receptors have 
tremendous heterogeneity according to the brain region where they are expressed, brain 
sections should be used whenever possible to avoid summation of the effects by the various 
receptor subtypes in the brain homogenates. Anyhow, the biochemical and pharmacological 
characterization of ligand binding is more convenient with brain homogenates because of the 
easier preparation of samples, the simpler binding assay procedures and the faster analysis of 
data. For these reasons, binding of most of the radioactive ligands to the  picrotoxinin binding 
site of the GABAA receptor has been characterized with brain homogenates. Nevertheless, 
binding kinetics in brain sections and in homogenates are largely similar. 
The picrotoxin derivative [3H]α-dihydropicrotoxin has low affinity (Kd about 1 µM) 
and yields high (~ 80 %) nonspecific binding (Ticku et al., 1978) in brain homogenates. 
[3H]EBOB has a high affinity (Kd about 5 nM) and 3-6  % of the binding is nonspecific 
(Kume and Albin, 1994). [3H]TBOB has a relatively high affinity (Kd 60 nM), and 10-20 % 
of the total binding is nonspecific (Lawrence et al., 1985). In brain homogenates, 35S-labeled 
t-butylbicyclophosphorothionate ([35S]TBPS) has a high affinity (Kd about 15 nM) and about 
30 % nonspecific binding (Squires et al., 1983). However, with brain sections, nonspecific 
binding is very low (Edgar and Schwartz, 1990). The 35S label emits high energy β radiation 
as compared to 3H, which enables shorter exposure periods. For these reasons [35S]TBPS has 
proved superior to the other compounds in the picrotoxinin site receptor autoradiography, and 
so was chosen for the present studies.  
[35S]TBPS binding is considered to represent resting receptors, whereas its dissociation 
by GABA and other positive modulators is thought to be a biochemical measure of receptor 
activation, i.e., chloride flux (Im and Blakeman, 1991). Usually, low micromolar GABA leads 
to displacement of [35S]TBPS binding from brain homogenates or sections (Squires et al., 
1983; Edgar and Schwartz, 1990; Olsen et al., 1990; Korpi et al., 1995b), whereas GABA 
antagonists reverse the inhibitory effect of GABA (Squires et al., 1983; Squires and Saederup, 
1987). However, in the cerebellar granule cell layer, a minor receptor population with 
[35S]TBPS binding insensitive to the inhibitory effect of GABA has been reported (Edgar and 
Schwartz, 1990; Korpi and Lüddens, 1993). Edgar et al. (1990) found that in the presence of 
50 mM K2HPO4/ NaH2PO4 and 200 mM NaCl, 1 µM GABA displaced only 11 % of the 
[35S]TBPS binding in the internal rim of the cerebellar granule cell layer, while it was more 
effective in the molecular layer and the external rim of the granule cell layer. Korpi and 
Lüddens (1993) demonstrated that [35S]TBPS binding in the cerebellar granule cell layer was 
actually insensitive to 50 µM GABA in 50 mM Tris-HCl buffer supplemented with 120 mM 
NaCl, while, in all other brain regions, the binding was displaced.  
The first purpose of the thesis study was to develop an autoradiographic method to 
better visualize the GABA-insensitive component of [35S]TBPS binding (Korpi and Lüddens, 
1993). For this purpose, we modified the standard incubation conditions (Edgar and Schwartz, 
1990; Olsen et al., 1990; Korpi and Lüddens, 1993). To improve the sensitivity of the 
autoradiographic assay we increased the specific activity of the radioligand and always used 
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as high [35S]TBPS concentrations (3-6 nM) as possible without exceeding the activity of the 
14C standard. 90 min incubation with [35S]TBPS in the standard buffer (50 mM Tris-HCl 
supplemented with 120 mM NaCl, pH 7.4) at room temperature was used, since it allows 
association of high basal [35S]TBPS binding but still maintains the integrity of brain sections 
so that they tolerate the prolonged washing. A washing protocol of 3 x 30 min in ice-cold 
hypotonic washing buffer (10 mM Tris-HCl, pH 7.4), instead of 3 x 30 s in the standard 
incubation buffer, decreased nonspecific binding without affecting specific binding (I: Fig. 
2). These modifications improved the signal-to-noise ratio of the assay, and we were able to 
use long film exposure times without an excessive background (I: Fig. 1).  
GABA decreased [35S]TBPS binding already at 10 µM concentration in most brain 
regions, but longer film exposure revealed that in certain areas the [35S]TBPS binding 
persisted in the presence of 1 mM GABA (I: Fig. 1). Differential responses were detected, 
e.g., in the inferior colliculus and the thalamus. Both regions displayed high basal [35S]TBPS 
binding; some binding was left in the presence of 30 µM GABA in both areas but, in the 
presence of 1 mM GABA, [35S]TBPS binding was detected only in the thalamus. However, 
the GABA-insensitive [35S]TBPS binding component represented only a small fraction of the 
total binding, since most of the binding was GABA-sensitive in the thalamus also. Increasing 
the GABA concentration to 10 mM did not cause further reduction in the [35S]TBPS binding 
(data not shown). Thus, this binding component was named the GABA-insensitive (GIS) 
[35S]TBPS binding. 
Regardless of our modifications of the standard autoradiographic procedure, the 
fundamental characteristics of the [35S]TBPS binding still remained. These included 
competitive displacement by picrotoxinin (I: Fig. 1), reversibility of the binding (Figure 6; 
Sinkkonen S.T. et al., unpublished results) and the absolute anion dependence of the binding, 
since no specific binding was detected when incubation was performed in 1 mM HEPES [N-
(2-hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) ; pH 7.4] in the absence of halide 
anions (data not shown). These results show that the modified autoradiographic procedure 
represents normal [35S]TBPS binding. This was confirmed by a direct comparison between 
the standard procedure and our modified autoradiographic procedure with mouse brain 
sections (III). Basal [35S]TBPS binding in wild-type (γ2+/+) mice was largely similar in these 
two protocols (III: Figs. 2 and 3).  
Even though some glycine receptor isoforms are picrotoxinin-sensitive (Elster et al., 
1998), [35S]TBPS binding to glycine receptors has not been detected (Rienitz et al., 1987). In 
electrophysiological recordings, picrotoxinin also blocks GABAC receptors (Enz and Cutting, 
1999), but [35S]TBPS binding to these receptors has not been studied. However, since 
GABAC receptors are predominantly expressed in the retina (reviewed in Bormann, 2000), 
they cannot be related to GIS-[35S]TBPS binding. These results indicate that the modified 
autoradiographic procedure with high sensitivity makes it possible to study minor GABAA 
receptor populations, and that receptors with poor coupling between the agonist and 
convulsant sites are also present outside the cerebellum (Korpi and Lüddens, 1993).  
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Figure 6. Reversibility of GIS-
[35S]TBPS binding on rat brain 
sections. Control, the modified 
autoradiographic procedure (4.2.2.); 
+ 1 h in B, standard 90-min 
incubation (in the absence or 
presence of 1 mM GABA, the upper 
and lower rows, respectively) 
followed by an additional 1-hour 
incubation in the fresh incubation 
buffer; + 1 h with GABA, standard 
90-min incubation (in the absence 
or presence of 1 mM GABA, the 
upper and lower rows, respectively) 
followed by an additional 1-hour 
incubation in the fresh incubation 
buffer supplemented with 1 mM 
GABA. Ctx, cerebral cortex; Gr, 
cerebellar granule cell layer; IC, 
inferior colliculus; Mol, cerebellar 
molecular layer; Th, thalamus. Two 
upper left images are from a film 
exposed for 2 days, while the other 
images are from a film exposed for 
12 weeks, and, therefore, these two 
sets of images were processed 
using different scalings. Similar 
results were obtained from 3 rats.  
 
To exclude the possibility that the GIS-[35S]TBPS binding in selected brain regions is 
due to different [35S]TBPS binding affinities in different brain regions, we studied the 
displacement of [35S]TBPS by cold TBPS in the modified autoradiographic conditions (Figure 
7; Sinkkonen S.T. et al., unpublished results). The nonlinear regression fit of [35S]TBPS 
binding saturation curves revealed largely similar [35S]TBPS binding affinities ( Kd about 40 
nM) throughout the rat brain. Thus, the affinity of basal [35S]TBPS binding cannot explain the 
brain regional heterogeneity in GABA-sensitivity.  
 
 
 
Figure 7. Regional [35S]TBPS binding affinity on rat brain sections. Two nM [35S]TBPS was 
incubated for 90 min with various cold TBPS concentrations to generate binding saturation curves. 
Data are mean ± standard error, n = 4. Ctx, cerebral cortex; Gr, cerebellar granule cell layer; IC, 
inferior colliculus; Mol, cerebellar molecular layer; Th, thalamus. 100 µM picrotoxinin was used to 
determine nonspecific binding. Nonlinear regression fit (GraphPad Prism) of [35S]TBPS binding 
saturation curves revealed similar Kd values in different brain regions. 
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5.2. Localization and prevalence of GABA-insensitive [35S]TBPS binding in the 
brain (I, II) 
When the inhibitory effect of high (1 mM) GABA concentration on [35S]TBPS binding was 
studied in rat, mouse, human and chicken brain sections, two main findings were made: 1) a 
minor population of GABAA receptors with poor coupling between agonist and convulsant 
binding sites is present in all the species studied in some but not in all brain regions, and 2) 
these receptors are highly conserved in the cerebellar granule cell layer, the deep layers of the 
neocortex and the thalamus. 
The GIS-[35S]TBPS binding was detected in the rat (I: Fig. 3), human (I: Fig. 4), 
chicken (I: Fig. 4) and mouse cerebellar granule cell layer (II: Fig. 2), and amounted to 6-16 
% of the basal [35S]TBPS binding. As mentioned in the section Material and methods (4.2.), 
the basal [35S]TBPS binding has not reached equilibrium during the 90-min incubation 
(presumably about 70 % of the equilibrium binding level), but binding in the presence of 1 
mM GABA should represent the binding level in equilibrium (Maksay and Simonyi, 1986). 
This makes it difficult to estimate the precise proportion of the GIS-[35S]TBPS binding 
component in the total basal binding. Another confounding factor is that using one 
concentration of [35S]TBPS in the binding assay does not allow direct estimation of the total 
receptor number, even though the amount of [35S]TBPS binding is suggestive of it. Taking 
these two factors into account, it seems safe to estimate that a minor but fairly constant 
proportion, probably more than a few but less than ten percent, of all the [35S]TBPS binding 
in the cerebellar granule cell layer, is GABA-insensitive. In addition to the cerebellar granule 
cell layer, GIS-[35S]TBPS binding was detected in the thalamus and the deep layers of the 
neocortex in rodent and human brains but not in chicken brain. In these regions, it constituted 
a few percentages of the basal binding in these incubation conditions. 
Comparison of the brain regional localization of GIS-[35S]TBPS binding with two other 
well-known GABAA receptor pharmacological heterogeneities, the high-affinity 
[3H]muscimol and the  DIS-[3H]Ro 15-4513 binding, revealed similarities (I, Fig. 5). All 
three pharmacological fingerprints were detected in the cerebellar granule cell layer. In 
addition, GIS-[35S]TBPS and [3H]muscimol colocalized in the thalamus and in the geniculate 
area, but they differed in the cerebrocortical distribution, as GIS-[35S]TBPS was enriched in 
the deep layers whereas [3H]muscimol was found mainly in the external layers. In the cortex, 
DIS-[3H]Ro 15-4513 binding was distributed uniformly. DIS-[3H]Ro 15-4513 failed to 
colocalize with GIS-[35S]TBPS binding in the geniculate area, subiculum, or thalamus, but 
was present in the hippocampus, which was almost devoid of GIS-[35S]TBPS binding. 
These findings together show that the GIS-[35S]TBPS binding formed a novel 
pharmacological heterogeneity of GABAA receptors with unique brain regional localization. 
Although GIS-[35S]TBPS binding constituted only a minor receptor population in selected 
brain regions, several things suggest that these receptors may be of biological significance. 
Firstly, this kind of prevalence has been detected for various minor GABAA receptor subtypes 
(Table 1). Secondly, from the evolutionary point of view, conservation of a biological process 
(GIS-[35S]TBPS binding) across different species usually argues for functional relevance. 
Thirdly, the GABAA receptors in these brain regions might contribute to the regulation of 
such processes as attention, vigilance and memory, sensory information processing, and/or 
motor coordination.  
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5.3. Roles of different GABAA receptor subunits in GABA-insensitive [35S]TBPS 
binding 
5.3.1. Correlation with receptor subunit mRNA localization by in situ 
hybridization 
5.3.1.1. Adult rat (II) 
To find out which GABAA subunits could be responsible for the pharmacological fingerprint 
of the GIS-[35S]TBPS binding, ligand autoradiography and in situ hybridization (ISH) 
techniques were combined. Although ISH gives information on the subunit mRNA level and 
ligand autoradiography on the protein level (usually subunit complexes), these measures have 
correlations, e. g., between α4 and α6 subunits and DIS-[3H]Ro 15-4513 binding (Lüddens et 
al., 1990; Wisden et al., 1991) and between δ and α6 subunits and high-affinity [3H]muscimol 
binding (Quirk et al., 1995; Mäkelä et al., 1997). Thus, comparison of ISH and receptor 
autoradiography signals is relevant. But one has to bear in mind the detection limit of ISH, 
and that small amounts of mRNA might be sufficient to produce enough protein for a minor 
receptor population. Localization of GABAA receptor subunit transcripts in the rat brain has 
been published previously (Wisden et al., 1992; Sinkkonen et al., 2000). 
 The α1 subunit mRNA expression was detected throughout the brain, including all the 
areas of GIS-[35S]TBPS binding (II: Fig. 1). However, high α1 mRNA expression was also 
detected in brain regions with normal GABA sensitivity of [35S]TBPS binding. The α2 
mRNA colocalized with the GIS-[35S]TBPS binding in the cortex, but only α3 and α5 were 
enriched in the deep layers of the cortex similarly to GIS-[35S]TBPS binding. The α4 mRNA 
expression had the best regional correlation with the GIS-[35S]TBPS binding in the forebrain, 
with expression in the thalamus and in the geniculate area. However, α4 mRNA was 
expressed in the striatum and the external parts of cortex, where GIS-[35S]TBPS binding was 
not detected. The globus pallidus was devoid of an α4 mRNA signal. The α6 mRNA 
colocalized with the GIS-[35S]TBPS binding in the granule cell layer of the cerebellum. 
Superimposing figures of α4 and α6 mRNA expression patterns yields a map almost identical 
to the GIS-[35S]TBPS binding localization, with the exceptions of the striatum, globus 
pallidus and different cerebrocortical distribution.  
The β1 subunit mRNA expression was low outside the hippocampus, but some 
expression was seen in the cortex. The β2 subunit mRNA colocalized in many brain areas 
with GIS-[35S]TBPS binding, but was not enriched in the deep layers of the cortex. The β3 
mRNA was detected in the cerebellar granule cell layer and cerebral cortex but not in other 
regions of the GIS-[35S]TBPS binding. 
Of the γ subunit family, only γ2 was detected in the areas of the GIS-[35S]TBPS 
binding, but it was also expressed in most other brain regions.  
The δ subunit mRNA expression in the cerebellar granule cell layer, thalamus and 
geniculate area was largely similar to the localization of GIS-[35S]TBPS binding. However, δ 
mRNA in the cerebral cortex was distributed in the outer layers rather than in the deep layers 
(where the GIS-[35S]TBPS binding was), a difference that was similar to that between GIS-
[35S]TBPS and [3H]muscimol binding. The δ mRNA was present in the striatum and the 
hippocampus, which were devoid of GIS-[35S]TBPS binding. In contrast, δ mRNA was not 
expressed in the globus pallidus, which displayed GIS-[35S]TBPS binding. Altogether, the 
expression pattern of δ mRNA was in good, but not in perfect, correlation with the GIS-
[35S]TBPS binding.  
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The ε and θ subunits were not expressed in those regions that had GIS-[35S]TBPS 
binding, which was in accordance with their restricted expression patterns and their 
enrichment in the brain stem locus coeruleus (Sinkkonen et al., 2000). 
 
5.3.1.2. Developing rat 
 To find out whether GIS-[35S]TBPS binding is present during brain development, rats of 
three different ages (P0, P6 and P12; P, postnatal day) were tested. Horizontal sections at the 
thalamus level and an identical autoradiographic procedure to that used in adult rats were 
used. Basal picrotoxinin-sensitive [35S]TBPS binding was seen throughout the brain in all age 
groups (data not shown). One mM GABA displaced all the binding from the P0 and P6 brain 
sections, and only a little binding was left on the P12 sections (Figure 8; Sinkkonen S.T. et 
al., unpublished results). In a striking difference from the adult brain, this GIS-[35S]TBPS 
binding had a totally different localization. In contrast to the binding component seen in the 
cerebellar granule cell layer and thalamus of the adult brain, these areas were not labeled in 
the P12 brain in the presence of 1 mM GABA. The strongest binding was seen in the external 
layer of the infralimbic cortex, which is not particularly labeled in the adult brain.  It was 
impossible to find any GABAA receptor subunit mRNA enriched in the external layer of the 
infralimbic cortex (Figure 8). There was some GIS- [35S]TBPS binding also in the deep layers 
of the cortex and the entorhinal cortex. The entorhinal cortex expressed 
α1, α2, α4, α5, β2, β3, γ2 and γ3 mRNAs, the α1 mRNA signal was especially strong at P12. 
The deep layers of the cortex contained particularly α1, α3, α5, β2, β3, γ2 and θ subunit 
mRNAs. In contrast to the “development” of the pharmacological fingerprint after post-natal 
day 12, the GABAA receptor subunit mRNAs have adult-like expression already at this age 
(II: Fig. 1; Figure 8). So, the “development” of GIS-[35S]TBPS binding cannot be explained 
simply by induction of the expression of any known subunit. Instead, it has to be seen as a 
change at a later step of the receptor formation (e.g., post-translational modification, receptor 
complex assembly, interaction with intracellular proteins), or due to some as yet unknown 
receptor subunit (with late developmental expression). 
 
5.3.2. GABA-insensitive [35S]TBPS binding in genetically engineered mouse 
lines 
On the basis of the brain regional distribution of the GIS-[35S]TBPS, [3H]muscimol and DIS-
[3H]Ro 15-4513 binding, and the mRNA expression pattern of the different subunits, 
candidate receptor subunits were revealed and their roles were probed using brain sections 
from genetically engineered mouse lines. The mouse lines were provided by collaborators. 
The α4 subunit-deficient mouse line is unfortunately not available at present, and thus the role 
of the α4 subunit could thus not be studied.   
 
5.3.2.1. The β3 subunit knockout mice (β3-/-) (II) 
Recombinant homomeric β3 receptors display [35S]TBPS binding that is largely insensitive to 
the inhibitory effect of GABA (Slany et al., 1995; III: Table 1). In addition, the β3 subunit 
mRNA is strongly expressed in the cerebellar granule cell layer, and is detectable in the 
cerebral cortex. However, expression   in  the  thalamus is  negligible  (II: Fig. 1).  For these   
reasons, we  tested whether homomeric β3 receptors could be responsible for GIS-[35S]TBPS 
binding in the brain, and applied brain sections from β3 subunit knockout (β3-/-) mice 
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together with their wild-type controls for autoradiographic assay (II: Fig. 2). The proportion 
of the GIS binding component in the basal [35S]TBPS binding was similar in the two 
genotypes. This suggests that, in the native brain, homomeric β3 receptors are rare, if they 
exist at all, and cannot explain the GIS-[35S]TBPS binding. 
 
 
 
Figure 8. Comparison of the regional localization of the GABAA receptor subunit mRNAs with the 
GIS-[35S]TBPS binding (G, upper right corner) in serial P12 rat brain sections. Images are processed 
using identical scaling for brightness and contrast to (I: Fig. 1) to allow comparison of transcription 
levels of different receptor subunits and amount of GIS-[35S]TBPS binding between 12-day-old and 
adult brains. CtxIn, internal rim of cortex; Ent, entorhinal cortex; Gr, cerebellar granule cell layer; 
InC, external part of the infralimbic cortex; Th, thalamus.  
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5.3.2.2. The δ subunit knockout mice (δ-/-) (II) 
A good correlation between GIS-[35S]TBPS binding and δ subunit-associated high-affinity 
[3H]muscimol binding, together with δ mRNA localization, suggested a role for the δ subunit 
in GIS-[35S]TBPS binding after exclusion of the role of homomeric β3 receptors. In addition 
to complete deletion of δ subunit expression, δ-/- mice have complex alterations in their 
GABAAergic system. In the thalamus, the δ subunit knockout mice have decreased high-
affinity [3H]muscimol binding but increased total [3H]Ro 15-4513 binding. The forebrain γ2 
subunit expression is upregulated but the α4 subunit expression is decreased (Korpi et al., 
2002b; Peng et al., 2002). Nevertheless, the formation of α4βγ2 receptors is increased, as 
revealed by immunoprecipitation studies and the increased proportion of DIS-[3H]Ro 15-4513 
binding (Korpi et al., 2002b). In the cerebellum, δ-/- mice display increased [3H]Ro 15-4513 
binding and an increased DIS-[3H]Ro 15-4513 binding component, but a decreased amount of 
high-affinity [3H]muscimol binding (Tretter et al., 2001; Korpi et al., 2002b). Simultaneously, 
γ2 subunit expression is upregulated and coassembly of α6 and γ2 subunits is increased. In 
contrast to cerebellar extracts of control mice, where 97 % of the receptors were of αβγ2 or 
αβδ subtypes, and the numbers of γ1 and γ3 subunit-containing receptors are negligible, in the 
δ-/- mice 24 % of all cerebellar GABAA receptors are devoid of γ or δ subunits (Tretter et al., 
2001). 
 When [35S]TBPS binding autoradiography was applied to δ-/- and their wild-type 
control mouse brain sections, high basal binding was detected throughout the brains of both 
genotypes (II: Fig. 2). However, when incubation was performed in the presence of 1 mM 
GABA, the cerebellar granule cell layer of the δ-/- mice had 24.4 ± 1.5 % (mean ± standard 
error) of basal [35S]TBPS binding left, which was double that of the wild-type controls (12.2 ± 
1.5 %, p < 0.01, one-way ANOVA and Newman-Keuls Multiple post-hoc test). The δ-/- mice 
also had a higher proportion of GIS-[35S]TBPS binding in the thalamus (4.3 ± 0.2 vs. 3.0 ± 
0.3 %, p < 0.01), whereas the amount of GIS-[35S]TBPS binding was similar in brain regions 
devoid of δ expression, e.g., in the inferior colliculus the GIS-[35S]TBPS binding amounted to 
0.6 % of the basal binding in both mouse lines. These results indicate that the GIS-[35S]TBPS 
binding can be formed without δ subunits. However, owing to the compensatory alterations 
observed in the δ-/- mouse brains (Tretter et al., 2001; Korpi et al., 2002b; Peng et al., 2002), 
one cannot rule out the possibility that δ subunit-containing receptors might participate in the 
formation of GIS-[35S]TBPS binding in the wild-type animals.  
  
5.3.2.3. The α6 subunit knockout mice (α6-/-) (II) 
GIS-[35S]TBPS binding is detected in the cerebellar granule cell layer together with high-
affinity [3H]muscimol and DIS-[3H]Ro 15-4513 binding, and together with α6 subunit 
expression. There are currently two α6 subunit knockout lines available, both of which have a 
neomycin gene insertion in exon 8 of the α6 subunit gene (Homanics et al., 1997b; Jones et 
al., 1997). Deletion of the α6 subunit in the mouse genome results in complex but similar 
adaptations in the GABAAergic systems of both knockout mouse lines. In the cerebellar 
granule cell layer, the α6-/- mice have about 80 % reduced translation of δ subunit protein 
despite normal amounts of δ mRNA (Jones et al., 1997), and the remaining δ subunits are not 
detected on the plasma membrane (Nusser et al., 1999). Protein levels for the β2, β3 and γ2 
subunits are decreased by about 50, 20 and 40 %, respectively, and the total number of 
receptors is decreased by about 50 % (Nusser et al., 1999). DIS-[3H]Ro 15-4513 binding is 
totally abolished and high-affinity [3H]muscimol binding is greatly reduced (Mäkelä et al., 
1997).  
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 In line with the previous report of [35S]TBPS binding to α6-/- brain sections (Mäkelä 
et al., 1997), the basal binding in the cerebellar granule cell layer did not significantly differ 
from the wild-type control values (332 ± 86 vs. 416 ± 45 nCi/g for α6-/- and wild-type 
controls, respectively), whereas the binding was decreased in virtually all the other brain 
regions when compared to wild-type control mice (II: Fig. 2). One mM GABA decreased 
[35S]TBPS binding to 5.1 ± 0.7 %, which was significantly reduced from that of the wild-type 
controls (12.2 ± 1.5 %, p < 0.01). The strongly reduced GIS-[35S]TBPS binding component of 
α6-/- mice in the cerebellar granule cell layer suggests a role for α6 in the formation of this 
pharmacological fingerprint. In addition to changes in the cerebellar granule cell layer, both 
α6-/- mouse lines display decreased expression of α1 and β2 subunits in the forebrain due to 
the suppression of the neighboring β2-α6-α1-γ2 gene cluster expression by the neomycin 
gene (Uusi-Oukari et al., 2000). These nonspecific changes were also demonstrated in our 
experiments by reduced amount of GIS-[35S]TBPS binding in the forebrains of α6-/- mice. 
 
5.3.2.4. Mice with ectopic α6 subunit expression (Thy1α6) (IV) 
If the α6 subunit participates in the formation of GIS-[35S]TBPS binding, as suggested by the 
effects of its deletion, then ectopic expression of the α6 subunit outside its natural 
environment, the cerebellar granule cell layer, should  produce GIS-[35S]TBPS binding. For 
this reason, brain sections from the transgenic Thy1α6 mouse line (Wisden et al., 2002), 
where the GABAA receptor α6 subunit is expressed under the control of the panneuronal Thy-
1.2 promoter (Caroni, 1997), were studied. Depending on the accidental incorporation 
position of the transgene in the mouse genome, inheritable transgene expression patterns in 
random brain regions are produced. In the case of Thy1α6 mice, regionally limited expression 
of the α6 subunit protein was achieved (Wisden et al., 2002). The α6 protein is detected in 
some of the cells in selected brain regions, such as the deep cerebellar nuclei, the deep layers 
of the neocortex, subiculum, hippocampal CA1 and CA3 pyramidal cells and the hippocampal 
dentate granule cells. In the forebrain, α6 coassembled with the α1, α3, β1, β2, β3 and γ2 
subunits, whereas no coassembly with the δ subunit was detected (Wisden et al., 2002). In 
accordance with ectopic α6 subunit expression and incorporation to receptor complexes, DIS-
[3H]Ro 15-4513 binding was increased in the hippocampal CA1 region and the deep layers of 
the cerebral cortex (Wisden et al., 2002). 
 [35S]TBPS autoradiography revealed high basal binding throughout the Thy1α6 and 
their C57BL/6 control mouse brain sections (IV: Fig. 1). Brain regional binding density was 
otherwise similar, but Thy1α6 had 28 % less binding in the hippocampal CA1 region than 
their control animals (p < 0.001, unpaired t-test). One mM GABA produced a typical 
forebrain GIS-[35S]TBPS  binding pattern in control mouse brain sections, since it resulted in 
almost complete abolition of [35S]TBPS binding (e.g., 0.7 ± 0.1 % of the basal binding left in 
the hippocampal CA1 region) of all other brain regions but the thalamus. In contrast, the 
hippocampal CA1 region of the Thy1α6 mice still had 8.9 ± 0.4 % of basal binding left. This 
result argues strongly for a role of the α6 subunit in the formation of GIS-[35S]TBPS binding 
in the native cerebellum. 
 
5.3.2.5. Mice heterozygous for the γ2 subunit deletion (γ2+/-) (III) 
The α6 subunit-containing receptors cannot explain the GIS-[35S]TBPS binding outside the  
cerebellum. Nevertheless, the γ2 subunit confers GABA-sensitivity of [35S]TBPS binding on 
the α6β2 receptors (Korpi and Lüddens, 1993; Im et al., 1994). Functionally, the γ2 subunit 
enhances the efficacy of GABA by promoting higher conductance and a longer lifetime of 
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activated channels (Lorez et al., 2000). For these reasons, we wanted to probe the effects of γ2 
subunit deletion on GIS-[35S]TBPS binding. The mice homozygous for the deletion of the γ2 
subunit have normal embryonic development, including normal levels of other receptor 
subunits, but die soon after birth (Günther et al., 1995). The mice heterozygous for the γ2 
knockout (γ2+/-) have a decreased number of BZ binding sites, but a normal total number of 
GABAA receptors (Crestani et al., 1999). However, γ2 subunit-dependent receptor clustering 
to the postsynaptic membranes is decreased. Electrophysiologically, the γ2+/- mice display an 
increased proportion of low-conductance channel activity, suggestive of functional expression 
of receptors composed only of α and β subunits (Crestani et al., 1999). 
 [35S]TBPS autoradiography with adult γ2+/- mouse brain sections revealed high 
convulsant site binding throughout the brain. Basal binding was increased in the cortex, 
thalamus and hippocampus, as compared with the wild-type controls (III: Fig. 3). Adding 1 
mM GABA revealed a wide-spread increase in the GIS-[35S]TBPS binding component of the 
mutant mice, a change that was virtually opposite to the decreased [3H]Ro 15-4513 binding 
(III: Fig. 1). Since the δ subunit-related high-affinity [3H]muscimol binding remained 
unchanged (III: Fig. 4), these results suggest that αβ GABAA receptors might participate in 
the formation of GIS-[35S]TBPS binding in the brain. E.g., in the inferior colliculus, where 
only the α1 subunits among the α subunit family are highly expressed (Korpi et al., 2002a), 
these receptors might be of α1β2/3 composition. In addition, these results were supported by 
the finding that GABA modulation of [35S]TBPS binding to the γ2+/- mouse forebrain was 
further decreased by Zn2+, while it had fewer effects in the wild-type controls. Zn2+ is known 
to inhibit αβ receptors at higher potency than αβδ or αβγ receptors (Krishek et al., 1998).  
 
5.3.3. Demonstration of GABA-insensitive [35S]TBPS binding in recombinant 
receptors expressed in HEK 293 cells (III) 
Based on the results with genetically engineered mouse lines, various subunit combinations 
were expressed in HEK 293 cells in order to determine the GABA-sensitivity of [35S]TBPS 
binding in these receptor subtypes. As previously shown, the α6β2 receptors devoid of γ2 
subunits display [35S]TBPS binding that is insensitive to the inhibitory effect of at least 10 
µM GABA (Korpi and Lüddens, 1993; Im et al., 1994). Also, α6β3 receptors displayed 
[35S]TBPS binding that was partially (55 %) insensitive to 10 µM GABA (Korpi and 
Lüddens, 1997). In the present experiments, a third of the [35S]TBPS binding was not 
abolished in the presence of 1 mM GABA in the α6β3 receptors, whereas [35S]TBPS binding 
to the α6β3γ2  receptors was fully displaced by GABA (III: Table 1; Figure 9). These and 
previous data (Korpi and Lüddens, 1993; Im et al., 1994, Korpi and Lüddens, 1997) clearly 
indicate that the α6β2/3 receptors form [35S]TBPS binding sites with poor coupling to agonist 
binding sites, while γ2 confers the full GABA sensitivity.  
The γ2+/- mice showed widespread enhancement of their GIS-[35S]TBPS binding. Since 
α1 is the major α subunit in the brain, it was hypothesized that the γ2 subunit affects the 
GABA-sensitivity of [35S]TBPS binding to the α1-receptors similarly to the α6 subunit-
containing receptors. In agreement, about 20-30 % of the [35S]TBPS binding to the α1β3 
receptors was insensitive to 1 mM GABA, when the same amount of subunit plasmids for 
both subunits was used in the transfection. When the amount of the α1 plasmid was raised or 
the γ2 subunit was cotransfected, the GABA-sensitivity of [35S]TBPS binding was restored 
(III: Table 1; Figure 9). When β2 subunit was cotransfected with the α1 subunit (III: Table 
1), [35S]TBPS binding was totally GABA-sensitive, which was in accordance with previous 
results (Korpi and Lüddens, 1993; Im et al., 1994). [35S]TBPS binding to homomeric β2 
receptors was weak and fully displaceable by GABA (III: Table 1).  
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Figure 9. [35S]TBPS binding and its modulation by GABA in various recombinant receptor subtypes 
expressed in HEK 293 cells. A. Inclusion of γ2 subunit into α6β3 receptor complexes changes 
[35S]TBPS binding sensitive to 1 mM GABA. Data are mean ± standard error, n = 3 transfections for 
each subunit combination (III: Table 1). B. Also α1β3 receptors display partially GIS-[35S]TBPS 
binding, but increasing the amount of α1 subunit plasmid in transfection procedure or inclusion of γ2 
subunit into α1β3 receptor complexes convert [35S]TBPS binding sensitive to the inhibitory effect of 1 
mM GABA. Data are mean ± standard error, n = 3 - 7 transfections for each subunit combination (III: 
Table 1). In parenthesis the amount of respective subunit (in µg plasmid/plate) used in transfections. 
C. Substituting γ2 subunit with δ in α1 subunit-containing receptors confers [35S]TBPS binding from 
GABA-sensitive to GABA-insensitive. Note that α1β2 receptors are fully GABA sensitive (Korpi and 
Lüddens, 1993; Im et al., 1994; III: Table 1), which confirms incorporation of δ subunits in the receptor 
complexes. Data are mean ± standard error, n = 2 - 5 transfections for both subunit combinations. The 
basal [35S]TBPS binding levels for α1β2γ2 and α1β2δ combinations were 88 ± 21 and 54 ± 13 fmol/mg 
protein. The amounts of subunit plasmids (in µg plasmid/plate) used in transfections were α1: 2, β2: 
10, γ2: 0.2, δ: 0.3. These experiments were carried out by Korpi E.R. in the University of Heidelberg, 
Germany. D. Similar to α1 subunit-containing receptors, substitution of γ2 by δ seems to confer 
[35S]TBPS binding to α6-receptors GABA-insensitive. However, also α6β2 receptors display GIS-
[35S]TBPS binding (Korpi and Lüddens, 1993; Im et al., 1994), which makes judgement of the 
incorporation of δ subunits difficult. Data are mean ± standard error, n = 2 - 4 transfections for both 
subunit combinations. The basal [35S]TBPS binding levels for α6β2γ2 and α6β2δ combinations were 
54 ± 13 and 63 ± 5 fmol/mg protein. The amounts of subunit plasmids (in µg plasmid/plate) used in 
transfections were α6: 2, β2: 10, γ2: 0.2, δ: 0.3. These experiments were carried out by Korpi E.R. in 
the University of Heidelberg, Germany. 
 
It has been shown that 65 % of [35S]TBPS binding to α6β3δ receptors is insensitive to 
the inhibitory effect of 10 µM GABA (Korpi and Lüddens, 1997), but there are currently no 
published data on [35S]TBPS binding to δ subunit-containing receptors in the presence of 
higher GABA concentrations. One possible explanation for this is the decreasing effect of 
GABAA receptor ligand binding by δ subunit transfection, which makes binding studies with 
recombinant δ-GABAA receptors difficult. Hevers et al. (2000) were able to 
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electrophysiologically demonstrate the functional expression of the δ subunit in αβδ and 
αβγ2δ combinations, but, in ligand binding assays with cell homogenates, cotransfection of δ 
with the αβγ2 combination greatly reduced the binding levels to the GABA agonist, BZ and 
convulsant binding sites. The effect was detected irrespective of the type of α subunit present 
in tranfection. E.g., [35S]TBPS binding to α4 and α6 subunit-containing receptors was 
decreased to almost background levels, and it was also clearly decreased in α1 subunit-
containing receptors (Hevers et al., 2000). Nevertheless, when it was managed to express δ 
subunit in HEK 293 cells together with α1 and β2, the α1β2δ receptors formed displayed 
relatively low basal [35S]TBPS binding, as expected, but as a striking difference from control 
α1β2γ2 receptors, [35S]TBPS binding was not decreased by GABA (Figure 9; Korpi E. R., 
unpublished results). One has to bear in mind that recombinant β2 and α1β2 receptors display 
totally GABA-sensitive [35S]TBPS binding (Korpi and Lüddens, 1993; Im et al., 1994; III: 
Table 1), which suggests that incorporation of δ subunit to receptor complexes is responsible 
for the GIS-[35S]TBPS binding detected in these experiments. In the native brain, δ is 
preferentially assembled with the α6 and α4 subunits (Jones et al., 1997; Sur et al., 1999). 
Due to technical difficulties in obtaining reliable expression levels of the α4 subunit in HEK 
293 cells, we have not been able to study recombinant receptors comprising this subunit. In 
contrast, δ subunit expression together with α6 and β2 subunits was successful and revealed 
largely similar results to the α1 subunit-containing receptors: low basal [35S]TBPS binding 
together with low sensitivity to the inhibitory effect of GABA. [35S]TBPS binding to the 
α6β2γ2 receptors was fully GABA-sensitive, as expected (Korpi and Lüddens, 1993). 
Anyhow, the results obtained with coexpression of α6, β2 and δ subunits do not necessarily 
imply formation of α6β2δ receptors, since α6β2 receptors are able to form the GIS-
[35S]TBPS, as has previously been shown (Korpi and Lüddens, 1993; Im et al., 1994). 
However, these results do not rule out the possibility that α6βδ receptors display GIS-
[35S]TBPS binding, which is supported by the finding that [35S]TBPS binding to α6β3δ was 
only partially displaced by 10 µM GABA (Korpi and Lüddens, 1997). Although the results 
presented here with recombinant δ subunit expression are preliminary, they suggest that 
GABAA receptors containing the δ subunit might participate in forming the GIS-[35S]TBPS 
pharmacology in the native brain.   
 
5.4. A possible mechanism of atypical coupling between GABA and convulsant 
binding sites 
During the initial characterization of the GIS-[35S]TBPS binding in the native brain, we 
probed the effects of other GABA site agonists on [35S]TBPS binding. Muscimol, as a 
prototypical and potent agonist, produced an identical pharmacological fingerprint at 1 mM 
concentration (data not shown). The effect of the endogenous amino acids β-alanine and 
taurine, which are known to potentiate both GABAA and glycine receptors (Horikoshi et al., 
1988), were tested up to 100 mM concentrations. At this highest concentration, β-alanine 
revealed a similar [35S]TBPS binding component to 1 mM GABA or muscimol, whereas the 
taurine effect at 100 mM concentration was comparable to the effects of 10-30 µM GABA 
(data not shown).  
Even though other GABA site agonists failed to displace more [35S]TBPS binding from 
the brain sections than GABA, the residual binding could still be modulated by various 
GABAA receptor allosteric modulators. The thalamic component of GIS-[35S]TBPS binding 
was further decreased by drugs acting on BZ, barbiturate, loreclezole and neurosteroid 
binding sites, and by Mg2+ (I: Table 1). The GIS-[35S]TBPS binding in the cerebellar granule 
cell layer was largely similarly affected, but it was insensitive to Mg2+ modulation. The 
selective GABAC receptor agonist cis-4-aminocrotonic acid did not affect GIS-[35S]TBPS 
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binding. Even though some predictions of receptor subunit composition might be made on the 
basis of this pharmacology, it is safer, owing to the high drug concentrations and long 
incubation periods, to make only two basic assumptions: 1) the receptor population 
responsible for GIS-[35S]TBPS binding is regionally heterogeneous, and 2) GABA seem not 
to have full efficacy on these receptors, since the effect of a saturating (1 mM) concentration 
can still be potentiated. While the heterogeneity of GIS-[35S]TBPS binding can be explained 
by the differential subunit composition of the receptors, it is harder to imagine the 
circumstances in which the natural agonist does not possess full efficacy. However, Brown et 
al. (2002) provided an interesting finding when they showed that THIP, a restricted GABA 
analog and a partial agonist in α1β2/3γ2 and α4β3γ2 receptors (Ebert et al., 1994; Ebert et al., 
1997; Brown et al., 2002), was more effective in the α4β3δ receptors than GABA. 
Unfortunately, Brown et al. (2002) did not demonstrate competition between GABA and 
THIP, which would have established the idea of GABA being only a partial agonist in 
recombinant α4β3δ receptors. 
Nevertheless, on the basis of the idea that THIP might be more efficacious than GABA 
by acting as a full agonist of the GABA site, we applied THIP in an [35S]TBPS 
autoradiographic assay with mouse brain sections. As shown in Figure 10 (Sinkkonen S.T. et 
al., unpublished results), THIP was more effective than GABA in displacing [35S]TBPS 
binding from the cerebellar granule cell layer and the thalamus. At 10 mM concentration, it 
displaced virtually all [35S]TBPS binding. The effect of THIP could be inhibited by 
simultaneous application of GABA, which demonstrates competitive displacement of THIP 
from the agonist binding site. These results suggest that GABA is not a full agonist, at least in 
respect of [35S]TBPS dissociation, in the receptors responsible for GIS-[35S]TBPS binding in 
the native brain. Thus, this might provide the first demonstration of native receptors, where 
GABA acts as a partial agonist. 
 
 
 
 
Figure 10. Effect of GABA and THIP on 
[35S]TBPS binding to mouse brain 
sections. A. GABA yielded similar 
residual [35S]TBPS binding at 1 mM and 
10 mM concentrations, while 1 mM THIP 
inhibited more [35S]TBPS binding than 
GABA maximally. THIP at 10 mM 
concentration abolished [35S]TBPS 
binding almost to background levels. 
B. GABA competitively blocked the 
inhibitory effect of THIP on [35S]TBPS 
binding. The autoradiographic procedure 
developed to reveal GIS-[35S]TBPS 
binding was used. Similar results were 
obtained from 6 mice. 
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5.5. Mice with ectopic α6 subunit expression (Thy1α6) as a model system of 
altered balance between synaptic and extrasynaptic inhibition (IV) 
As explained in section 5.3.2.4., the transgenic Thy1α6 mouse line has ectopic α6 subunit 
expression in some brain regions. But, as a striking difference from its normal synaptic 
enrichment in the natural environment (cerebellar granule cell layer), the transgene product is 
almost solely located on the extrasynaptic membranes of the soma and the dendrites (Wisden 
et al., 2002). Together with ectopic α6 expression, Thy1α6 mice have increased GABAAergic 
extrasynaptic inhibition. However, they display a simultanous decrease in synaptic inhibition, 
since the sIPSC frequency and mIPSC amplitude are decreased by 37 and 30 %, respectively. 
The α6-immunoaffinity column showed coassembly of α1, α3, β1, β2, β3 and γ2 subunits 
together with α6, whereas no δ subunit was detected, presumably reflecting the non-
overlapping expression patterns of the δ and Thy1α6 genes. As indicated by the 
immunoaffinity column results and the increased DIS-[3H]Ro 15-4513 binding, many of the 
α6 subunits were assembled in α6βγ2 receptors (Wisden et al., 2002). However, our 
preliminary screening revealed the GIS-[35S]TBPS binding in the brain regions of ectopic α6 
expression, which suggested the additional presence of α6β receptors. For this reason, we 
extended the characterization of these ectopic receptor subtypes, and performed behavioral 
analysis with the Thy1α6 mice. 
 
5.5.1. Functional α6 subunit expression and its effects on other subunit mRNA 
levels 
ISH with an oligonucleotide probe against mouse α6 subunit mRNA revealed a consistent α6 
expression pattern in Thy1α6 mouse frontal brain sections (Figure 11; Sinkkonen S.T. et al., 
unpublished results). The strongest expression was detected in the hippocampal CA1 region. 
Other areas of clear expression were the hippocampal dentate gyrus and the CA3 area, the 
deep layers of the neocortex and the amygdala. No α6 subunit mRNA was detected in the 
forebrain of wild-type mice, as expected. To confirm the functional expression of α6 subunit-
containing GABAA receptors in the forebrain of Thy1α6 mice, whole-cell patch-clamp was 
applied to acutely isolated CA1 pyramidal cells from control and Thy1α6 mice. The α4/6-
selective non-competitive antagonist furosemide blocked the GABA-induced currents only in 
cells from Thy1α6 mice (IV: Fig. 3), which confirmed the functional expression of the 
Thy1α6 transgene.  
To test whether ectopic α6 expression in the hippocampus changes other receptor 
subunit mRNA levels expressed in the hippocampus (Wisden et al., 1992; Sperk et al., 1997), 
oligonucleotide probes against α1-5, γ2 and δ mRNAs were used on both male and female  
Thy1α6 (n = 8 and 13 for males and females, respectively) and control (n = 7 and 11 for 
males and females, respectively) mouse brain sections. The expression levels of β1-3 subunit 
mRNAs were not examined; although they are hippocampally expressed, the type of β subunit 
variant does not crucially influence the receptor’s physiological properties (Korpi et al., 
2002a), and thus their mutual relations were not of particular interest in the present study. ISH 
revealed clear expression patterns for subunit mRNAs in the hippocampal CA1 area and the 
dentate gyrus (Figure 11). Since different oligonucleotide probes have different specific 
activities and hybridization properties, the expression levels of the different subunit mRNAs 
are not comparable. In contrast, comparison between different mouse lines is justified. 
Expression levels in CA1 for control and Thy1α6 mice were (in nCi/g, n = 14 - 21) for α1 
229 ± 21 vs. 217 ± 22 (mean ± standard error, expression level for Thy1α6 was 95 % of that 
of the control), α2 120 ± 11 vs. 117 ± 6 (97 %), α3 5.6 ± 0.4 vs. 5.7 ± 0.4 (100 %), α4 8.1 ± 
0.9 vs. 7.6 ± 0.4 (94 %), α5 79 ± 4 vs. 74 ± 3 (93 %), γ2 169 ± 8 vs. 160 ± 5 (95 %) and for δ 
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3.4 ± 0.1 vs. 3.1 ± 0.2 (89 %), respectively. In the dentate gyrus, the differences in expression 
levels between the mouse lines were even smaller (data not shown). Three-way ANOVA 
(factors: gender, mouse line, subunit) revealed no differences in receptor subunit mRNA 
levels between genders or mouse lines [F(1,254) = 0.16, ns, and F(1,254) = 0.34, ns, for 
mouse line factors in CA1 and the dentate gyrus, respectively]. Thus, functional expression of 
α6 subunits in the forebrain of Thy1α6 mice does not interfere with the expression of other 
GABAA receptor subunit mRNAs. However, the possible changes in subunit translation 
and/or subunit assembly cannot be ruled out on the basis of the ISH findings. 
 
 
 
Figure 11. GABAA receptor subunit expression in the 
hippocampus of control and Thy1α6 mice. ISH with mouse brain 
sections was performed otherwise similarly to rat brain sections 
(see 4.3.), excepct that oligonucleotide probes were synthesized 
(CyberGene Ab, Huddinge, Sweden) complementary to mouse 
subunit cDNA sequences as follows: α1 (cDNA nucleotides 1331-
1375; GenBank accession number M86566), α2 (1144-1188; 
M86567), α3 (1404- 1448; M86568), α4 (542-586; NM_010251), 
α5 (1477-1521; BC062112), α6 (1291-1335; NM_008068), 
γ2 (1352-1396; BC031762), δ (1160-1204; NM_008072). Due to 
different specific activities and hybridization properties of 
oligonucleotide probes expression levels of different subunit 
mRNAs can not be comparared. However, comparison between 
different mouse lines is justified, and thus representative ISH 
autoradiographs for both mouse lines are processed from the 
same films with identical scaling for brightness and contrast. 
Quantification of subunit expression levels revealed no 
statistically significant differences between mouse lines either in 
the CA1 area or dentate gyrus AM, amygdala; CA1 and CA3, 
respective hippocampal areas; Ctx, cerebral cortex; DG, dentate 
gyrus. 
 
 
5.5.2. GABAA receptor subtype alterations 
Since the α6 subunit was incorporated into the functional receptors of the Thy1α6 mouse 
hippocampal pyramidal cells, it should also be possible to detect those receptors in ligand 
autoradiographic assays. In fact, increased forebrain DIS-[3H]Ro 15-4513 binding suggesting 
upregulation of α6βγ2 receptors was detected on Thy1α6 mouse brain sections (Wisden et al., 
2002; IV: Fig. 1). In the previous study (Wisden et al., 2002) the coassembly of α6 and γ2 
subunits was confirmed by applying extracted forebrain GABAA receptors from Thy1α6 mice 
on an α6-immunoaffinity column, and by Western blotting of receptors retained by the 
column with the γ2 antibody. Further analysis with [3H]muscimol binding indicated that most 
α6 subunit-containing GABAA receptors in Thy1α6 forebrain contained γ2 subunits. No δ 
subunit with α6 could be detected. However, in addition to upregulated DIS-[3H]Ro 15-4513 
binding, GIS-[35S]TBPS binding was also detected in the forebrain regions of Thy1α6 mice, 
suggesting the presence of α6β receptors (IV: Fig. 1). The highest level of GIS-[35S]TBPS 
binding was detected in the hippocampal CA1 region, which was also the region with the 
greatest increase in DIS-[3H]Ro 15-4513 binding. In this region, about 10 % of the basal 
[35S]TBPS binding was not displaced by GABA.  
Previous analysis of the subunit content of Thy1α6 mouse GABAA receptors was 
performed with whole forebrain extracts. Due to the large number of GABAA receptors in 
many other brain regions besides hippocampus, and due to the detection limit of the assay, it 
is possible that these experiments failed to detect minor receptor subtypes. For example, 
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solubilization and precipitation of the receptors from brain homogenates may cause a loss of 
about 50 % of the receptors (Tretter et al., 2001). In order to get more precise estimates of the 
hippocampal GABAA receptors of the Thy1α6 and control mice, bare hippocampi from both 
mouse lines were dissected and analyzed (IV: Fig. 2). The total amount of receptors in the 
hippocampal extracts was determined by immunoprecipitation with a mixture of α1, β1, β2 
and β3 antibodies and subsequent [3H]muscimol binding. In parallel, hippocampal extracts 
(hippocampi from 10 or 5 control or Thy1α6 animals, respectively, were pooled) were 
chromatographed on immunoaffinity columns containing antibodies against the γ1, γ2, γ3, and 
δ subunits. The column efflux was subjected to immunoprecipitation with a mixture of α1, 
β1, β2 and β3 antibodies and subsequent [3H]muscimol binding. After chromatography, 
roughly 30 % of all the receptors present in control or in the Thy1α6 hippocampus extracts, 
respectively, could still be found in the column efflux. Due to the unexpectedly high 
proportion of receptors devoid of γ or δ subunits in both mouse lines, the subunit composition 
of the receptors remaining in the efflux was studied. For this, immunoprecipitation with 
subunit-specific antibodies and subsequent [3H]muscimol binding assays were applied. 
Immunoprecipitation of control mouse hippocampal extracts indicated that most of the 
receptors still present in the efflux contained γ2 subunits, indicating that the anti-γ2 column 
could not completely retain all the γ2-containing receptors. No α6, γ1, γ3, or δ subunit-
containing receptors could be identified in this efflux. So, no significant amounts of αβ 
receptors could be detected in the hippocampi of the control mice. In the experiments with 
Thy1α6 mouse hippocampal extracts, about 60 % of the receptors in the column efflux still 
contained the γ2 subunits. This indicates that, like the situation with the control mice, the anti-
γ2 column could not completely retain all the γ2-containing receptors. However, no γ1, γ3 or δ 
subunits were detected. These data indicate that about 10 % of the GABAA receptors in the 
Thy1α6 hippocampi were of αβ stoichiometry. Furthermore, most of the receptors found in 
the column efflux of the Thy1α6 mice contained α4 and α6 subunits, thus suggesting that 
most, if not all, αβ receptors contained α4 or α6 subunits. 
In the previous study (Wisden et al., 2002) Scatchard analysis of [3H]Ro 15-4513 
binding to mouse forebrain homogenates indicated a 28 % increase in BZ binding in the 
Thy1α6 mice, 80 % of which was due to the increased DIS binding component. This suggests 
that the number of non-α6βγ2 receptors was not decreased. Our autoradiographic assay 
showed a 25 % increase in [3H]Ro 15-4513 binding (64 ± 1 vs. 80 ± 4 nCi/mg for control and 
Thy1α6 mice, respectively; mean ± standard error, n = 5, p = 0.0045, unpaired t-test) but a 28 
% decrease in [35S]TBPS binding (335 ± 13 vs. 240 ± 9 nCi/mg, for control and Thy1α6 
mice, respectively, n = 7 and 8, p < 0.001, unpaired t-test) in the CA1 area of the Thy1α6 
mice. The autoradiographic assay does not allow direct estimation of total GABAA receptor 
numbers in the hippocampus of Thy1α6 and control mice, and in the Scatchard analysis of 
[3H]Ro 15-4513 binding whole forebrain membranes were used (Wisden et al., 2002). In 
these circumstances, and without knowledge of the subcellular localization of [35S]TBPS or 
[3H]Ro 15-4513 binding, it is not safe to speculate about changes in the total GABAA receptor 
levels of the Thy1α6 mice. However, these data together clearly demonstrate the presence of 
α6βγ2 and α6β receptors, which, according to the immunohistochemical data (Wisden et al., 
2002), are exclusively extrasynaptic.    
  
5.5.3. Behavioral significance of altered balance between synaptic and 
extrasynaptic inhibition 
To test the functional significance of the changed balance between synaptic and extrasynaptic 
inhibition, Thy1α6 and control mice were exposed to behavioral assays. Since most of our 
knowledge of the altered GABAAergic system in the Thy1α6 mice derives from the 
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hippocampal CA1 region (Wisden et al., 2002), the area of highest expression of ectopic α6-
containing receptors according to our receptor pharmacological studies, hippocampus-related 
behavioral tests were applied. The Thy1α6 transgene has regionally restricted expression, and 
in the brain regions where it is expressed, only part of the cells are immunopositive (Wisden 
et al., 2002), in keeping with 35 % of the CA1 pyramidal cells showing furosemide sensitivity 
(IV: Fig. 3). For these reasons, no drastic phenotype was expected. 
 
5.5.3.1. Basic behavior 
Thy1α6 mice look normal, and grow and breed normally. All behavioral tests were run on 
both male and female control and Thy1α6 mice, and no significant gender differences were 
detected. Thus data from the two genders were pooled. The Thy1α6 mice displayed grossly 
normal behavior in the basic behavioral assessment made according to the SHIRPA protocol 
(Rogers et al., 1997). Differences from controls were detected only in the startle reflex and the 
struggle-escape behavior. In the startle reflex, the Thy1α6 mice responded to abrupt tones 
more actively (IV: Fig. 4), acoustic stimuli usually producing a jump. The startle reflex is a 
protective reaction that is mediated by a brain-stem circuit, but modulated by forebrain areas 
such as the amygdala (Koch, 1999). The hippocampus, in turn, may modulate the startle 
reflex via projections from the ventral hippocampus to the amygdala (Pitkänen et al., 2000). 
As the α6 transgene is expressed both in the amygdala and in the hippocampus of Thy1α6 
mice (Figure 11), it might be involved in the changed startle reflex. Thy1α6 mice also had 
enhanced struggle-escape behavior (IV: Fig. 4), meaning heightened touch reflex, aggression 
and vocalization towards the observer. Struggle-escape behavior involves complex behavioral 
responses and cannot be linked to any particular brain region. 
In patients with panic disorder disturbed hippocampal GABAAergic system has been 
reported (Kaschka et al., 1995). In the GABAAergic animal model of human anxiety (γ2+/- 
mouse line; Crestani et al., 1999) the phenotype is caused by reduced synaptic clustering of 
GABAA receptors and the resulting diminished synaptic inhibition (Crestani et al., 1999). 
Moreover, an enhanced startle reflex, similar to that observed in Thy1α6 mice, has been 
detected in another mouse model of pathological anxiety, the BALB mice (Plappert and Pilz, 
2002). Thus, Thy1α6 mice were studied in the light-dark test, a common paradigm for testing 
baseline anxiety (Crawley and Goodwin, 1980) to see whether decreased synaptic inhibition 
caused an altered phenotype. However, Thy1α6 had a performance similar to their control 
animals, and thus revealed no differences in background anxiety levels. The hippocampus is 
also of crucial importance in other cognitive functions such as exploratory behavior, learning 
and memory. To probe for these hippocampal functions in Thy1α6 mice, the T-maze test with 
continuous alternation task protocol (Gerlai, 1998) was applied. As with the light-dark test, 
Thy1α6 mice had a similar performance to their control animals in all the parameters 
measured. In conclusion, the basic behavioral experiments without external stimuli revealed 
no differences between control and Thy1α6 mouse phenotypes. This indicates that in the 
Thy1α6 mice, there are no widespread deficits in GABAA receptor function, and that the 
compensatory decrease in the inhibitory synaptic transmission after increased tonic inhibition 
sustains adequate hippocampal function under normal circumstances. 
 
5.5.3.2. Convulsion tests 
In the basic behavioral tests, the Thy1α6 displayed disturbances only after strong external 
stimuli, a sudden loud noise (startle reflex) or the hand of the observer (struggle escape 
behavior). Next the inhibitory capacity of the altered GABAAergic system in Thy1α6 mice 
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was studied with strong chemical stimuli, the GABAA receptor antagonists DMCM and 
picrotoxinin injected intraperitoneally (i.p.). Both compounds cause convulsions by blocking 
GABAAergic inhibition in the cortex, amygdala and hippocampal formation (Vergnes et al., 
2000). Convulsant actions of DMCM are mediated solely by α1 subunit-containing GABAA 
receptors (Crestani et al., 2002b). In α6-containing receptors, DMCM has agonist effects in 
vitro (Im et al., 1995b; Stevenson et al., 1995; Knoflach et al., 1996; Saxena and Macdonald, 
1996). Whether this happens in vivo, is currently not known. When giving DMCM we thus 
inhibited mainly synaptic α1βγ2 receptors in the hippocampus of both mouse lines, and 
possibly also positively modulated α6βγ2 receptors in the Thy1α6 mice. However, the 
Thy1α6 mice had a shorter latency to the writhing clonus induced by DMCM (IV: Fig. 5). 
This demonstrates that reducing the already decreased synaptic inhibition in Thy1α6 mice 
was critical for the onset of convulsions. Similar to DMCM, the GABAA receptor subtype 
non-selective antagonist picrotoxinin caused (generalized tonic-clonic) convulsions in the 
Thy1α6 with shorter latency as compared with their control animals (IV: Fig. 5). These data 
demonstrate that the Thy1α6 mice are more sensitive to the convulsions produced by GABAA 
receptor antagonists.  
In electrophysiological recordings of CA1 pyramidal cells the increased background 
inhibition of the Thy1α6 mice was revealed after an increase of extracellular GABA 
concentration by GABA uptake blocker NO-711 (Wisden et al., 2002). By administering 
another GABA uptake blocker, the antiepileptic drug tiagabine (Fink-Jensen et al., 1992; 
Dalby, 2000), we hoped to increase the function of high-affinity α6-receptors in the 
extrasynaptic loci similar to the in vitro situation. Interestingly, tiagabine (i.p., 30 min prior to 
i.p. picrotoxinin) delayed the picrotoxinin-induced generalized tonic-clonic convulsions 
already at a 3.2 mg/kg dose in the Thy1α6 mice, but not in their control animals (IV, Fig. 6). 
This suggests that tonic GABAAergic conductance was increased by the elevated GABA level 
in vivo, similar to that detected in vitro (Wisden et al., 2002), and demonstrates the behavioral 
function of increased tonic conductance for the first time. However, higher tiagabine doses 
had an antiepileptic effect in the control mice also, and the overall effect of tiagabine was 
greater in the control mice (IV: Fig. 6). In addition to delaying convulsions, the highest 
tiagabine dose prevented convulsions in 6 out of 7 control mice for the 900-s observation 
period, whereas it prevented convulsions in only 2 out of 11 Thy1α6 mice. 
 In conclusion, functional extrasynaptic α6 subunit expression in α6βγ2 and α6β 
combinations in the hippocampal CA1 region of Thy1α6 mice increases tonic but decreases 
phasic inhibition without compensatory alterations in other GABAA receptor subunit mRNA 
levels. The compensation of increased tonic conductance by a decrease in synaptic 
transmission sustains normal behavior, but in controlling strong excitation the synaptic 
component of inhibition dominates. 
 
5.6. GABAA receptor subtype-selective actions of niflumate revealed by 
[35S]TBPS autoradiography (V) 
In a search for compounds affecting the GIS-[35S]TBPS binding, the effects of niflumate 
(niflumic acid; 2-[3-(trifluoromethyl)-phenyl]aminonicotinic acid), a non-steroidal anti-
inflammatory drug (NSAID), on the pharmacological fingerprint was tested on the rat brain 
autoradiography. Previously, direct actions by niflumate on GABAA receptors have not been 
reported, but both negative and positive modulation of GABA-induced currents in Xenopus 
oocytes injected with rat brain total RNA (White and Aylwin, 1990) or with rat cortical 
poly(A)+RNA (Woodward et al., 1994) have been found. In addition, niflumate had been 
shown to decrease both [35S]TBPS and [3H]EBOB bindings to convulsant binding sites in rat 
brain homogenates (Evoniuk and Skolnick, 1988; Maksay et al., 1998).  
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5.6.1. Effects in the brain 
The original experiment revealed that the GIS-[35S]TBPS binding was increased in the 
cerebellar granule cell layer by 100 µM niflumate (not shown). No effect on the forebrain in 
the presence of 1 mM GABA was detected. This was somewhat surprising, since a decreasing 
effect of [3H]EBOB binding to cerebellar membranes was previously detected (Maksay et al., 
1998). In the following experiments, the effects of various niflumate concentrations on 
[35S]TBPS binding were tested without GABA or with 3 µM or 1 mM GABA (V: Fig. 2). 
Brain regional heterogeneity of the effects was revealed, as niflumate potentiated the 
inhibitory effect of 3 µM GABA on [35S]TBPS binding in most brain regions, but in the 
cerebellar granule cell layer it inhibited the effect of GABA (V: Table 2). These effects were 
detected up to a niflumate concentration of 1 000 µM, which decreased [35S]TBPS also in the 
cerebellar granule cell layer. In the presence of 1 mM GABA, only the GIS-[35S]TBPS 
component was visible, and in the cerebellar granule cell layer it was increased by nifumate 
concentration-dependently up to 300 µM, but at 1000 µM concentration it was decreased (V: 
Table 3). The thalamic component of GIS-[35S]TBPS binding was increased by 10 and 30 
µM niflumate, whereas 100 and 300 µM concentrations were inactive and 1000 µM niflumate 
decreased the binding.  
 
5.6.2. Actions on recombinant receptors 
The brain regional variation of niflumate effects on [35S]TBPS binding led to a search for 
structural correlates for it. In the case of GABAA receptors, the pharmacological 
heterogeneities can usually be explained by different receptor subunit combinations. For this 
reason, we selected candidate subunits and expressed them in Xenopus oocytes. The direct 
actions of niflumate on the different recombinant GABAA receptor subtypes were then 
studied using two-electrode voltage-clamp recordings. 
 
5.6.2.1. Negative modulation 
Furosemide selectively and non-competitively inhibited the effects of GABA on recombinant 
receptors containing α4/6 and and β2/3 subunits (see 2.5.8.) and on [35S]TBPS binding in the 
cerebellar granule cell layer and the thalamus (V: Fig. 2), similarly to the effects of niflumate. 
Niflumate and furosemide also share some structural similarity (V: Fig. 1). For these reasons 
the negative modulation by niflumate in the cerebellar granule cell layer was hypothesized to 
share the same structural requirements as the furosemide actions, and α6 and β2 subunit-
containing receptors were selected. Niflumate alone was without effect or had only minor 
effects with high concentrations on α6 subunit-containing receptors. Niflumate inhibited 
GABA-induced currents in a concentration-dependent manner in α6β2 and α6β2γ2 GABAA 
receptors (V: Figs. 3 and 7). In α6β2γ2 receptors, niflumate reduced the maximal GABA 
currents but did not affect the EC50 for GABA (V: Fig. 4) suggesting a non-competitive 
mechanism of action similar to furosemide (Korpi et al., 1995a). A chimeric α1 subunit, 
where a 258 bp fragment including the TM1 and TM2 domains of the α1 subunit is 
substituted with that of the α6 subunit gene to confer furosemide sensitivity (Jackel et al., 
1998), was enough to introduce the negative modulation by niflumate to α1β2γ2 receptors, 
which strengthened the idea of furosemide and niflumate sharing the same binding/effector 
site on the α6 subunit. These results indicate that niflumate acts as a negative non-competitive 
modulator in native and recombinant GABAA receptors composed of α6 and β2 subunits with 
or without γ2 subunits. 
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5.6.2.2. Positive modulation 
The GABA-potentiating effect of niflumate was seen throughout the brain in the [35S]TBPS 
autoradiography. For this reason, the prototypical and most abundant α1β2γ2 GABAA 
receptor subtype (McKernan and Whiting, 1996) was selected for studies on positive 
modulation. Niflumate dose-dependently potentiated the 3 µM GABA-induced currents by 
about 60 % in α1β2γ2 receptors with EC50 of 31 ± 3 µM (V: Fig. 3). Niflumate did not 
increase the efficacy of GABA, but increased its potency, indicating an allosteric mechanism 
of action (V: Fig. 4). In α1β2 receptors, niflumate did not have any effect up to 100 µM 
concentrations, but 1000 µM niflumate inhibited the GABA response by 30 % (V: Fig. 7). 
This shows that positive modulation by niflumate is dependent on the presence of the 
γ2 subunit together with a suitable α subunit. Since niflumate potentiation in α1β2γ2 
receptors was not blocked by the BZ binding site antagonist flumazenil (V: Fig. 8), these data 
suggest that niflumate potentiation is mediated via a novel site of the GABAA receptors 
dependent on α, β and γ subunits. 
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6. GENERAL DISCUSSION  
6.1. Receptor subunit combinations leading to GABA-insensitive [35S]TBPS 
binding in the brain 
[35S]TBPS binding insensitive up to 50 µM GABA was first reported in the cerebellar granule 
cell layer (Edgar and Schwartz, 1990; Korpi and Lüddens, 1993). In the present study this 
minor proportion of the total [35S]TBPS binding was found to be totally GABA-insensitive, 
since GABA up to 10 mM could not displace it. Thus, it was named the GABA-insensitive 
(GIS) [35S]TBPS binding, and it was also found in some forebrain areas, most notably the 
thalamus (I). In a search for the subunit combinations causing this pharmacological 
fingerprint in the brain, strong evidence for a positive correlation with the α6 subunit and a 
negative correlation with the γ2 subunit was revealed in mutant mouse lines (II, III). In the 
present experiments recombinant β3, α6β3, α1β3 and α1β2δ GABAA receptors bound 
[35S]TBPS in a way that was totally or partially insensitive to the inhibitory effect of GABA 
(III: Table 1; Figure 9). Previously, α6β2 (Korpi and Lüddens, 1993; Im et al., 1994), and 
α6β3 and α6β3δ (Korpi and Lüddens, 1997) receptors had displayed [35S]TBPS binding that 
was totally or partially insensitive to the inhibitory effect of 10 µM GABA. However, 
[35S]TBPS binding to α1β2, α1βγ2 and α6βγ2 receptors is GABA-sensitive (III; Korpi and 
Lüddens, 1993). These results indicate that there are four main factors which determine the 
modulatory effect of GABA on [35S]TBPS binding. Firstly, the α6 subunit induces GABA-
insensitivity when compared to the α1 subunit, as indicated by GIS-[35S]TBPS binding to 
α6β2 but not to α1β2 receptors. Secondly, inclusion of the γ2 subunit in the receptor complex 
converts [35S]TBPS binding to α1β3 and α6β2/3 receptors GABA-sensitive. Thirdly, δ makes 
[35S]TBPS binding even to α1β2 receptors insensitive to GABA. Fourthly, β3 subunits are 
more susceptible than β2 subunits to causing poor coupling between GABA and convulsant 
sites, at least in the presence of α1 subunit, as indicated by GIS-[35S]TBPS binding to α1β3 
receptors but not to α1β2 receptors. Also, receptors composed only of β3 subunits displayed 
GIS-[35S]TBPS binding, but homomeric β2 receptors did not. What is the exact mechanism 
leading to GABA-insensitivity of [35S]TBPS binding to these receptor subtypes is currently 
unknown, but it may include atypical conformation of agonist or convulsant binding sites, or 
atypical coupling between these. 
 From the above-summarized results it can be deduced that, in the native brain, at least 
the greatest part of the GIS-[35S]TBPS binding in the cerebellar granule cell layer is caused by 
α6β2/3 and/or α6β2/3δ receptors. While data for α6βδ receptors is preliminary (Figure 9), 
and it is not totally certain that δ subunits are incorporated into recombinant α6β2δ receptors 
in the present set of experiments, or in the previous experiments with α6β3δ receptors (Korpi 
and Lüddens, 1997), since α6β receptors would already display GIS-[35S]TBPS binding, the 
incorporation of δ to α1β2δ receptors is certain (Figure 9). Since δ is able to confer GIS-
[35S]TBPS binding to α1β2 receptors, it is presumable that α6βδ displays also GIS-
[35S]TBPS binding. So, in the native brain, both α6β2/3 and α6β2/3δ combinations resulting 
in GIS-[35S]TBPS binding are possible. Using subunit-specific antibodies and combining 
immunoaffinity chromatography with immunoprecipitation and Western blot analysis with 
subsequent binding studies, it is possible to determine and quantify the GABAA receptor 
subtypes in the brain. In the cerebellum, the major receptor subtypes are α1βγ2, α6βγ2, 
α1α6βγ2, α6βδ and α1α6βδ (Quirk et al., 1994; Pöltl et al., 2003). The α6βδ receptors 
constitute about 23 % of all receptors in the cerebellum (Quirk et al., 1994). Coassembly of 
α1 and δ subunits is very limited (Quirk et al., 1994), but a minor population of α1βδ 
receptors may also be present (Pöltl et al., 2003), and altogether 97 % of receptors contain γ2 
or δ subunit (Tretter et al., 2001). However, the quantitation techniques have limited 
sensitivity. The solubilization and precipitation of the receptors from brain membranes cause 
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loss of about 50 % of the receptors (Tretter et al., 2001), and each precipitation step with 
subunit-specific antibodies has its own sensitivity. Thus, detection of minor receptor subtypes 
is difficult (Quirk et al., 1994). Also, detection of a minor subtype of cerebellar granule cell 
layer is further hampered by the receptors of the molecular layer. Nevertheless, if α6β 
receptors exist in vivo, they seem to constitute a minor population, a few percentages, of the 
total number of cerebellar receptors. Since GIS-[35S]TBPS binding consists of 6-15 % of the 
basal [35S]TBPS binding in the cerebellar granule cell layer, depending on the species studied 
(I, II), it seems likely that both α6β and α6βδ receptors participate in its formation. Since we 
do not know how GABA actually modulates [35S]TBPS binding in these receptors (total or 
partial insensitivity of [35S]TBPS binding), it is possible that the about 10 % of the GIS-
[35S]TBPS binding component represents the α6βδ receptors with a prevalence of 23 % of the 
total cerebellar receptor population (Quirk et al., 1994). However, in the δ-/- mice there is a 
remarkable correlation between the number of receptors devoid of γ or δ subunits (24 %; 
(Tretter et al., 2001) and the proportion of GIS-[35S]TBPS binding of the total binding (24 %; 
II), which suggests that, in these mice, GIS-[35S]TBPS binding represents α6β and possibly 
other αβ3 receptors.  
In addition to the cerebellar granule cell layer, the GIS-[35S]TBPS binding is also found 
in selected forebrain regions, mainly the thalamus and deep layers of the cortex, where it 
represent a few percentages of the total [35S]TBPS binding (I). Its localization is in good 
correlation with the expression of the δ and α4 subunits (II). In the thalamus, α4βδ receptors 
compose 13 % and α4βγ2 8 % of all GABAA receptors (Sur et al., 1999), but about 50 % of 
the α4 subunit-containing receptors in the brain are devoid of γ or δ subunits (Bencsits et al., 
1999). Due to the difficulties with α4 subunit expression in HEK 293 cells, we have not been 
able to study the GABA sensitivity of [35S]TBPS binding in different α4 subunit-containing 
GABAA receptors. Furthermore, mouse lines devoid of α4 do not exist. However, since the 
α4 subunit is the closest subunit to α6 in respect of pharmacological properties (insensitive to 
BZ full agonists; Benke et al., 1997, but sensitive to furosemide; Knoflach et al., 1996) and 
preferential assembly with the δ subunit (Sur et al., 1999), and even α1β2δ receptors display 
GIS-[35S]TBPS binding, it is highly likely that native α4β and α4βδ receptors would bind 
[35S]TBPS in a GABA-insensitive manner. The role of α4βδ receptors is supported by the 
finding that THIP, a partial agonist in α1/4βγ2 receptors (Ebert et al., 1994; Ebert et al., 1997; 
Brown et al., 2002) but a full agonist in α4βδ receptors (Brown et al., 2002), displaces all 
[35S]TBPS binding from the thalamus at high concentrations, while GABA competitively 
decreases the effect of THIP (Figure 10). 
In addition to the previously discussed receptor subtypes, recombinant α3β3γ2/3 and 
α5β3γ2/3 receptors also bind [35S]TBPS in the presence of 1 mM GABA (Lüddens and 
Korpi, 1995). The α3 and α5 are the only subunits whose expression is enriched in the deep 
layers of the cerebral cortex similarly to the distribution of GIS-[35S]TBPS binding (II: Fig. 
1). The α5 is additionally expressed in the hippocampus, where it might participate in forming 
the tiny proportion of GIS-[35S]TBPS binding detected (II: Fig. 1). α5 seems to be located 
exclusively extrasynaptically (Brünig et al., 2002; Crestani et al., 2002a). This is in line with 
tonic GABAAergic inhibition being reduced in the hippocampus of a mouse line devoid of α5 
subunits (Caraiscos et al., 2004). The α3 is located on both synaptic and extrasynaptic 
membranes (Brünig et al., 2002). In addition, THIP is as effective as GABA in α5β3γ2 
receptors, but in α3β3γ2 receptors it has only about 50 % of the efficacy of GABA (Ebert et 
al., 1994). As the receptor subtypes previously proposed to produce GIS-[35S]TBPS binding 
(α6β2/3, α6β2/3δ, α4β, α4βδ) are also extrasynaptic (δ subunit-containing receptors 
exclusively extrasynaptic; Nusser et al., 1998a), and the γ2 subunit is required for 
postsynaptic clustering (Crestani et al., 1999), these data suggest that GIS-[35S]TBPS binding 
preferentially represents receptors on extrasynaptic loci. Why α3β3γ2 and α5β3γ2 receptors 
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display GIS-[35S]TBPS binding despite the presence of γ2 subunits is currently unknown, but 
it might be at least partially related to the β3 subunit variant. 
All the evidence presented above about the roles of the different subunits in GIS-
[35S]TBPS binding is indirect. Also the subcellular localization of GIS-[35S]TBPS binding on 
extrasynaptic membranes is deduced from the presumed subunit combinations. [35S]TBPS 
binding cannot be studied at the cellular level owing to its dissociation with photographic 
emulsion. Only photoaffinity labeling of receptors with [35S]TBPS or similar derivatives and 
subsequent electron microscopic detection of the signal would allow direct demonstration of 
the subcellular localization directly. Unfortunately, no suitable photoaffinity ligand for the 
convulsant binding site is available, even though irreversible binding of some TBOB 
derivatives has been suggested (Lewin et al., 1989). On the other hand, it is unlikely that the 
allosteric interaction, or lack of it, between the agonist and the convulsant sites (GIS-
[35S]TBPS binding) could be demonstrated with photoaffinity labeling. Thus, in this respect 
we have at present to rely on indirect and deductive data. 
 
6.2. Properties and significance of extrasynaptic GABAA receptors 
Extrasynaptic receptors give rise to tonic inhibition, which is common to all neurotransmitter 
systems (reviewed in Zoli et al., 1999). Only a small fraction of the postsynaptic neuronal 
membrane area participates in forming synapses. After subunit assembly in the cytoplasm, the 
receptors are inserted to neuronal membranes, where they diffuse somewhat arbitrarily. In 
order to achieve the receptor enrichment on postsynaptic membranes there must be ways to 
retain receptors juxtaposed to the presynaptic terminal. Gephyrin participates in this process 
with GABAA receptors (Kneussel et al., 1999) and is colocalized with α1, α2, α3 and γ2 
subunits in many brain regions, but not with α6 or δ subunits (Sassoè-Pognetto et al., 2000). 
Lack of colocalization with gephyrin does not necessarily mean extrasynaptic localization, 
since other clustering proteins are also proposed (Kneussel et al., 2001). The γ2 subunit is 
essential for synaptic anchoring of the major GABAA receptor subtypes as deduced from 
dramatically reduced postsynaptic receptor clusters in γ2 knockout mice (Essrich et al., 1998). 
On the basis of immunohistochemical studies it has been suggested that α6βδ receptors are 
exclusively extrasynaptic. The α6βγ2 receptors are found in both synaptic and extrasynaptic 
membranes, while the α1βγ2 receptors are mainly located in synapses, but at lower 
concentrations also on extrasynaptic membranes (Nusser et al., 1998a). The previous 
considerations about the structural requirements of synaptic receptors (γ2 subunits) fit with 
the immunohistochemical data, and also indicate that the α6β receptors proposed in the 
current study would be extrasynaptic. Their presence is supported by detection of α6β 
receptors, but not α6βδ, in the hippocampus of Thy1α6 mice together with GIS-[35S]TBPS 
binding (IV; Wisden et al., 2002). Also, in the δ-/- mice GIS-[35S]TBPS is found in the 
cerebellar granule cell layer, indicating that α6βδ receptors are not the only possible receptors 
responsible for the pharmacological fingerprint. Receptor subtypes with both α1 and α6 
subunits also exist, mainly in synaptic compartments, but they will not be dealt with here. 
However, one should not be too pragmatic in biology, and it is likely that all the receptor 
subtypes exist in both synaptic and extrasynaptic loci, but their proportions in the two 
compartments varies, depending on subunit composition. 
Tonic GABAAergic conductance was first proposed by Birnir et al. (1994) in the 
hippocampal dentate gyrus. Thereafter, it was found and characterized in the cerebellar 
granule cell layer (Kaneda et al., 1995; Brickley et al., 1996; Tia et al., 1996a; Wall and 
Usowicz, 1997). Some properties of synaptic and extrasynaptic receptors in the cerebellar 
granule cell layer are listed in Table 3. When interpreting the functional correlates of GIS-
[35S]TBPS binding, it has to be remembered that the receptors responsible for GIS-[35S]TBPS 
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binding are actually highly sensitive to low concentrations of GABA, but that [35S]TBPS 
binding to these receptors is not efficiently displaced by GABA. This suggests that the 
“problem” is not in the agonist binding per se, but rather in the coupling between agonist and 
convulsant sites and/or channel activation. One interpretation of the situation is that GABA is 
not a full agonist in the receptors responsible for GIS-[35S]TBPS binding. What might be the 
rationale behind the scheme where a natural agonist has only partial efficacy? The explanation 
may be related to the localization of these receptors outside synapses. For synaptic receptors, 
which have access to the agonist for only a very limited period of time, it is important to be 
able to activate as large and fast postsynaptic response as possible. In those receptors the 
response is proportional to the efficacy of the agonist. However, for the extrasynaptic 
receptors, which are permanently bathed in submicromolar GABA (Lerma et al., 1986; 
Tossman et al., 1986; Attwell et al., 1993; Richerson and Wu, 2003), and which will usually 
not encounter much higher agonist concentrations, the important property might be not the 
full but the permanent activation, which is ensured by the high affinity for GABA and the low 
receptor desensitization (Table 2). Here, it is important to note that “typical” receptors with 
lower GABA sensitivity may also participate in forming tonic conductance; those receptors 
just have a lower open probability in the presence of low agonist concentrations. On the other 
hand, low ambient agonist concentrations do not cause desensitization, which would take 
place at higher agonist concentrations, and receptors would remain functional despite 
permanent stimulation. 
What might be the functional correlate of the findings that GIS-[35S]TBPS binding can 
be totally abolished by either application of THIP instead of GABA, or by inclusion of the γ2 
subunit in the receptor complex? It is possible that partial and full agonists affect receptor 
channel conductance or mean open time differentially (Lindquist et al., 2003; Mortensen et 
al., 2004). Similarly, inclusion of the γ2 subunit into αβ receptors may affect channel 
conductance and mean open time (Lorez et al., 2000). However, the totally different time 
scales of [35S]TBPS binding (min - hour) and channel kinetics (ms) makes it impossible to 
deduce any solid conclusion about the receptor channel functional correlate of GIS-[35S]TBPS 
binding.  
The presence of GIS-[35S]TBPS binding in the cerebellar granule cells with well-known 
tonic inhibition (I), its decrease in the α6-/- mice together with decreased tonic inhibition (II), 
and its induction in the hippocampal CA1 pyramidal cells together with an increase in tonic 
inhibition in the Thy1α6 mice (IV; Wisden et al., 2002), show that GIS-[35S]TBPS binding 
can be used to image the extrasynaptic receptors causing tonic conductance. However, there is 
an important exception, the δ-/- mice. In these mice GIS-[35S]TBPS binding in the cerebellar 
granule cell layer is increased (II), but the tonic GABAAergic inhibition is practically 
abolished (Stell et al., 2003). Also, GIS-[35S]TBPS binding is very low in some areas with 
marked tonic inhibition, e.g., the hippocampus (CA1 region: Birnir et al., 2000; Bai et al., 
2001; Semyanov et al., 2003; Caraiscos et al., 2004; dentate gyrus: Nusser and Mody, 2002; 
Stell et al., 2003; Wei et al., 2003). Thus, even though, in many cases GIS-[35S]TBPS binding 
is suggestive of the presence of pronounced tonic GABAAergic inhibition, even without the δ 
subunit, as indicated by the Thy1α6 mice (IV; Wisden et al., 2002), it should not be 
considered obligatory for it. 
 In general, tonic inhibition deriving from extrasynaptic receptors is suggested to set a 
background level for overall neuronal excitability by controlling membrane properties, such 
as membrane input resistance and time constant (Häusser and Clark, 1997; Mody, 2001; 
Mitchell and Silver, 2003). More specific functions in most brain areas are still unrevealed, 
but in the cerebellar cortex the role of tonic inhibition is beginning to be solved. Tonic 
inhibition of the granule cells, which contributes more than 90 % of the total inhibitory charge 
transfer (Brickley et al.,  1996; Hamann et al., 2002), decreases the  number of excited granule  
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cells in vitro (Hamann et al., 2002). Recently it was demonstrated that tonic inhibition also 
reduces spontaneous firing rates of granule cells in vivo (Chadderton et al., 2004). In addition, 
it allows temporal summation of excitatory postsynaptic currents, which is important in 
regulating granule cell bursting (Chadderton et al., 2004). Thus, tonic inhibition improves the 
signal-to-noise ratio of sensory information transfer through the cerebellar cortex (Chadderton 
et al., 2004). Reduction of the number of granule cells activated decreases the rate of Purkinje 
cell firing, which is suggested to improve the information storage capacity of the cerebellum 
(Hamann et al., 2002). Vice versa, reduction of tonic conductance enables single mossy fiber 
 
Table 2. Properties of selected GABAA receptor subtypes in the cerebellar granule cells. 
      
      
Receptor subtype α1β2/3γ2 α6β2/3γ2 α6β2/3δ α6β2/3 References 
      
      
Subcellular 
localization 
synaptic synaptic & 
extrasynaptic 
extrasynaptic extrasynaptic Nusser et al., 1998a; IV 
 
 
Form of inhibition phasic phasic & 
tonic 
tonic tonic (?) Nusser et al., 1998a; IV 
 
 
Autoradiographic 
imaging 
DS-[3H]Ro 
15-4513 
DIS-[3H]Ro 
15-4513 
[3H]musc & 
GIS-
[35S]TBPS 
GIS-
[35S]TBPS 
Korpi and Lüddens, 
1997; Mäkelä et al., 
1997; Korpi et al., 2002b; 
II, III, IV, Figure 9 
 
GABA EC50 (µM) 8.0 1.8 0.19 0.46 V; Saxena and 
Macdonald, 1996 
 
Desensitization fast poor poor poor Tia et al., 1996b; Haas 
and Macdonald, 1999 
Modulation by 
drugs 
     
 
            GABA ++ ++ + (?) + (?) I, II, III, IV, Figure 9 
 
            THIP + ++ ++ (?) ++ (?) Ebert et al., 1997,   
Figure 10 
 
            Diazepam ++ 0 0 0 Saxena and Macdonald, 
1996 
 
            DMCM - + + + Im et al., 1995b; 
Knoflach et al., 1996; 
Saxena and Macdonald, 
1996 
             picrotoxinin - - - - Saxena and Macdonald, 
1996 
 
             furosemide 0 - - -  Korpi et al., 1995a; 
Korpi and Lüddens, 
1997; V 
             niflumate ++ - - (?) - V 
 
 
DS, diazepam-sensitive; DIS, diazepam-insensitive; [3H]musc, high-affinity [3H]muscimol 
autoradiographic procedure. (++), full agonist or full positive modulator; (+), partial agonist or weak 
positive modulator; (0), inactive; (-), negative modulator. (?), hypothesized.  
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action potential to be transferred through the granule cell layer, which makes the network 
sensitive to minor stimuli when required (Chadderton et al., 2004). Thus, tonic inhibition in 
the cerebellar granule cells seems to be crucial for normal performance of the cerebellar 
cortex. This is supported by the finding that in the α6-/- mice, where GABAAergic tonic 
inhibition is abolished (Brickley et al., 2001) together with decreased GIS-[35S]TBPS binding 
(II), normal motor performance is maintained by induction of potassium “leak” conductance 
(Brickley et al., 2001). In this context, it seems likely that in the δ-/- mice, which display 
normal motor performance but decreased GABAAergic tonic conductance (Stell et al., 2003), 
some as yet unrevealed compensation may take place.   
Inhibition in the hippocampus is reviewed in Section 2.4.7. Normally, CA1 pyramidal 
cells possess tonic inhibition (Birnir et al., 2000; Bai et al., 2001; Semyanov et al., 2003; 
Caraiscos et al., 2004), but its contribution to the total inhibitory charge transfer has not been 
quantified. Since CA1 pyramidal cells constitute the main output of the hippocampus, the 
tone setting tonic inhibition presumably has a large influence on hippocampal function as 
suggested by homology with the cerebellar function. For this reason the Thy1α6 mice offer, 
for the first time, an intriguing possibility to study the effects of different forms of inhibition 
on animal behavior. A hypothetical model of the GABAAergic system in the Thy1α6 mouse 
CA1 pyramidal cells leading to behavioral consequences may be provided (IV:Fig. 7). The 
Thy1α6 model suggests that increasing extracellular GABA levels upregulates tonic 
inhibition in vivo, similar to the effects detected in vitro (Wisden et al., 2002), which has the 
lengthened latency to convulsions as its behavioral correlate (IV: Fig. 6). If tonic inhibition 
were more important in absolute terms than phasic inhibition in CA1 pyramidal cell function, 
it would be likely that the Thy1α6 would benefit from tiagabine more than their control 
animals in the whole dose range tested. Since this is not the case (IV: Fig. 6), it has to be 
concluded that tonic inhibition cannot substitute for phasic inhibition in circumstances with 
strong excitation. Nevertheless, the Thy1α6 mice might serve as a useful tool in future studies 
of the pathophysiology of epilepsy, and in research on antiepileptic drugs. In fact, recently a 
structural variation in the δ subunit gene was found that caused a decrease in GABA-gated 
currents, and was genetically linked to generalized epilepsy (Dibbens et al., 2004). This may 
indicate that tonic inhibition, or its disturbance, is important in the expression of human 
epilepsy. However, it is important to keep in mind that, in the native hippocampal 
environment, the α6 subunit does not exist, and thus the results presented here have to be 
considered as suggestive rather than conclusive.  
While many basic physiological characteristics of GABAAergic tonic inhibition are still 
unclear, the chief question at the moment concerns drug therapy: where are the primary 
targets of GABAAergic drugs, in synapses or on extrasynaptic membranes? GABAAergic 
drugs usually exert their actions by enhancing the agonistic effect of GABA. It has been 
estimated that peak GABA concentrations in the synaptic cleft reach 0.3 - 3 mM (Mozrzymas 
et al., 1999; Perrais and Ropert, 1999), but most GABAA receptor subtypes have an EC50 for 
GABA below 50 µM (Hevers and Lüddens, 1998). The discrepancy between the receptors’ 
affinity for GABA and the apparently overwhelming agonist concentrations in the synaptic 
cleft makes it tempting to speculate that the primary targets for GABAAergic drugs are the 
extrasynaptic receptors. In these receptors, positive modulators would have powerful effects 
on inhibitory tone in the presence of low ambient GABA. In fact, their effects would be 
independent of synaptic activity. Also, another interesting point arises when thinking about 
the penetration of drugs to their effectory sites. The drugs initially diffuse throughout the 
extracellular space, and thus their concentrations on extracellular membranes are presumably 
similar to those in synapses. Later on, drugs are probably concentrated in synapses due to 
enrichment of the receptors with high affinity to the drugs. Anyhow, it has been demonstrated 
that the tonic conductance in CA1 pyramidal neurons of rat hippocampal slices is potentiated 
by midazolam and propofol more than the phasic conductance (Bai et al., 2001). Vigabatrin, 
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an antiepileptic drug that increases brain GABA levels, reduces phasic but increases tonic 
inhibition (Overstreet and Westbrook, 2001; Wu et al., 2003). In addition, neurosteroid 
modulation was reduced in the δ-/- mouse hippocampal dentate gyrus in conjunction with 
deletion of extrasynaptic δ-receptors (Stell et al., 2003). THIP, which is currently developed 
as a hypnotic, has a markedly higher affinity, and also a higher efficacy, on extrasynaptic 
receptors than on prototypical synaptic α1βγ2 receptors (Ebert et al., 1994; Ebert et al., 1997; 
Brown et al., 2002), which might make it relatively selective for increasing tonic inhibition in 
vivo. At least its clinically effective concentration (~1 µM; Madsen et al., 1983; Faulhaber et 
al., 1997) is far closer to the EC50 of the extrasynaptic receptors, and 2 µM THIP has been 
shown to activate extrasynaptic GABAA receptors in CA1 pyramidal neurons of hippocampal 
slices (Lindquist et al., 2003). Taking all these things together, and accepting the fact that the 
subunit composition of the receptor determines its subcellular localization, there should be 
possibilities to introduce novel compounds acting selectively on phasic or tonic conductance. 
With these compounds, selective and possibly safer treatment could be feasible. This is 
supported by the recent finding that no tolerance was developed to the anxiolytic actions of 
THIP (Liang et al., 2004), which were markedly enhanced in an anxious rat model of the 
premenstrual syndrome with upregulated hippocampal α4βδ receptors (Gulinello et al., 
2003). Considering only some of the brain regions where tonic conductance could be 
selectively modulated, novel treatments affecting e.g. memory performance and seizure 
threshold (hippocampus), sleep and anesthesia (thalamus) and motor coordination 
(cerebellum) could be envisaged. In addition, selective compounds could be used to elucidate 
the significance of the complex balance between the two forms of GABAAergic inhibition. 
However, if the unidentified compensatory mechanisms seen in the Thy1α6 (Wisden et al., 
2002) and GAT-1 deficient mice (Jensen et al., 2003), which balance the increased tonic 
inhibition with reduction in phasic inhibition, apply also for drug therapy, the issue is 
obviously more complex. This seems to hold true for vigabatrin (Overstreet and Westbrook, 
2001; Wu et al., 2003). 
 
6.3. Use of GABA-insensitive [35S]TBPS binding in monitoring alterations of 
GABAAergic system in animal models of neurological and psychiatric diseases  
In order to better understand the pathophysiology of neurological and psychiatric diseases, 
and to obtain better cure for them, we constantly need basic research and laboratory animals. 
Hopefully in the future many things can be solved with cell or organ cultures, but in the case 
of such a complex organism as the brain, we shall still be, for a long period of time, dependent 
on experimental animals. In addition, with the advances in gene manipulation technology and 
knowledge of genetic liability to the diseases, more and more accurate animal models for 
human neurological and psychiatric diseases can be produced. In many cases the animal 
models are so similar to human diseases that they offer a fairly straight-forward link to the 
crucial changes leading to human pathological conditions. In a recent report, Zambrowicz and 
Sands ( 2003) retrospectively analyzed the knockout mouse phenotypes of the drug targets of 
the 100 best-selling drugs, and found that the drug efficacy could have been predicted from 
the respective mouse phenotype. Even though the matter may not be this simple, it clearly 
shows the potential of animal modeling in biomedical research and drug discovery. 
Thus, presumably the number of animal models, mostly mouse lines, of different 
neurological and psychiatric diseases will increase dramatically in the future. Additionally, 
crossbreeding of different mouse lines will create a new source of research models. 
Considering the complexity and plasticity of the brain, there will be a great need for 
techniques that can be used for rapid characterization of basic neurotransmitter systems in 
different disease models. Thus far, most researchers have concentrated their work on some 
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particular neurotransmitter and a subclass of its receptors, but I think that when getting deeper 
into the pathophysiology of diseases, we should be more aware of the other systems as well. 
Manipulating, e.g., NMDA type glutamate receptors might cause alterations in the 
GABAergic system also. Considering the wide range of approaches, from single cell RT-PCR 
revealing the subunit mRNA levels of individual neurons to electrophysiological studies with 
certain neuronal populations or detailed behavioral characterization of living animals, it will 
be almost impossible to perform even all the relevant studies to characterize the animal 
models. In this scenario, an approach that describes receptor level alterations with brain 
regional resolution would be a good starting point. Ligand autoradiography with protocols 
revealing different receptor subtypes should be ideal for this purpose, since with a limited 
number of brain samples, enough serial sections for many parallel assays are obtained. In 
general, ligand autoradiographic procedures do not require processing of the tissue, and they 
are technically relatively easy to perform. Still, they reveal relevant information about 
receptor populations in different brain regions, and could be used to direct future studies. As 
an example we may consider the autoradiographic “screening” of the γ2+/- mice (III), an 
animal model of the human generalized anxiety disorder (Crestani et al., 1999). Solely based 
on the receptor autoradiographic results, it could be predicted that the amount of synaptic γ2-
receptors in many brain regions is decreased (reduced [3H]Ro 15-4513 binding) together with 
regionally similar upregulation of extrasynaptic αβ receptors (increased GIS-[35S]TBPS 
binding). In addition, [3H]muscimol binding was unchanged, which suggests that the δ 
subunits do not replace the reduced γ2 subunits. With this panel of three receptor 
autoradiographic protocols, we have a fairly accurate estimate of the GABAA receptor system 
in γ2+/- mice, and would be able to direct the following studies according to these findings. 
Taking all these considerations into account, here I propose that, similar to the SHIRPA 
protocol in behavioral studies, there should be a basic screening protocol for receptor level 
changes that should be performed for all new animal models with GABAAergic system 
alterations. Before proceeding to more detailed studies with the model, a basic 
characterization of the major GABAA receptor subtype levels in different brain regions should 
be performed. This would build a solid ground for the following studies, and allow judgment 
of the significance of the findings from, e.g., behavioral studies.  
Could poor coupling with agonist and convulsant sites of the GABAA receptor be used 
to image the possible changes in the GABAAergic system in human patients? Currently PET 
and SPECT can be used to image BZ binding sites, and, for example,  a decrease in BZ 
binding in patients with generalized anxiety disorder (SPECT; Tiihonen et al., 1997) and in 
patients with Angelman’ syndrome (PET; Holopainen et al., 2001) has been reported. 
However, no proper PET or SPECT ligands for other GABAA receptor binding sites have 
been introduced. Convulsant site ligand TBOB, or its derivatives, have been tested, but they 
have too rapid clearance from the brain, and they are too lipophilic to be useful for PET or 
SPECT (Culbert et al., 1993; Snyder et al., 1995). Moreover, while [11C]flumazenil, as a BZ 
antagonist, can safely be used in PET or SPECT studies, it is not so clear that channel 
blockers, such as TBPS, could ever be suitable ligands in vivo, despite the low tracer amounts 
needed for human binding. In addition, reaching similar conditions in vivo that we apply in 
vitro to reveal the GIS-[35S]TBPS binding (90 min in the presence of 1 mM GABA) is not 
realistic. Thus, in order to be able to image extrasynaptic GABAA receptors with PET or 
SPECT in vivo, we should probably think about the possibilities offered by such compounds 
as THIP, which seem to have a much higher affinity for the extrasynaptic than the synaptic 
receptors (Ebert et al., 1994; Brown et al., 2002). In fact, in receptor autoradiography, 
[3H]THIP seems to label only a subset of GABA binding sites (Hösli et al., 1985), but the 
subcellular localization of these sites has not been determined. 
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6.4. Use of [35S]TBPS autoradiography in drug research 
[35S]TBPS has a high affinity and specificity for native GABAA receptors, which make it a 
good ligand in receptor autoradiography with brain sections. [35S]TBPS binding dissociates in 
a good correlation with GABAA receptor activation, as measured by chloride flux (Im and 
Blakeman, 1991). Thus, [35S]TBPS binding and its dissociation can be used as a biochemical 
measure of receptor activation. Basically [35S]TBPS dissociation and receptor activation are 
caused by GABA, but compounds that modulate the effect of GABA, in a positive or a 
negative way, also affect [35S]TBPS. Thus [35S]TBPS binding and its modulation can be used 
to reveal allosteric interactions in the receptor complex. These properties together make 
[35S]TBPS autoradiography a powerful tool in drug research.  
 When a heterogeneity in [35S]TBPS binding on brain section autoradiography is 
revealed (e.g., by a novel drug compound), two important general assumptions are justified: 
1) there are at least two structurally different receptor subtypes in respect to the binding site of 
the novel compound, or in respect to coupling between the convulsant and the drug binding 
site, or in respect to coupling between GABA and the convulsant binding sites, and 2) the 
ligand autoradiographic heterogeneity probably represents receptor functional heterogeneity. 
From the first assumption it follows that heterogeneity can usually be replicated in [35S]TBPS 
binding to recombinant receptors, once correct structural needs (i.e., correct subunit 
combination) are met, which may be used to confirm the findings with native receptors. From 
the second assumption it follows that the heterogeneity represents a property that potentially 
bears functional significance. The above described theoretical considerations of [35S]TBPS 
autoradiography may be exemplified by the work that aimed to clarify the possible actions of 
niflumate on brain GABAA receptors (V). Both positive and negative modulation of receptor 
function (as deduced by modulation of the GABA effect on [35S]TBPS binding with brain 
sections) had correlates on recombinant receptor function. The proper subunit combinations 
were originally chosen on the basis of brain regional heterogeneity of niflumate effects 
offered by the spatial resolution of receptor autoradiography with brain sections. Subsequent 
studies with recombinant receptors revealed that negative modulation was mediated by the 
furosemide binding site, whereas the binding site responsible for positive modulation has not 
been described before. Thus, the pharmacotherapeutically attractive idea of positive-negative 
modulation of different receptor subtypes by one compound was initially revealed by a simple 
autoradiographic procedure. Similarly, the original finding that GABA is not a full agonist in 
all native GABAA receptors (Figure 10) was provided by [35S]TBPS autoradiography.    
  [35S]TBPS autoradiography is a suitable method for high-throughput screening of 
novel GABAAergic compounds. Given the multiplicity of the available genetically engineered 
mouse lines, the pharmacology of which may also be conveniently studied, [35S]TBPS 
autoradiography offers a simple and inexpensive way to rapidly characterize the receptor 
subtype specific actions of various compounds in the natural neuronal environment. Most 
importantly, the pharmacological heterogeneities revealed by the autoradiographic procedure 
are likely to bear functional correlates. 
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7. CONCLUSIONS 
The aim of the current project was to characterize the atypical property of poor coupling 
between the GABAA receptor agonist and convulsant binding sites, named the GABA-
insensitive (GIS) [35S]TBPS binding. The main results and conclusions of the study were: 
 
1.  A modification of the standard receptor autoradiographic procedure was achieved, 
which allowed reproducible imaging of GIS-[35S]TBPS binding on brain sections.  
 
2.  The GIS-[35S]TBPS binding is conserved during evolution, since it was detected in 
human, rodent and avian cerebellar granule cell layer. The GIS-[35S]TBPS binding was 
also detected in the thalamus and in the deep layers of the neocortex in human and 
rodent brain. It can be estimated that 6-16 % (quantified proportion of GIS-[35S]TBPS 
binding) of the basal [35S]TBPS binding in the cerebellar granule cell layer represents a 
minor population of native GABAA receptors. The proportion of receptors displaying 
GIS-[35S]TBPS binding among all GABAA receptors in the forebrain regions is smaller. 
The prevalence of a receptor population displaying GIS-[35S]TBPS binding is typical 
for many GABAA receptor subtypes. 
 
3.  The present experiments revealed that several receptor subunits affect the agonist 
modulation of [35S]TBPS binding. 1) The α6 subunit induces GIS-[35S]TBPS binding 
when compared to the α1 subunit. 2) Inclusion of the γ2 subunit in the receptor complex 
abolishes the GIS-[35S]TBPS binding. 3) Inclusion of the δ subunit induces GIS-
[35S]TBPS binding. 4) The β3 subunits are more likely than the β2 subunits to induce 
GIS-[35S]TBPS binding. Thus, in the native brain, at least the majority of the GIS-
[35S]TBPS binding in the cerebellar granule cell layer is caused by α6β2/3 and/or 
α6β2/3δ receptors. The identity of the receptors forming the forebrain GIS-[35S]TBPS 
binding component is uncertain, but it is likely that α4β, α4βδ, α3β3γ2/3 and α5β3γ2/3 
GABAA receptors participate in forebrain GIS-[35S]TBPS binding. Since THIP, a partial 
GABA site agonist in α1/4βγ2 receptors but full a agonist in α4βδ receptors, was able 
to competitively displace GIS-[35S]TBPS binding, it is possible that GIS-[35S]TBPS 
binding in the brain represents native receptors, where GABA is only a partial agonist.  
 
4.  Since the γ2 subunit is generally required for synaptic enrichment of GABAA receptors, 
and δ subunit-containing receptors are exclusively extrasynaptic, the receptor subtypes 
displaying GIS-[35S]TBPS in the native brain are deduced to be extrasynaptic. These 
receptors are high-affinity sensors of extracellular GABA, and, at least in the cerebellar 
granule cell layer, are responsible for the major part of the GABAAergic inhibition. 
Induction of GIS-[35S]TBPS binding together with formation of α6β (and α6βγ2) 
receptors in the mouse hippocampus after ectopic α6 subunit expression (Thy1α6 
mice), and following increased tonic but decreased phasic inhibition, resulted in 
increased sensitivity to convulsions. While increasing extracellular GABA level delayed 
convulsions in the Thy1α6 mice, presumably owing to increased tonic inhibition, it was 
not able to fully counteract the decreased phasic inhibition. These results reveal the first 
behavioral correlate of tonic inhibition, but highlight the significance of phasic 
inhibition during strong excitation. 
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5. Niflumate, a NSAID, was shown to decrease the inhibitory effect of GABA on 
[35S]TBPS binding in the cerebellar granule cell layer, while on other brain regions it 
potentiated the effect of GABA. Using recombinant receptors expressed in Xenopus 
laevis oocytes, it was demonstrated that negative modulation had the same structural 
requirement as furosemide action, i.e., the α6 subunit, while positive modulation was 
dependent on the presence of α1 and γ2 subunits. The binding site for positive 
modulation has not been described before. These results indicate that GIS-[35S]TBPS 
binding, like [35S]TBPS autoradiography in general, can be used to screen receptor 
subtype-selective drug actions, and to reveal novel allosteric binding sites of the 
GABAA receptors. 
 
In conclusion, the autoradiographic procedure revealing the GIS-[35S]TBPS binding can be 
used to image extrasynaptic GABAA receptors. In these receptors, GABA possibly acts only 
as a partial agonist. The method can generally be used to image and quantify brain regional 
alterations in the extrasynaptic GABAAergic system in various animal models of neurological 
and psychiatric diseases. In addition, it can be used in reveal novel allosteric interactions in 
the receptor complex, and thus in the search for novel GABAA receptor subtype-selective 
drugs. 
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